



ATRIO Bronze Rx (Basin) (PPO)
ATRIO Bronze Rx (Rogue) (PPO)
ATRIO Bronze Rx (Umpqua) (PPO)
ATRIO Silver Rx (PPO)
ATRIO Silver Rx (Willamette) (PPO)
ATRIO Gold Rx (PPO)
ATRIO Gold Rx (Willamette) (PPO)

2021 Formulary (List of Covered Drugs)

**PLEASE READ: THIS DOCUMENT CONTAINS INFORMATION
ABOUT THE DRUGS WE COVER IN THIS PLAN**

HPMS Approved Formulary File 21045, Version Number 8

This formulary was updated on 10/05/2020. For more recent information or other questions, please contact ATRIO Health Plans at 1-877-672-8620 or, for TTY users, 1-800-735-2900, 8 a.m. to 8 p.m., daily, or visit www.atriohp.com.

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to “we,” “us,” or “our,” it means ATRIO Health Plans. When it refers to “plan” or “our plan,” it means ATRIO Bronze Rx (Basin) (PPO), ATRIO Bronze Rx (Rogue) (PPO), ATRIO Bronze Rx (Umpqua) (PPO), ATRIO Silver Rx (PPO), ATRIO Silver Rx (Willamette) (PPO), ATRIO Gold Rx (PPO), and ATRIO Gold Rx (Willamette) (PPO).

This document includes a list of the drugs (formulary) for our plan which is current as of 10/05/2020. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.

What is the ATRIO Health Plans Formulary?

A formulary is a list of covered drugs selected by ATRIO Health Plans in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. ATRIO Health Plans will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at an ATRIO Health Plans network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on the steps you may take to request an exception, and you can also find information in the section below entitled “How do I request an exception to the ATRIO Health Plans Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost-sharing tier. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, or add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 30-day supply of the drug.

- If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the ATRIO Health Plan Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2020 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2021 coverage year except as described above. This means these drugs will remain available at the same cost sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of 10/05/2020. To get updated information about the drugs covered by ATRIO Health Plans, please contact us. Our contact information appears on the front and back cover pages.

ATRIO Health Plans will update formularies monthly and provide a document that lists the formulary changes. This list will be posted on www.atriohp.com or can be sent to you by calling 1-877-672-8620, Daily, 8am-8pm. TTY/TDD users should call 1-800-735-2900.

How do I use the Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 1. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, “Cardiovascular Agents”. If you know what your drug is used for, look for the category name in the list that begins on page 1. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins on page I-1. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

ATRIO Health Plans covers both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** ATRIO Health Plans requires you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from ATRIO Health Plans before you fill your prescriptions. If you don't get approval, ATRIO Health Plans may not cover the drug.
- **Quantity Limits:** For certain drugs, ATRIO Health Plans limits the amount of the drug that ATRIO Health Plans will cover. For example, ATRIO Health Plans provides 30 per prescription for simvastatin. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, ATRIO Health Plans requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, ATRIO Health Plans may not cover Drug B unless you try Drug A first. If Drug A does not work for you, ATRIO Health Plans will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 1. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask ATRIO Health Plans to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, “How do I request an exception to the ATRIO Health Plans’ formulary?” on page iv for information about how to request an exception.

What are over-the counter (OTC) drugs?

OTC drugs are non-prescription drugs that are not normally covered by a Medicare Prescription Drug Plan. ATRIO Health Plans pays for certain OTC drugs. ATRIO Health Plans will provide these OTC drugs at no cost to you. The cost to ATRIO Health Plans of these OTC drugs will not count toward your total Part D drug costs (that is, the amount you pay does not count for the coverage gap).

COVERED OVER-THE-COUNTER (OTC) DRUGS

| Generic Name | Brand Name – For Reference Only (ATRIO only covers generic as OTC) | Dosage Form |
|--|---|---|
| Cetirizine Hydrochloride | (Zyrtec) | Chewable Tablet, Solution, Tablet |
| Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride | (Zyrtec-D) | 12 Hour Tablet |
| Fexofenadine Hydrochloride | (Allegra) | 12 Hour Tablet, 24 Hour Tablet, Tablet Rapdis, Suspension |
| Fexofenadine/Pseudoephedrine Hydrochloride | (Allegra-D) | 12 Hour Tablet, 24 Hour Tablet |
| Ketotifen Fumarate | (Zaditor) | Ophthalmic Drops |
| Levocetirizine Dihydrochloride | (Xyzal) | Tablet |
| Loratadine | (Claritin) | Solution, Tablet, Tablet Rapdis, Chewable Tablet |
| Loratadine/Pseudoephedrine Hydrochloride | (Claritin-D) | 12 Hour Tablet, 24 Hour Tablet |
| Olopatadine Hydrochloride | (Pataday) | Ophthalmic Drops |

What if my drug is not on the Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Customer Service and ask if your drug is covered.

If you learn that ATRIO Health Plans does not cover your drug, you have two options:

- You can ask Customer Service for a list of similar drugs that are covered by ATRIO Health Plans. When you receive the list, show it to your doctor and ask him or her to prescribe a similar drug that is covered by ATRIO Health Plans.
- You can ask ATRIO Health Plans to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the ATRIO Health Plans’ Formulary?

You can ask ATRIO Health Plans to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at a lower cost-sharing level (if this drug is not on the specialty tier). If approved this would lower the amount you must pay for your drug.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, ATRIO Health Plans limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, ATRIO Health Plans will only approve your request for an exception if the alternative drugs included on the plan's formulary, [the lower cost-sharing drug] or additional utilization restrictions would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, or utilization restriction exception. **When you request a formulary or utilization restriction exception you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply (unless you have a prescription written for fewer days) when you go to a network pharmacy. After your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

If you are being admitted or discharged from a facility, we will cover "early refills" of previously covered drugs as needed upon admission to or discharge from the facility.

For more information

For more detailed information about your ATRIO Health Plans prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about ATRIO Health Plans, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

ATRIO Health Plans Formulary

The formulary below provides coverage information about some of the drugs covered by ATRIO Health Plans. If you have trouble finding your drug in the list, turn to the Index that begins on page I-1.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., CRESTOR) and generic drugs are listed in lower-case italics (e.g., *rosuvastatin*).

The information in the Requirements/Limits column tells you if ATRIO Health Plans has any special requirements for coverage of your drug.

COST SHARING TIERS

Douglas County Plans

| ATRIO Bronze Rx (Umpqua) (PPO) | | | ATRIO Silver Rx (PPO) | | | ATRIO Gold Rx (PPO) | | |
|--------------------------------|-----------------|---------------|--------------------------------|-----------------|---------------|--------------------------------|-----------------|---------------|
| Standard Retail Cost Sharing | | | Standard Retail Cost Sharing | | | Standard Retail Cost Sharing | | |
| Tier | 30-day supply | 90-day supply | Tier | 30-day supply | 90-day supply | Tier | 30-day supply | 90-day supply |
| Tier 1 (Preferred Generic) | \$10 copay | \$20 copay | Tier 1 (Preferred Generic) | \$6 copay | \$12 copay | Tier 1 (Preferred Generic) | \$4 copay | \$8 copay |
| Tier 2 (Generic) | \$20 copay | \$40 copay | Tier 2 (Generic) | \$15 copay | \$30 copay | Tier 2 (Generic) | \$10 copay | \$20 copay |
| Tier 3 (Preferred Brand) | \$45 copay | \$90 copay | Tier 3 (Preferred Brand) | \$40 copay | \$80 copay | Tier 3 (Preferred Brand) | \$35 copay | \$70 copay |
| Tier 4 (Non-Preferred Drug) | \$95 copay | \$190 copay | Tier 4 (Non-Preferred Drug) | \$85 copay | \$170 copay | Tier 4 (Non-Preferred Drug) | \$75 copay | \$150 copay |
| Tier 5 (Specialty Tier) | 30% of the cost | Not Available | Tier 5 (Specialty Tier) | 29% of the cost | Not Available | Tier 5 (Specialty Tier) | 33% of the cost | Not Available |
| Tier 6 (Select Care Drugs) | \$0 | \$0 | Tier 6 (Select Care Drugs) | \$0 | \$0 | Tier 6 (Select Care Drugs) | \$0 | \$0 |

Klamath County Plans

| ATRIO Bronze Rx (Basin) (PPO) | | | ATRIO Silver Rx (PPO) | | | ATRIO Gold Rx (PPO) | | |
|--------------------------------|-----------------|---------------|--------------------------------|-----------------|---------------|--------------------------------|-----------------|---------------|
| Standard Retail Cost Sharing | | | Standard Retail Cost Sharing | | | Standard Retail Cost Sharing | | |
| Tier | 30-day supply | 90-day supply | Tier | 30-day supply | 90-day supply | Tier | 30-day supply | 90-day supply |
| Tier 1 (Preferred Generic) | \$10 copay | \$20 copay | Tier 1 (Preferred Generic) | \$6 copay | \$12 copay | Tier 1 (Preferred Generic) | \$4 copay | \$8 copay |
| Tier 2 (Generic) | \$20 copay | \$40 copay | Tier 2 (Generic) | \$15 copay | \$30 copay | Tier 2 (Generic) | \$10 copay | \$20 copay |
| Tier 3 (Preferred Brand) | \$45 copay | \$90 copay | Tier 3 (Preferred Brand) | \$40 copay | \$80 copay | Tier 3 (Preferred Brand) | \$35 copay | \$70 copay |
| Tier 4 (Non-Preferred Drug) | \$95 copay | \$190 copay | Tier 4 (Non-Preferred Drug) | \$85 copay | \$170 copay | Tier 4 (Non-Preferred Drug) | \$75 copay | \$150 copay |
| Tier 5 (Specialty Tier) | 28% of the cost | Not Available | Tier 5 (Specialty Tier) | 29% of the cost | Not Available | Tier 5 (Specialty Tier) | 33% of the cost | Not Available |
| Tier 6 (Select Care Drugs) | \$0 | \$0 | Tier 6 (Select Care Drugs) | \$0 | \$0 | Tier 6 (Select Care Drugs) | \$0 | \$0 |

Jackson County Plans

| ATRIO Bronze Rx (Rogue) (PPO) | | | ATRIO Silver Rx (PPO) | | |
|-------------------------------|-----------------|---------------|------------------------------|-----------------|---------------|
| Standard Retail Cost Sharing | | | Standard Retail Cost Sharing | | |
| Tier | 30-day supply | 90-day supply | Tier | 30-day supply | 90-day supply |
| Tier 1 (Preferred Generic) | \$10 copay | \$20 copay | Tier 1 (Preferred Generic) | \$6 copay | \$12 copay |
| Tier 2 (Generic) | \$20 copay | \$40 copay | Tier 2 (Generic) | \$15 copay | \$30 copay |
| Tier 3 (Preferred Brand) | \$45 copay | \$90 copay | Tier 3 (Preferred Brand) | \$40 copay | \$80 copay |
| Tier 4 (Non-Preferred Drug) | \$95 copay | \$190 copay | Tier 4 (Non-Preferred Drug) | \$85 copay | \$170 copay |
| Tier 5 (Specialty Tier) | 28% of the cost | Not Available | Tier 5 (Specialty Tier) | 29% of the cost | Not Available |
| Tier 6 (Select Care Drugs) | \$0 | \$0 | Tier 6 (Select Care Drugs) | \$0 | \$0 |

Josephine County Plans

| ATRIO Bronze Rx (Rogue) (PPO) | | | ATRIO Silver Rx (PPO) | | |
|-------------------------------|-----------------|---------------|------------------------------|-----------------|---------------|
| Standard Retail Cost Sharing | | | Standard Retail Cost Sharing | | |
| Tier | 30-day supply | 90-day supply | Tier | 30-day supply | 90-day supply |
| Tier 1 (Preferred Generic) | \$10 copay | \$20 copay | Tier 1 (Preferred Generic) | \$6 copay | \$12 copay |
| Tier 2 (Generic) | \$20 copay | \$40 copay | Tier 2 (Generic) | \$15 copay | \$30 copay |
| Tier 3 (Preferred Brand) | \$45 copay | \$90 copay | Tier 3 (Preferred Brand) | \$40 copay | \$80 copay |
| Tier 4 (Non-Preferred Drug) | \$95 copay | \$190 copay | Tier 4 (Non-Preferred Drug) | \$85 copay | \$170 copay |
| Tier 5 (Specialty Tier) | 28% of the cost | Not Available | Tier 5 (Specialty Tier) | 29% of the cost | Not Available |
| Tier 6 (Select Care Drugs) | \$0 | \$0 | Tier 6 (Select Care Drugs) | \$0 | \$0 |

Marion & Polk County Plans

| ATRIO Silver Rx (Willamette) (PPO) | | | ATRIO Gold Rx (Willamette) (PPO) | | |
|------------------------------------|-----------------|---------------|----------------------------------|-----------------|---------------|
| Standard Retail Cost Sharing | | | Standard Retail Cost Sharing | | |
| Tier | 30-day supply | 90-day supply | Tier | 30-day supply | 90-day supply |
| Tier 1 (Preferred Generic) | \$6 copay | \$12 copay | Tier 1 (Preferred Generic) | \$4 copay | \$8 copay |
| Tier 2 (Generic) | \$15 copay | \$30 copay | Tier 2 (Generic) | \$10 copay | \$20 copay |
| Tier 3 (Preferred Brand) | \$40 copay | \$80 copay | Tier 3 (Preferred Brand) | \$35 copay | \$70 copay |
| Tier 4 (Non-Preferred Drug) | \$85 copay | \$170 copay | Tier 4 (Non-Preferred Drug) | \$75 copay | \$150 copay |
| Tier 5 (Specialty Tier) | 29% of the cost | Not Available | Tier 5 (Specialty Tier) | 33% of the cost | Not Available |
| Tier 6 (Select Care Drugs) | \$0 | \$0 | Tier 6 (Select Care Drugs) | \$0 | \$0 |

The following Utilization Management Restriction abbreviations may be found within the body of this document

COVERAGE NOTES ABBREVIATIONS

| ABBREVIATION | DESCRIPTION | EXPLANATION |
|--------------|--|--|
| PA | Prior Authorization Restriction | You (or your physician) are required to get prior authorization from ATRIO Health Plans before you fill your prescription for this drug. Without prior approval, ATRIO Health Plans may not cover this drug. |
| PA BvD | Prior Authorization Restriction for Part B vs Part D Determination | This drug may be eligible for payment under Medicare Part B or Part D. You (or your physician) are required to get prior authorization from ATRIO Health Plans to determine that this drug is covered under Medicare Part D before you fill your prescription for this drug. Without prior approval, ATRIO Health Plans may not cover this drug. |
| PA NSO | Prior Authorization Restriction for New Starts Only | If you are a new member or if you have not taken this drug before, you (or your physician) are required to get prior authorization from ATRIO Health Plans before you fill your prescription for this drug. Without prior approval, ATRIO Health Plans may not cover this drug. |
| QL | Quantity Limit Restriction | ATRIO Health Plans limits the amount of this drug that is covered per prescription, or within a specific time frame. |
| ST | Step Therapy Restriction | Before ATRIO Health Plans will provide coverage for this drug, you must first try another drug(s) to treat your medical condition. This drug may only be covered if the other drug(s) does not work for you. |

OTHER SPECIAL REQUIREMENTS FOR COVERAGE

| ABBREVIATION | DESCRIPTION | EXPLANATION |
|--------------|--------------------------|---|
| LA | Limited Access Drug | This prescription may be available only at certain pharmacies. For more information consult your Pharmacy Directory or call Customer Service at 1-877-672-8620, Daily, 8am-8pm. TTY/TDD users should call 1-800-735-2900. |
| NDS | Non-Extended Days Supply | This drug is not available for a 90 day supply. |
| NM | No Mail Order | This drug is not available at mail order pharmacy |

Table of Contents

| | |
|---|-----|
| Analgesics..... | 3 |
| Anesthetics..... | 10 |
| Anti-Addiction/Substance Abuse Treatment Agents..... | 10 |
| Antianxiety Agents..... | 12 |
| Antibacterials..... | 13 |
| Anticancer Agents..... | 22 |
| Anticonvulsants..... | 39 |
| Antidementia Agents..... | 45 |
| Antidepressants..... | 46 |
| Antidiabetic Agents..... | 49 |
| Antifungals..... | 54 |
| Antigout Agents..... | 56 |
| Antihistamines..... | 56 |
| Anti-Infectives (Skin And Mucous Membrane)..... | 57 |
| Antimigraine Agents..... | 58 |
| Antimycobacterials..... | 59 |
| Antinausea Agents..... | 60 |
| Antiparasite Agents..... | 62 |
| Antiparkinsonian Agents..... | 63 |
| Antipsychotic Agents..... | 65 |
| Antivirals (Systemic)..... | 71 |
| Blood Products/Modifiers/Volume Expanders..... | 78 |
| Caloric Agents..... | 82 |
| Cardiovascular Agents..... | 86 |
| Central Nervous System Agents..... | 99 |
| Contraceptives..... | 104 |
| Dental And Oral Agents..... | 112 |
| Dermatological Agents..... | 112 |
| Devices..... | 118 |
| Enzyme Replacement/Modifiers..... | 119 |
| Eye, Ear, Nose, Throat Agents..... | 121 |
| Gastrointestinal Agents..... | 126 |
| Genitourinary Agents..... | 131 |
| Heavy Metal Antagonists..... | 132 |
| Hormonal Agents, Stimulant/Replacement/Modifying..... | 132 |
| Immunological Agents..... | 141 |

| | |
|--|-----|
| Inflammatory Bowel Disease Agents..... | 152 |
| Irrigating Solutions..... | 153 |
| Metabolic Bone Disease Agents..... | 153 |
| Miscellaneous Therapeutic Agents..... | 155 |
| Ophthalmic Agents..... | 158 |
| Replacement Preparations..... | 159 |
| Respiratory Tract Agents..... | 161 |
| Skeletal Muscle Relaxants..... | 166 |
| Sleep Disorder Agents..... | 167 |
| Vasodilating Agents..... | 167 |
| Vitamins And Minerals..... | 168 |

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| Analgesics | | |
| Analgesics, Miscellaneous | | |
| <i>acetaminophen-codeine oral solution</i> 120-12 mg/5 ml | 1 | NDS; QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral tablet</i> 300-15 mg, 300-30 mg | 2 | NDS; QL (360 per 30 days) |
| <i>acetaminophen-codeine oral tablet</i> 300-60 mg | 2 | NDS; QL (180 per 30 days) |
| <i>ascomp with codeine oral capsule</i> 30-50-325-40 mg | 4 | NDS; QL (180 per 30 days) |
| <i>buprenorphine hcl injection solution</i> (Buprenex) 0.3 mg/ml | 2 | |
| <i>buprenorphine hcl injection syringe</i> 0.3 mg/ml | 2 | |
| <i>buprenorphine transdermal patch</i> (Butrans) weekly 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour | 2 | NDS; QL (4 per 28 days) |
| <i>butalbital compound w/codeine oral capsule</i> 30-50-325-40 mg | 4 | NDS; QL (180 per 30 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule</i> 50-300-40-30 mg (Fioricet with Codeine) | 4 | NDS; QL (180 per 30 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule</i> 50-325-40-30 mg | 2 | NDS; QL (180 per 30 days) |
| <i>butalbital-acetaminophen oral tablet</i> (Tencon) 50-325 mg | 2 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral capsule</i> 50-325-40 mg (Zebutal) | 4 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral tablet</i> 50-325-40 mg (Esgic) | 2 | QL (180 per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule</i> 50-325-40 mg (Fiorinal) | 4 | QL (180 per 30 days) |
| <i>butalbital-aspirin-caffeine oral tablet</i> 50-325-40 mg | 2 | QL (180 per 30 days) |
| <i>butorphanol nasal spray, non-aerosol</i> 10 mg/ml | 2 | NDS; QL (5 per 28 days) |
| <i>codeine sulfate oral tablet</i> 30 mg, 60 mg | 2 | NDS; QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>endocet oral tablet 10-325 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> | 2 | NDS; QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> | 2 | NDS; QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg</i> (Actiq) | 5 | PA; NM; NDS; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> (Duragesic) | 2 | NDS; QL (10 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | 4 | NDS; QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg</i> (Vicodin HP) | 4 | NDS; QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg</i> (Lorcet HD) | 2 | NDS; QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 2.5-325 mg</i> | 2 | NDS; QL (240 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-300 mg</i> | 4 | NDS; QL (240 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-325 mg</i> (Lorcet (hydrocodone)) | 2 | NDS; QL (240 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 7.5-300 mg</i> | 4 | NDS; QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 7.5-325 mg</i> (Norco) | 2 | NDS; QL (180 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg</i> (Ibudone) | 4 | NDS; QL (150 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 5-200 mg</i> | 4 | NDS; QL (150 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 7.5-200 mg</i> | 2 | NDS; QL (150 per 30 days) |
| <i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| <i>hydromorphone oral liquid 1 mg/ml</i> (Dilaudid) | 2 | NDS; QL (1200 per 30 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> (Dilaudid) | 2 | NDS; QL (180 per 30 days) |
| LAZANDA NASAL SPRAY, NON-AEROSOL 100 MCG/SPRAY, 300 MCG/SPRAY, 400 MCG/SPRAY | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>lorcet (hydrocodone) oral tablet 5-325 mg</i> | 2 | NDS; QL (240 per 30 days) |
| <i>lorcet hd oral tablet 10-325 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>lorcet plus oral tablet 7.5-325 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>methadone injection solution 10 mg/ml</i> | 2 | |
| <i>methadone oral solution 10 mg/5 ml</i> | 2 | NDS; QL (600 per 30 days) |
| <i>methadone oral solution 5 mg/5 ml</i> | 2 | NDS; QL (1200 per 30 days) |
| <i>methadone oral tablet 10 mg</i> (Dolophine) | 2 | NDS; QL (120 per 30 days) |
| <i>methadone oral tablet 5 mg</i> (Dolophine) | 2 | NDS; QL (180 per 30 days) |
| <i>methadose oral tablet, soluble 40 mg</i> | 2 | NDS; QL (30 per 30 days) |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 2 | NDS; QL (180 per 30 days) |
| <i>morphine intravenous solution 10 mg/ml, 4 mg/ml, 8 mg/ml</i> | 2 | PA BvD |
| <i>morphine oral solution 10 mg/5 ml</i> | 2 | NDS; QL (700 per 30 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | NDS; QL (300 per 30 days) |
| MORPHINE ORAL TABLET 15 MG | 2 | NDS; QL (180 per 30 days) |
| MORPHINE ORAL TABLET 30 MG | 2 | NDS; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>morphine oral tablet extended release 100 mg, 200 mg, 60 mg</i> (MS Contin) | 2 | NDS; QL (60 per 30 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg</i> (MS Contin) | 2 | NDS; QL (90 per 30 days) |
| <i>oxycodone oral capsule 5 mg</i> | 4 | NDS; QL (180 per 30 days) |
| <i>oxycodone oral concentrate 20 mg/ml</i> | 4 | NDS; QL (120 per 30 days) |
| <i>oxycodone oral solution 5 mg/5 ml</i> | 4 | NDS; QL (1300 per 30 days) |
| <i>oxycodone oral tablet 10 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>oxycodone oral tablet 15 mg, 30 mg</i> (Roxicodone) | 2 | NDS; QL (120 per 30 days) |
| <i>oxycodone oral tablet 20 mg</i> | 2 | NDS; QL (120 per 30 days) |
| <i>oxycodone oral tablet 5 mg</i> (Roxicodone) | 2 | NDS; QL (180 per 30 days) |
| <i>oxycodone oral tablet, oral only, ext. rel. 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg</i> (OxyContin) | 3 | NDS; QL (60 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> (Endocet) | 2 | NDS; QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg</i> (Endocet) | 2 | NDS; QL (360 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet 7.5-325 mg</i> (Endocet) | 2 | NDS; QL (240 per 30 days) |
| <i>oxycodone-aspirin oral tablet 4.8355-325 mg</i> | 2 | NDS; QL (360 per 30 days) |
| OXYCONTIN ORAL TABLET, ORAL ONLY, EXT. REL. 12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 3 | NDS; QL (60 per 30 days) |
| <i>oxymorphone oral tablet 10 mg</i> | 4 | NDS; QL (120 per 30 days) |
| <i>oxymorphone oral tablet 5 mg</i> | 4 | NDS; QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg</i> | 4 | NDS; QL (60 per 30 days) |
| <i>tencon oral tablet 50-325 mg</i> | 2 | QL (180 per 30 days) |
| <i>tramadol oral tablet 50 mg</i> (Ultram) | 1 | NDS; QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> (Ultracet) | 2 | NDS; QL (300 per 30 days) |
| <i>vicodin hp oral tablet 10-300 mg</i> | 4 | NDS; QL (180 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 13.5 MG, 18 MG, 9 MG | 3 | NDS; QL (60 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 27 MG | 3 | NDS; QL (120 per 30 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 36 MG | 3 | NDS; QL (240 per 30 days) |
| <i>zebutal oral capsule 50-325-40 mg</i> | 4 | QL (180 per 30 days) |
| Nonsteroidal Anti-Inflammatory Agents | | |
| CALDOLOR INTRAVENOUS RECON SOLN 800 MG/8 ML (100 MG/ML) | 4 | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 50 mg</i> (Celebrex) | 2 | QL (60 per 30 days) |
| <i>celecoxib oral capsule 400 mg</i> (Celebrex) | 4 | QL (60 per 30 days) |
| <i>diclofenac epolamine transdermal patch 12 hour 1.3 %</i> (Flector) | 4 | PA; QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> (Voltaren-XR) | 2 | QL (60 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (drlec) 25 mg</i> | 2 | QL (150 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (drlec) 50 mg</i> | 2 | QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>diclofenac sodium oral tablet, delayed release (drlec) 75 mg</i> | 2 | QL (60 per 30 days) |
| <i>diclofenac sodium topical drops 1.5 %</i> | 2 | QL (300 per 30 days) |
| <i>diclofenac sodium topical gel 1 %</i> (Voltaren) | 2 | |
| <i>diclofenac sodium topical gel 3 %</i> (Solaraze) | 4 | PA; QL (100 per 28 days) |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 50-200 mg-mcg</i> (Arthrotec 50) | 4 | |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 75-200 mg-mcg</i> (Arthrotec 75) | 4 | |
| <i>diflunisal oral tablet 500 mg</i> | 2 | |
| DUEXIS ORAL TABLET 800-26.6 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 4 | |
| <i>etodolac oral tablet 400 mg</i> (Lodine) | 4 | |
| <i>etodolac oral tablet 500 mg</i> | 4 | |
| <i>fenoprofen oral tablet 600 mg</i> (Nalfon) | 4 | |
| <i>flurbiprofen oral tablet 100 mg</i> | 2 | |
| <i>ibu oral tablet 400 mg, 600 mg, 800 mg</i> | 1 | |
| <i>ibuprofen oral suspension 100 mg/5 ml</i> (Children's Advil) | 2 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> (IBU) | 1 | |
| <i>indomethacin oral capsule 25 mg</i> | 2 | QL (240 per 30 days) |
| <i>indomethacin oral capsule 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>indomethacin oral capsule, extended release 75 mg</i> | 4 | QL (60 per 30 days) |
| <i>ketoprofen oral capsule 25 mg, 50 mg, 75 mg</i> | 4 | |
| <i>ketoprofen oral capsule, ext rel. pellets 24 hr 200 mg</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>ketorolac injection cartridge 15 mg/ml</i> | 2 | QL (40 per 30 days) |
| <i>ketorolac injection cartridge 30 mg/ml</i> | 2 | QL (20 per 30 days) |
| <i>ketorolac injection solution 15 mg/ml</i> | 2 | QL (40 per 30 days) |
| <i>ketorolac injection solution 30 mg/ml (1 ml)</i> | 2 | QL (20 per 30 days) |
| <i>ketorolac injection syringe 15 mg/ml</i> | 2 | QL (40 per 30 days) |
| <i>ketorolac injection syringe 30 mg/ml</i> | 2 | QL (20 per 30 days) |
| <i>ketorolac intramuscular cartridge 60 mg/2 ml</i> | 2 | QL (20 per 30 days) |
| <i>ketorolac intramuscular solution 60 mg/2 ml</i> | 2 | QL (20 per 30 days) |
| <i>ketorolac intramuscular syringe 60 mg/2 ml</i> | 2 | QL (20 per 30 days) |
| <i>ketorolac oral tablet 10 mg</i> | 2 | QL (20 per 30 days) |
| <i>mefenamic acid oral capsule 250 mg</i> | 4 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg (Mobic)</i> | 1 | |
| <i>nabumetone oral tablet 500 mg, 750 mg (Relafen)</i> | 2 | |
| <i>naproxen oral tablet 250 mg, 375 mg</i> | 1 | |
| <i>naproxen oral tablet 500 mg (Naprosyn)</i> | 1 | |
| <i>naproxen oral tablet, delayed release (drlec) 375 mg, 500 mg (EC-Naprosyn)</i> | 2 | |
| <i>naproxen-esomeprazole oral tablet, ir, delayed rel, biphasic 375-20 mg, 500-20 mg (Vimovo)</i> | 5 | PA; NM; NDS; QL (60 per 30 days) |
| PENNSAID TOPICAL SOLUTION IN METERED-DOSE PUMP 20 MG/GRAM /ACTUATION(2 %) | 5 | PA; NM; NDS; QL (224 per 28 days) |
| <i>piroxicam oral capsule 10 mg, 20 mg (Feldene)</i> | 4 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 2 | |
| <i>tolmetin oral capsule 400 mg</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| <i>tolmetin oral tablet 200 mg, 600 mg</i> | 4 | |
| Anesthetics | | |
| Local Anesthetics | | |
| <i>glydo mucous membrane jelly in applicator 2 %</i> | 2 | QL (30 per 30 days) |
| <i>lidocaine (pf) injection solution 10 mg/ml (1 %), 15 mg/ml (1.5 %), 20 mg/ml (2 %), 5 mg/ml (0.5 %)</i> (Xylocaine-MPF) | 1 | |
| <i>lidocaine (pf) injection solution 40 mg/ml (4 %)</i> | 1 | |
| <i>lidocaine (pf) intravenous solution 20 mg/ml (2 %)</i> (Xylocaine (Cardiac) (PF)) | 1 | |
| <i>lidocaine hcl injection solution 10 mg/ml (1 %), 20 mg/ml (2 %), 5 mg/ml (0.5 %)</i> (Xylocaine) | 1 | |
| <i>lidocaine hcl mucous membrane jelly 2 %</i> | 2 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 2 | PA |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> (Lidoderm) | 2 | PA; QL (90 per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | 4 | PA; QL (90 per 30 days) |
| <i>lidocaine viscous mucous membrane solution 2 %</i> | 2 | |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | 4 | PA; QL (30 per 30 days) |
| ZTLIDO TOPICAL ADHESIVE PATCH,MEDICATED 1.8 % | 3 | PA; QL (90 per 30 days) |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| Anti-Addiction/Substance Abuse Treatment Agents | | |
| <i>acamprosate oral tablet, delayed release (drlec) 333 mg</i> | 2 | |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | 2 | QL (90 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>buprenorphine-naloxone sublingual film 12-3 mg, 8-2 mg</i> (Suboxone) | 4 | QL (60 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg, 4-1 mg</i> (Suboxone) | 4 | QL (30 per 30 days) |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 2 | QL (90 per 30 days) |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 2 | |
| CHANTIX CONTINUING MONTH BOX ORAL TABLET 1 MG | 3 | QL (336 per 365 days) |
| CHANTIX ORAL TABLET 0.5 MG, 1 MG | 3 | QL (336 per 365 days) |
| CHANTIX STARTING MONTH BOX ORAL TABLETS,DOSE PACK 0.5 MG (11)- 1 MG (42) | 3 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> (Antabuse) | 2 | |
| LUCEMYRA ORAL TABLET 0.18 MG | 5 | NM; NDS; QL (228 per 14 days) |
| <i>naloxone injection solution 0.4 mg/ml</i> | 2 | |
| <i>naloxone injection syringe 0.4 mg/ml, 1 mg/ml</i> | 2 | |
| <i>naltrexone oral tablet 50 mg</i> | 2 | |
| NARCAN NASAL SPRAY, NON-AEROSOL 4 MG/ACTUATION | 3 | QL (4 per 30 days) |
| NICOTROL INHALATION CARTRIDGE 10 MG | 4 | QL (1008 per 90 days) |
| SUBLOCADE SUBCUTANEOUS SOLUTION, EXTENDED REL SYRINGE 100 MG/0.5 ML | 5 | NM; NDS; QL (0.5 per 30 days) |
| SUBLOCADE SUBCUTANEOUS SOLUTION, EXTENDED REL SYRINGE 300 MG/1.5 ML | 5 | NM; NDS; QL (1.5 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| Antianxiety Agents | | |
| Benzodiazepines | | |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> (Xanax) | 1 | NDS; QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> (Xanax) | 1 | NDS; QL (150 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg</i> (Xanax XR) | 2 | NDS; QL (120 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 3 mg</i> (Xanax XR) | 2 | NDS; QL (90 per 30 days) |
| <i>buspirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 2 | |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 1 | NDS; QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> (Klonopin) | 1 | NDS; QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> (Klonopin) | 1 | NDS; QL (300 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 4 | NDS; QL (90 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 2 mg</i> | 4 | NDS; QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg</i> | 2 | NDS; QL (180 per 30 days) |
| <i>clorazepate dipotassium oral tablet 7.5 mg</i> (Tranxene T-Tab) | 2 | NDS; QL (180 per 30 days) |
| <i>diazepam 5 mg/ml oral conc 5 mg/ml</i> | 4 | NDS; QL (1200 per 30 days) |
| <i>diazepam injection solution 5 mg/ml</i> | 2 | QL (10 per 28 days) |
| <i>diazepam injection syringe 5 mg/ml</i> | 2 | QL (10 per 28 days) |
| <i>diazepam oral concentrate 5 mg/ml</i> (Diazepam Intensol) | 4 | NDS; QL (1200 per 30 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | 4 | NDS; QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> (Valium) | 1 | NDS; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>estazolam oral tablet 1 mg</i> | 2 | NDS; QL (60 per 30 days) |
| <i>estazolam oral tablet 2 mg</i> | 2 | NDS; QL (30 per 30 days) |
| <i>flurazepam oral capsule 15 mg</i> | 2 | NDS; QL (60 per 30 days) |
| <i>flurazepam oral capsule 30 mg</i> | 2 | NDS; QL (30 per 30 days) |
| <i>lorazepam 2 mg/ml oral concent 2 mg/ml</i> (Lorazepam Intensol) | 2 | NDS; QL (150 per 30 days) |
| <i>lorazepam injection solution 2 mg/ml, 4 mg/ml</i> (Ativan) | 1 | QL (2 per 30 days) |
| <i>lorazepam injection syringe 2 mg/ml, 4 mg/ml</i> | 2 | QL (2 per 30 days) |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i> | 2 | NDS; QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> (Ativan) | 1 | NDS; QL (90 per 30 days) |
| <i>lorazepam oral tablet 2 mg</i> (Ativan) | 1 | NDS; QL (150 per 30 days) |
| <i>midazolam oral syrup 2 mg/ml</i> | 2 | NDS; QL (10 per 30 days) |
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 4 | NDS; QL (120 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> (Restoril) | 1 | NDS; QL (30 per 30 days) |
| <i>triazolam oral tablet 0.125 mg</i> | 2 | NDS; QL (120 per 30 days) |
| <i>triazolam oral tablet 0.25 mg</i> (Halcion) | 2 | NDS; QL (60 per 30 days) |
| Antibacterials | | |
| Aminoglycosides | | |
| BETHKIS INHALATION SOLUTION FOR NEBULIZATION 300 MG/4 ML | 5 | PA BvD; NM; NDS |
| <i>gentamicin injection solution 20 mg/2 ml, 40 mg/ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>gentamicin sulfate (ped) (pf) injection solution 20 mg/2 ml</i> | 2 | |
| <i>gentamicin sulfate (pf) intravenous solution 100 mg/10 ml, 60 mg/6 ml, 80 mg/8 ml</i> | 2 | |
| <i>neomycin oral tablet 500 mg</i> | 1 | |
| <i>streptomycin intramuscular recon soln 1 gram</i> | 5 | NM; NDS |
| TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE 28 MG | 5 | NM; NDS; QL (224 per 28 days) |
| <i>tobramycin in 0.225 % nacl (Tobi) inhalation solution for nebulization 300 mg/5 ml</i> | 5 | PA BvD; NM; NDS |
| <i>tobramycin sulfate injection solution 40 mg/ml</i> | 4 | |
| Antibacterials, Miscellaneous | | |
| <i>bacitracin intramuscular recon soln 50,000 unit</i> | 4 | |
| <i>chloramphenicol sod succinate intravenous recon soln 1 gram</i> | 2 | |
| CLINDAMYCIN 600 MG/50 ML-NS OUTER,SINGLE- USE,L/F 600 MG/50 ML | 2 | |
| <i>clindamycin 75 mg/5 ml soln 75 (Clindamycin mg/5 ml Pediatric)</i> | 4 | |
| CLINDAMYCIN 900 MG/50 ML-NS OUTER,SINGLE- USE,L/F 900 MG/50 ML | 2 | |
| <i>clindamycin hcl oral capsule 150 mg, (Cleocin HCl) 300 mg, 75 mg</i> | 1 | |
| <i>clindamycin in 5 % dextrose intravenous piggyback 300 mg/50 ml</i> | 2 | |
| CLINDAMYCIN IN 5 % DEXTROSE INTRAVENOUS PIGGYBACK 600 MG/50 ML, 900 MG/50 ML | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>clindamycin pediatric oral recon soln 75 mg/5 ml</i> | 4 | |
| <i>clindamycin phosphate injection solution 150 (mg/ml) (6 ml)</i> | 2 | |
| <i>clindamycin phosphate injection solution 150 mg/ml</i> (Cleocin) | 2 | |
| <i>clindamycin phosphate intravenous solution 600 mg/4 ml</i> | 2 | |
| <i>colistin (colistimethate na) injection recon soln 150 mg</i> (Coly-Mycin M Parenteral) | 5 | PA BvD; NM; NDS |
| <i>daptomycin intravenous recon soln 500 mg</i> (Cubicin) | 5 | NM; NDS |
| FIRVANQ ORAL RECON SOLN 25 MG/ML | 4 | |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i> (Zyvox) | 5 | NM; NDS |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> (Zyvox) | 5 | NM; NDS |
| <i>linezolid oral tablet 600 mg</i> (Zyvox) | 2 | |
| <i>methenamine hippurate oral tablet 1 gram</i> (Hiprex) | 2 | |
| <i>metronidazole in nacl (iso-os) intravenous piggyback 500 mg/100 ml</i> (Metro I.V.) | 2 | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> (Flagyl) | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 50 mg</i> (Macrochantin) | 2 | QL (120 per 30 days) |
| <i>nitrofurantoin macrocrystal oral capsule 25 mg</i> (Macrochantin) | 4 | QL (120 per 30 days) |
| <i>nitrofurantoin monohydlm-cryst oral capsule 100 mg</i> (Macrobid) | 2 | QL (60 per 30 days) |
| <i>polymyxin b sulfate injection recon soln 500,000 unit</i> | 2 | |
| SYNERCID INTRAVENOUS RECON SOLN 500 MG | 5 | NM; NDS |
| <i>trimethoprim oral tablet 100 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------------|
| <i>vancomycin intravenous recon soln</i> 1,000 mg, 10 gram, 5 gram, 500 mg, 750 mg | 2 | |
| <i>vancomycin oral capsule 125 mg</i> (Vancocin) | 4 | QL (40 per 30 days) |
| <i>vancomycin oral capsule 250 mg</i> (Vancocin) | 4 | QL (80 per 30 days) |
| XIFAXAN ORAL TABLET 200 MG | 5 | PA; NM; NDS; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| Cephalosporins | | |
| <i>cefactor oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cefactor oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml</i> | 4 | |
| <i>cefactor oral tablet extended release 12 hr 500 mg</i> | 4 | |
| <i>cefadroxil oral capsule 500 mg</i> | 2 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | 2 | |
| <i>cefadroxil oral tablet 1 gram</i> | 4 | |
| <i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i> | 2 | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 4 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 2 | |
| <i>cefixime oral capsule 400 mg</i> (Suprax) | 4 | |
| <i>cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> (Suprax) | 4 | |
| <i>cefotaxime injection recon soln 1 gram</i> | 2 | |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml, 50 mg/5 ml</i> | 4 | |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i> | 2 | |
| <i>cefprozil oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>ceftazidime injection recon soln 1 gram, 2 gram</i> (Fortaz) | 2 | |
| <i>ceftazidime injection recon soln 6 gram</i> (Tazicef) | 2 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 2 | |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram, 7.5 gram</i> | 2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> (Keflex) | 1 | |
| <i>cephalexin oral capsule 750 mg</i> (Keflex) | 4 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | 2 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG | 5 | NM; NDS |
| Macrolides | | |
| <i>azithromycin intravenous recon soln 500 mg</i> (Zithromax) | 2 | |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> (Zithromax) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>azithromycin oral tablet 250 mg (6 pack), 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>azithromycin oral tablet 250 mg, 500 mg</i> (Zithromax) | 1 | |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 4 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>clarithromycin oral tablet extended release 24 hr 500 mg</i> | 4 | |
| DIFICID ORAL TABLET 200 MG | 5 | NM; NDS; QL (20 per 10 days) |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml</i> (E.E.S. Granules) | 4 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml</i> (EryPed 400) | 4 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| Miscellaneous B-Lactam Antibiotics | | |
| <i>aztreonam injection recon soln 1 gram, 2 gram</i> (Azactam) | 2 | |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 5 | PA; NM; LA; NDS |
| <i>ertapenem injection recon soln 1 gram</i> (Invanz) | 4 | |
| <i>imipenem-cilastatin intravenous recon soln 250 mg</i> | 2 | |
| <i>imipenem-cilastatin intravenous recon soln 500 mg</i> (Primaxin IV) | 2 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> (Merrem) | 4 | |
| Penicillins | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 400-57 mg/5 ml</i> | 4 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 250-62.5 mg/5 ml</i> (Augmentin) | 4 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 600-42.9 mg/5 ml</i> (Augmentin ES-600) | 4 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg</i> | 4 | |
| <i>amoxicillin-pot clavulanate oral tablet 500-125 mg, 875-125 mg</i> (Augmentin) | 1 | |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg</i> (Augmentin XR) | 4 | |
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 4 | |
| <i>ampicillin oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg, 2 gram, 250 mg, 500 mg</i> | 2 | |
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i> (Unasyn) | 2 | |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>nafcillin 1 gml 50 ml inj 1 gram/50 ml</i> | 2 | |
| <i>nafcillin injection recon soln 1 gram</i> | 2 | |
| <i>nafcillin injection recon soln 10 gram</i> | 5 | NM; NDS |
| <i>nafcillin injection recon soln 2 gram</i> | 2 | |
| <i>penicillin g potassium injection recon (Pfizerpen-G) soln 20 million unit</i> | 4 | |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml, 600,000 unit/ml</i> | 2 | |
| <i>penicillin gk 5 million unit plf, latex-free 5 million unit (Pfizerpen-G)</i> | 4 | |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>pfizerpen-g injection recon soln 20 million unit</i> | 4 | |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram</i> | 2 | |
| <i>piperacillin-tazobactam intravenous recon soln 40.5 gram</i> | 4 | |
| Quinolones | | |
| BAXDELA ORAL TABLET 450 MG | 5 | PA; NM; NDS; QL (28 per 14 days) |
| <i>ciprofloxacin hcl oral tablet 100 mg</i> | 2 | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg (Cipro)</i> | 1 | |
| <i>ciprofloxacin hcl oral tablet 750 mg</i> | 1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ciprofloxacin oral suspension, microcapsule recon 250 mg/5 ml, 500 mg/5 ml</i> (Cipro) | 4 | |
| <i>levofloxacin in d5w intravenous piggyback 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml</i> | 2 | |
| <i>levofloxacin intravenous solution 25 mg/ml</i> | 4 | |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 4 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>moxifloxacin oral tablet 400 mg</i> | 4 | |
| Sulfonamides | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim intravenous solution 400-80 mg/5 ml</i> | 4 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> (Sulfatrim) | 4 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg</i> (Bactrim) | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 800-160 mg</i> (Bactrim DS) | 1 | |
| Tetracyclines | | |
| <i>demeclocycline oral tablet 150 mg, 300 mg</i> | 4 | |
| <i>doxy-100 intravenous recon soln 100 mg</i> | 2 | |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i> (Doxy-100) | 2 | |
| <i>doxycycline hyclate oral capsule 100 mg, 50 mg</i> (Morgidox) | 2 | |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 2 | |
| <i>doxycycline hyclate oral tablet, delayed release (drlec) 100 mg, 150 mg, 75 mg</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>doxycycline hyclate oral tablet, delayed release (drlec) 200 mg, 50 mg</i> (Doryx) | 4 | |
| <i>doxycycline monohydrate oral capsule 100 mg</i> (Mondoxyne NL) | 2 | |
| <i>doxycycline monohydrate oral capsule 150 mg</i> | 4 | |
| <i>doxycycline monohydrate oral capsule 50 mg</i> (Monodox) | 2 | |
| <i>doxycycline monohydrate oral capsule 75 mg</i> (Mondoxyne NL) | 4 | |
| <i>doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml</i> (Vibramycin) | 2 | |
| <i>doxycycline monohydrate oral tablet 100 mg</i> (Avidoxy) | 2 | |
| <i>doxycycline monohydrate oral tablet 150 mg, 75 mg</i> | 4 | |
| <i>doxycycline monohydrate oral tablet 50 mg</i> | 2 | |
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | |
| <i>minocycline oral tablet 100 mg, 50 mg, 75 mg</i> | 4 | |
| <i>mondoxyne nl oral capsule 100 mg</i> | 2 | |
| <i>mondoxyne nl oral capsule 75 mg</i> | 4 | |
| <i>okebo oral capsule 75 mg</i> | 4 | |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>tigecycline intravenous recon soln 50 mg</i> (Tygacil) | 5 | NM; NDS |
| Anticancer Agents | | |
| Anticancer Agents | | |
| ABRAXANE INTRAVENOUS SUSPENSION FOR RECONSTITUTION 100 MG | 5 | NM; NDS |
| ADCETRIS INTRAVENOUS RECON SOLN 50 MG | 5 | PA NSO; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| <i>adriamycin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml</i> | 2 | PA BvD |
| <i>adrucil intravenous solution 2.5 gram/50 ml, 500 mg/10 ml</i> | 2 | PA BvD |
| AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| AFINITOR ORAL TABLET 10 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| AFINITOR ORAL TABLET 2.5 MG, 5 MG, 7.5 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| ALIMTA INTRAVENOUS RECON SOLN 100 MG, 500 MG | 5 | NM; NDS |
| ALIQOPA INTRAVENOUS RECON SOLN 60 MG | 5 | PA NSO; NM; NDS; QL (3 per 28 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)- 180 MG (23) | 5 | PA NSO; NM; NDS |
| <i>anastrozole oral tablet 1 mg</i> (Arimidex) | 1 | |
| <i>arsenic trioxide intravenous solution 1 mg/ml</i> | 5 | NM; NDS |
| <i>arsenic trioxide intravenous solution 2 mg/ml</i> (Trisenox) | 5 | NM; NDS |
| AVASTIN INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>azacitidine injection recon soln 100 mg</i> (Vidaza) | 5 | NM; NDS |
| BALVERSA ORAL TABLET 3 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| BALVERSA ORAL TABLET 4 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| BAVENCIO INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS |
| BELEODAQ INTRAVENOUS RECON SOLN 500 MG | 5 | PA NSO; NM; NDS |
| BENDEKA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| BESPONSIA INTRAVENOUS RECON SOLN 0.9 MG (0.25 MG/ML INITIAL) | 5 | PA NSO; NM; NDS |
| <i>bexarotene oral capsule 75 mg</i> (Targretin) | 5 | PA NSO; NM; NDS; QL (420 per 30 days) |
| <i>bicalutamide oral tablet 50 mg</i> (Casodex) | 2 | |
| BLENREP INTRAVENOUS RECON SOLN 100 MG | 5 | PA NSO; NM; NDS |
| <i>bleomycin injection recon soln 15 unit, 30 unit</i> | 2 | |
| BLINCYTO INTRAVENOUS KIT 35 MCG | 5 | PA NSO; NM; NDS |
| BORTEZOMIB INTRAVENOUS RECON SOLN 3.5 MG | 5 | PA NSO; NM; NDS |
| BOSULIF ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| CAPRELSA ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>carboplatin intravenous solution 10 mg/ml</i> (Paraplatin) | 2 | |
| <i>cladribine intravenous solution 10 mg/10 ml</i> | 2 | PA BvD |
| <i>clofarabine intravenous solution 20 mg/20 ml</i> (Clolar) | 5 | NM; NDS |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 140 MG/DAY(80 MG X1-20 MG X3), 60 MG/DAY (20 MG X 3/DAY) | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA NSO; NM; LA; NDS; QL (63 per 28 days) |
| <i>cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg</i> | 5 | PA BvD; NM; NDS |
| <i>cyclophosphamide intravenous solution 200 mg/ml</i> | 5 | PA BvD; NM; NDS |
| CYCLOPHOSPHAMIDE ORAL CAPSULE 25 MG, 50 MG | 2 | PA BvD; ST |
| CYRAMZA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NM; NDS |
| DARZALEX FASPRO SUBCUTANEOUS SOLUTION 1,800 MG-30,000 UNIT/15 ML | 5 | PA NSO; NM; NDS |
| DARZALEX INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; LA; NDS |
| DAURISMO ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| <i>decitabine intravenous recon soln 50 mg</i> (Dacogen) | 5 | NM; NDS |
| <i>docetaxel intravenous solution 20 mg/2 ml (10 mg/ml), 20 mg/ml, 80 mg/8 ml (10 mg/ml)</i> | 5 | NM; NDS |
| <i>docetaxel intravenous solution 20 mg/ml (1 ml), 80 mg/4 ml (20 mg/ml)</i> (Taxotere) | 5 | NM; NDS |
| <i>doxorubicin intravenous solution 10 mg/5 ml, 2 mg/ml, 20 mg/10 ml, 50 mg/25 ml</i> (Adriamycin) | 2 | PA BvD |
| <i>doxorubicin, peg-liposomal intravenous suspension 2 mg/ml</i> (Doxil) | 5 | PA BvD; NM; NDS |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 4 | |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 4 | |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 4 | |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 4 | |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 4 | |
| EMCYT ORAL CAPSULE 140 MG | 5 | NM; NDS |
| EMPLICITI INTRAVENOUS RECON SOLN 300 MG, 400 MG | 5 | PA NSO; NM; NDS |
| ENHERTU INTRAVENOUS RECON SOLN 100 MG | 5 | PA NSO; NM; NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>erlotinib oral tablet 100 mg, 25 mg</i> (Tarceva) | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| <i>erlotinib oral tablet 150 mg</i> (Tarceva) | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG | 4 | |
| <i>etoposide intravenous solution 20 mg/ml</i> (Toposar) | 2 | |
| <i>exemestane oral tablet 25 mg</i> (Aromasin) | 4 | |
| FARYDAK ORAL CAPSULE 10 MG, 15 MG, 20 MG | 5 | PA NSO; NM; NDS |
| <i>floxuridine injection recon soln 0.5 gram</i> | 2 | PA BvD |
| <i>fluorouracil intravenous solution 1 gram/20 ml, 5 gram/100 ml, 500 mg/10 ml</i> | 2 | PA BvD |
| <i>flutamide oral capsule 125 mg</i> | 2 | |
| <i>fulvestrant intramuscular syringe 250 mg/5 ml</i> (Faslodex) | 5 | NM; NDS |
| GAVRETO ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| GAZYVA INTRAVENOUS SOLUTION 1,000 MG/40 ML | 5 | PA NSO; NM; NDS |
| <i>gemcitabine intravenous recon soln 1 gram, 200 mg</i> | 2 | |
| <i>gemcitabine intravenous recon soln 2 gram</i> | 5 | NM; NDS |
| <i>gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml), 200 mg/5.26 ml (38 mg/ml)</i> | 5 | NM; NDS |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| HERCEPTIN HYLECTA SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML | 5 | PA NSO; NM; NDS; QL (5 per 21 days) |
| HERCEPTIN INTRAVENOUS RECON SOLN 150 MG | 5 | PA NSO; NM; NDS |
| HERZUMA INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| <i>hydroxyurea oral capsule 500 mg</i> (Hydrea) | 2 | |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| ICLUSIG ORAL TABLET 15 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ICLUSIG ORAL TABLET 45 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>ifosfamide intravenous recon soln 1 gram</i> (Ifex) | 2 | |
| <i>ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml</i> | 2 | |
| <i>imatinib oral tablet 100 mg</i> (Gleevec) | 2 | PA NSO; QL (90 per 30 days) |
| <i>imatinib oral tablet 400 mg</i> (Gleevec) | 2 | PA NSO; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| IMFINZI INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS |
| IMLYGIC INJECTION SUSPENSION 10EXP6 (1 MILLION) PFU/ML | 5 | PA NSO; NM; NDS; QL (4 per 365 days) |
| IMLYGIC INJECTION SUSPENSION 10EXP8 (100 MILLION) PFU/ML | 5 | PA NSO; NM; NDS; QL (8 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|--|
| INFUGEM INTRAVENOUS PIGGYBACK 1,200 MG/120 ML (10 MG/ML), 1,300 MG/130 ML (10 MG/ML), 1,400 MG/140 ML (10 MG/ML), 1,500 MG/150 ML (10 MG/ML), 1,600 MG/160 ML (10 MG/ML), 1,700 MG/170 ML (10 MG/ML), 1,800 MG/180 ML (10 MG/ML), 1,900 MG/190 ML (10 MG/ML), 2,000 MG/200 ML (10 MG/ML), 2,200 MG/220 ML (10 MG/ML) | 5 | NM; NDS |
| INLYTA ORAL TABLET 1 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA NSO; NM; NDS; QL (5 per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| IRESSA ORAL TABLET 250 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>irinotecan intravenous solution 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml</i> (Camptosar) | 2 | |
| <i>irinotecan intravenous solution 500 mg/25 ml</i> | 2 | |
| IXEMPRA INTRAVENOUS RECON SOLN 15 MG, 45 MG | 5 | NM; NDS |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| KANJINTI INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |
| KEYTRUDA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS; QL (8 per 21 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 5 | PA NSO; NM; NDS; QL (49 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--|
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 5 | PA NSO; NM; NDS; QL (70 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 5 | PA NSO; NM; NDS; QL (91 per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 5 | PA NSO; NM; NDS; QL (42 per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 5 | PA NSO; NM; NDS; QL (63 per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| KYPROLIS INTRAVENOUS RECON SOLN 10 MG, 30 MG, 60 MG | 5 | PA NSO; NM; NDS |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2) | 5 | PA NSO; NM; NDS |
| <i>letrozole oral tablet 2.5 mg</i> (Femara) | 1 | |
| LEUKERAN ORAL TABLET 2 MG | 4 | |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 5 | NM; NDS |
| LIBTAYO INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS; QL (7 per 21 days) |
| LONSURF ORAL TABLET 15- 6.14 MG | 5 | PA NSO; NM; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20- 8.19 MG | 5 | PA NSO; NM; NDS; QL (80 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| LORBRENA ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| LUMOXITI INTRAVENOUS RECON SOLN 1 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | 5 | NM; NDS |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 5 | NM; NDS |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | NM; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG | 5 | NM; NDS |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5 | NM; NDS |
| MARQIBO INTRAVENOUS KIT 5 MG/31 ML(0.16 MG/ML) FINAL | 5 | PA NSO; NM; NDS |
| MATULANE ORAL CAPSULE 50 MG | 5 | NM; NDS |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 2 | |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>melphalan hcl intravenous recon soln (Alkeran (as HCl)) 50 mg</i> | 5 | NM; NDS |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| <i>methotrexate sodium (pf) injection recon soln 1 gram</i> | 2 | PA BvD |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 2 | PA BvD |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 2 | PA BvD |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | PA BvD; ST |
| <i>mitoxantrone intravenous concentrate 2 mg/ml</i> | 2 | |
| MONJUVI INTRAVENOUS RECON SOLN 200 MG | 5 | PA NSO; NM; NDS |
| MVASI INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| MYLOTARG INTRAVENOUS RECON SOLN 4.5 MG (1 MG/ML INITIAL CONC) | 5 | PA NSO; NM; NDS |
| NERLYNX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| NEXAVAR ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> (Nilandron) | 5 | NM; NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA NSO; NM; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA NSO; NM; LA; NDS |
| OGIVRI INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |
| ONCASPAR INJECTION SOLUTION 750 UNIT/ML | 5 | PA NSO; NM; NDS |
| ONIVYDE INTRAVENOUS DISPERSION 4.3 MG/ML | 5 | NM; NDS |
| ONTRUZANT INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |
| ONUREG ORAL TABLET 200 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (14 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10 ML, 240 MG/24 ML, 40 MG/4 ML | 5 | PA NSO; NM; NDS |
| <i>oxaliplatin intravenous recon soln 100 mg, 50 mg</i> | 2 | |
| <i>oxaliplatin intravenous solution 100 mg/20 ml, 50 mg/10 ml (5 mg/ml)</i> | 2 | |
| <i>paclitaxel intravenous concentrate 6 mg/ml</i> | 2 | PA BvD |
| PADCEV INTRAVENOUS RECON SOLN 20 MG, 30 MG | 5 | PA NSO; NM; NDS |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA NSO; NM; NDS; QL (14 per 21 days) |
| PERJETA INTRAVENOUS SOLUTION 420 MG/14 ML (30 MG/ML) | 5 | PA NSO; NM; NDS |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| POLIVY INTRAVENOUS RECON SOLN 140 MG | 5 | PA NSO; NM; NDS |
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| PORTRAZZA INTRAVENOUS SOLUTION 800 MG/50 ML (16 MG/ML) | 5 | PA NSO; NM; NDS; QL (100 per 21 days) |
| PROLEUKIN INTRAVENOUS RECON SOLN 22 MILLION UNIT | 5 | NM; NDS |
| PURIXAN ORAL SUSPENSION 20 MG/ML | 5 | NM; NDS |
| QINLOCK ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| REVLIMID ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 20 MG, 25 MG, 5 MG | 5 | PA NSO; NM; LA; NDS; QL (28 per 28 days) |
| RITUXAN HYCELA SUBCUTANEOUS SOLUTION 1400 MG/11.7 ML (120 MG/ML), 1600 MG/13.4 ML (120 MG/ML) | 5 | PA NSO; NM; NDS |
| RITUXAN INTRAVENOUS CONCENTRATE 10 MG/ML | 5 | PA NSO; NM; NDS |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| RUXIENCE INTRAVENOUS CONCENTRATE 10 MG/ML | 5 | PA NSO; NM; NDS |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| SARCLISA INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 5 | NM; NDS |
| SPRYCEL ORAL TABLET 100 MG, 140 MG, 50 MG, 70 MG, 80 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| SPRYCEL ORAL TABLET 20 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| SUTENT ORAL CAPSULE 12.5 MG, 25 MG, 37.5 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG | 5 | PA NSO; NM; NDS |
| SYLVANT INTRAVENOUS RECON SOLN 100 MG, 400 MG | 5 | PA NSO; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| SYNRIBO SUBCUTANEOUS RECON SOLN 3.5 MG | 5 | PA NSO; NM; NDS |
| TABLOID ORAL TABLET 40 MG | 4 | |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TAGRISSE ORAL TABLET 40 MG, 80 MG | 5 | PA NSO; NM; LA; NDS; QL (30 per 30 days) |
| TALZENNA ORAL CAPSULE 0.25 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| TALZENNA ORAL CAPSULE 1 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 2 | |
| TARGRETIN TOPICAL GEL 1 % | 5 | PA NSO; NM; NDS; QL (60 per 28 days) |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| TECENTRIQ INTRAVENOUS SOLUTION 1,200 MG/20 ML (60 MG/ML), 840 MG/14 ML (60 MG/ML) | 5 | PA NSO; NM; NDS |
| TEMODAR INTRAVENOUS RECON SOLN 100 MG | 5 | PA NSO; NM; NDS |
| <i>temsirolimus intravenous recon soln (Torisel) 30 mg/3 ml (10 mg/ml) (first)</i> | 5 | PA BvD; NM; NDS; QL (4 per 28 days) |
| <i>thiotepa injection recon soln 100 mg, 15 mg</i> (Tepadina) | 5 | NM; NDS |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION 50 MG | 4 | |
| <i>toposar intravenous solution 20 mg/ml</i> | 2 | |
| <i>topotecan intravenous recon soln 4 mg</i> (Hycamtin) | 5 | NM; NDS |
| <i>topotecan intravenous solution 4 mg/4 ml (1 mg/ml)</i> | 5 | NM; NDS |
| <i>toremifene oral tablet 60 mg</i> (Fareston) | 5 | NM; NDS |
| TRAZIMERA INTRAVENOUS RECON SOLN 420 MG | 5 | PA NSO; NM; NDS |
| TREANDA INTRAVENOUS RECON SOLN 100 MG, 25 MG | 5 | PA NSO; NM; NDS |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG | 5 | NM; NDS; QL (1 per 84 days) |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG | 5 | NM; NDS; QL (1 per 168 days) |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 3.75 MG | 5 | NM; NDS; QL (1 per 28 days) |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | 5 | NM; NDS |
| TRODELVY INTRAVENOUS RECON SOLN 180 MG | 5 | PA NSO; NM; NDS |
| TRUXIMA INTRAVENOUS CONCENTRATE 10 MG/ML | 5 | PA NSO; NM; NDS |
| TUKYSA ORAL TABLET 150 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| TURALIO ORAL CAPSULE 200 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---|
| TYKERB ORAL TABLET 250 MG | 5 | PA NSO; NM; NDS |
| UNITUXIN INTRAVENOUS SOLUTION 3.5 MG/ML | 5 | PA NSO; NM; NDS |
| <i>valrubicin intravesical solution 40 mg/ml</i> (Valstar) | 5 | NM; NDS |
| VECTIBIX INTRAVENOUS SOLUTION 100 MG/5 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML) | 5 | PA NSO; NM; NDS |
| VELCADE INJECTION RECON SOLN 3.5 MG | 5 | PA NSO; NM; NDS |
| VENCLEXTA ORAL TABLET 10 MG | 3 | PA NSO; LA; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA NSO; NM; LA; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 3 | PA NSO; LA; QL (30 per 30 days) |
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 5 | PA NSO; NM; LA; NDS |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| <i>vinblastine intravenous solution 1 mg/ml</i> | 2 | PA BvD |
| <i>vincasar pfs intravenous solution 1 mg/ml, 2 mg/2 ml</i> | 2 | PA BvD |
| <i>vincristine intravenous solution 1 mg/ml, 2 mg/2 ml</i> (Vincasar PFS) | 2 | PA BvD |
| <i>vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml</i> (Navelbine) | 2 | |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| VOTRIENT ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| VYXEOS INTRAVENOUS RECON SOLN 44-100 MG | 5 | PA BvD; NM; NDS |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | PA BvD; ST |
| XOSPATA ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (20 MG X 5) | 5 | PA NSO; NM; NDS; QL (20 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (20 MG X 2) | 5 | PA NSO; NM; NDS; QL (8 per 28 days) |
| XPOVIO ORAL TABLET 40MG TWICE WEEK (80 MG/WEEK), 80 MG/WEEK (20 MG X 4) | 5 | PA NSO; NM; NDS; QL (16 per 28 days) |
| XPOVIO ORAL TABLET 60 MG/WEEK (20 MG X 3) | 5 | PA NSO; NM; NDS; QL (12 per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 5 | PA NSO; NM; NDS; QL (24 per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 5 | PA NSO; NM; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) | 5 | PA NSO; NM; NDS |
| YONDELIS INTRAVENOUS RECON SOLN 1 MG | 5 | PA NSO; NM; NDS |
| YONSA ORAL TABLET 125 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| ZALTRAP INTRAVENOUS SOLUTION 100 MG/4 ML (25 MG/ML), 200 MG/8 ML (25 MG/ML) | 5 | PA NSO; NM; NDS |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| ZEPZELCA INTRAVENOUS RECON SOLN 4 MG | 5 | PA NSO; NM; NDS |
| ZIRABEV INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG | 4 | QL (1 per 84 days) |
| ZOLADEX SUBCUTANEOUS IMPLANT 3.6 MG | 4 | QL (1 per 28 days) |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | NM; NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| ZYTIGA ORAL TABLET 250 MG, 500 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| Anticonvulsants | | |
| Anticonvulsants | | |
| APTIOM ORAL TABLET 200 MG, 400 MG | 5 | NM; NDS; QL (30 per 30 days) |
| APTIOM ORAL TABLET 600 MG, 800 MG | 5 | NM; NDS; QL (60 per 30 days) |
| BANZEL ORAL SUSPENSION 40 MG/ML | 5 | NM; NDS |
| BANZEL ORAL TABLET 200 MG, 400 MG | 5 | NM; NDS |
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5 ML | 4 | QL (80 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 5 | NM; NDS; QL (600 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 5 | NM; NDS; QL (60 per 30 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> (Carbatrol) | 2 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> (Tegretol) | 2 | |
| <i>carbamazepine oral tablet 200 mg</i> (Epitol) | 2 | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> (Tegretol XR) | 2 | |
| <i>carbamazepine oral tablet, chewable 100 mg</i> | 2 | |
| CELONTIN ORAL CAPSULE 300 MG | 4 | |
| <i>clobazam oral suspension 2.5 mg/ml</i> (Onfi) | 4 | PA NSO; QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> (Onfi) | 4 | PA NSO; QL (60 per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 5-7.5-10 mg</i> (Diastat AcuDial) | 4 | |
| <i>diazepam rectal kit 2.5 mg</i> (Diastat) | 4 | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> (Depakote Sprinkles) | 2 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> (Depakote ER) | 2 | |
| <i>divalproex oral tablet, delayed release (drlec) 125 mg, 250 mg, 500 mg</i> (Depakote) | 2 | |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 5 | PA NSO; NM; NDS |
| <i>epitol oral tablet 200 mg</i> | 2 | |
| <i>ethosuximide oral capsule 250 mg</i> (Zarontin) | 2 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> (Zarontin) | 2 | |
| <i>felbamate oral suspension 600 mg/5 ml</i> (Felbatol) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>felbamate oral tablet 400 mg, 600 mg</i> (Felbatol) | 4 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 5 | PA NSO; NM; NDS |
| <i>fosphenytoin injection solution 100 mg per 2 ml, 500 mg per 10 ml</i> (Cerebyx) | 2 | |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | 5 | NM; NDS; QL (720 per 30 days) |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 8 MG | 5 | NM; NDS; QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 2 MG | 4 | QL (30 per 30 days) |
| FYCOMPA ORAL TABLET 4 MG, 6 MG | 5 | NM; NDS; QL (60 per 30 days) |
| <i>gabapentin oral capsule 100 mg, 300 mg</i> (Neurontin) | 1 | QL (360 per 30 days) |
| <i>gabapentin oral capsule 400 mg</i> (Neurontin) | 1 | QL (270 per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> (Neurontin) | 2 | QL (2160 per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> (Neurontin) | 2 | QL (180 per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> (Neurontin) | 2 | QL (120 per 30 days) |
| GRALISE 30-DAY STARTER PACK ORAL TABLET EXTENDED RELEASE 24 HR 300 MG (9)- 600 MG (69) | 4 | ST |
| GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 600 MG | 4 | ST; QL (90 per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> (Subvenite) | 1 | |
| <i>lamotrigine oral tablet disintegrating, dose pk 25 mg (21) - 50 mg (7)</i> (Lamictal ODT Starter (Blue)) | 4 | |
| <i>lamotrigine oral tablet disintegrating, dose pk 25 mg (14)- 50 mg (14)-100 mg (7)</i> (Lamictal ODT Starter (Orange)) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>lamotrigine oral tablet disintegrating, dose pk 50 mg (42) - 100 mg (14)</i> (Lamictal ODT Starter (Green)) | 4 | |
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 250 mg, 300 mg, 50 mg</i> (Lamictal XR) | 4 | |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> (Lamictal) | 2 | |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> (Lamictal ODT) | 4 | |
| <i>levetiracetam intravenous solution 500 mg/5 ml</i> (Keppra) | 2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> (Keppra) | 2 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> (Keppra) | 2 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> (Keppra XR) | 2 | |
| NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML) | 4 | QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> (Trileptal) | 4 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> (Trileptal) | 2 | |
| OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 150 MG, 300 MG | 4 | |
| OXTELLAR XR ORAL TABLET EXTENDED RELEASE 24 HR 600 MG | 5 | NM; NDS |
| PEGANONE ORAL TABLET 250 MG | 4 | |
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 2 | |
| <i>phenytoin oral suspension 125 mg/5 ml</i> (Dilantin-125) | 2 | |
| <i>phenytoin oral tablet, chewable 50 mg</i> (Dilantin Infatabs) | 2 | |
| <i>phenytoin sodium extended oral capsule 100 mg</i> (Dilantin Extended) | 2 | |
| <i>phenytoin sodium extended oral capsule 200 mg, 300 mg</i> (Phenytek) | 2 | |
| <i>phenytoin sodium intravenous solution 50 mg/ml</i> | 2 | |
| <i>phenytoin sodium intravenous syringe 50 mg/ml</i> | 2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg</i> (Lyrica) | 2 | QL (90 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> (Lyrica) | 4 | QL (900 per 30 days) |
| <i>primidone oral tablet 250 mg, 50 mg</i> (Mysoline) | 2 | |
| SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG | 4 | QL (60 per 30 days) |
| SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG, 750 MG | 4 | QL (120 per 30 days) |
| <i>subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | 1 | |
| SYMPAZAN ORAL FILM 10 MG, 20 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| SYMPAZAN ORAL FILM 5 MG | 4 | PA NSO; QL (60 per 30 days) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> (Gabitril) | 4 | |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> (Topamax) | 2 | |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> (Topamax) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | 2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | 2 | |
| <i>valproic acid oral capsule 250 mg</i> | 2 | |
| VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) | 4 | |
| <i>vigabatrin oral powder in packet 500 mg</i> (Vigadrone) | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> (Sabril) | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigadrone oral powder in packet 500 mg</i> | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| VIMPAT INTRAVENOUS SOLUTION 200 MG/20 ML | 3 | QL (200 per 5 days) |
| VIMPAT ORAL SOLUTION 10 MG/ML | 3 | QL (1200 per 30 days) |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 3 | QL (60 per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 350 MG/DAY (200 MG X1- 150MG X1) | 4 | QL (56 per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 50 MG | 4 | QL (30 per 30 days) |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 4 | QL (60 per 30 days) |
| XCOPRI TITRATION PACK ORAL TABLETS, DOSE PACK 12.5 MG (14)- 25 MG (14), 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|--------------------------|
| <i>zonisamide oral capsule 100 mg, 25 mg</i> (Zonegran) | 2 | |
| <i>zonisamide oral capsule 50 mg</i> | 2 | |
| Antidementia Agents | | |
| Antidementia Agents | | |
| <i>donepezil oral tablet 10 mg, 5 mg</i> (Aricept) | 2 | QL (30 per 30 days) |
| <i>donepezil oral tablet 23 mg</i> (Aricept) | 4 | QL (30 per 30 days) |
| <i>donepezil oral tablet, disintegrating 10 mg, 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>ergoloid oral tablet 1 mg</i> | 4 | |
| <i>galantamine oral capsule, ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> (Razadyne ER) | 2 | QL (30 per 30 days) |
| <i>galantamine oral solution 4 mg/ml</i> | 4 | QL (200 per 30 days) |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> (Razadyne) | 2 | QL (60 per 30 days) |
| <i>memantine oral capsule, sprinkle, er 24hr 14 mg, 21 mg, 28 mg, 7 mg</i> (Namenda XR) | 4 | PA; QL (30 per 30 days) |
| <i>memantine oral solution 2 mg/ml</i> | 4 | PA; QL (360 per 30 days) |
| <i>memantine oral tablet 10 mg, 5 mg</i> (Namenda) | 2 | PA; QL (60 per 30 days) |
| NAMZARIC ORAL CAP, SPRINKLE, ER 24HR DOSE PACK 7/14/21/28 MG-10 MG | 3 | ST |
| NAMZARIC ORAL CAPSULE, SPRINKLE, ER 24HR 14-10 MG, 21-10 MG, 28-10 MG, 7-10 MG | 3 | ST; QL (30 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | QL (60 per 30 days) |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hr, 9.5 mg/24 hr</i> (Exelon) | 4 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-------------------------|
| Antidepressants | | |
| Antidepressants | | |
| amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 2 | |
| amitriptyline-chlordiazepoxide oral tablet 12.5-5 mg, 25-10 mg | 2 | |
| amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg | 4 | |
| bupropion hcl oral tablet 100 mg, 75 mg | 2 | |
| bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg (Wellbutrin XL) | 2 | |
| bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg (Wellbutrin SR) | 2 | |
| citalopram oral solution 10 mg/5 ml | 2 | QL (600 per 30 days) |
| citalopram oral tablet 10 mg, 20 mg, 40 mg (Celexa) | 1 | QL (30 per 30 days) |
| clomipramine oral capsule 25 mg, 50 mg, 75 mg (Anafranil) | 4 | |
| desipramine oral tablet 10 mg, 25 mg (Norpramin) | 4 | |
| desipramine oral tablet 100 mg, 150 mg, 50 mg, 75 mg | 4 | |
| desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg (Pristiq) | 4 | QL (30 per 30 days) |
| doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 2 | |
| doxepin oral concentrate 10 mg/ml | 1 | |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 60 MG | 4 | ST; QL (60 per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG | 4 | ST; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>duloxetine oral capsule, delayed release(drlec) 20 mg, 30 mg, 60 mg</i> (Cymbalta) | 2 | QL (60 per 30 days) |
| <i>duloxetine oral capsule, delayed release(drlec) 40 mg</i> | 4 | QL (30 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i> | 2 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> (Lexapro) | 1 | |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) | 4 | ST |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 4 | ST; QL (30 per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg, 40 mg</i> (Prozac) | 1 | |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 4 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg</i> | 4 | |
| <i>maprotiline oral tablet 25 mg, 50 mg, 75 mg</i> | 2 | |
| MARPLAN ORAL TABLET 10 MG | 4 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg</i> (Remeron) | 2 | |
| <i>mirtazapine oral tablet 45 mg, 7.5 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>mirtazapine oral</i> (Remeron SolTab) <i>tablet, disintegrating 15 mg, 30 mg,</i> <i>45 mg</i> | 2 | |
| <i>nefazodone oral tablet 100 mg, 150</i> <i>mg, 200 mg, 250 mg, 50 mg</i> | 4 | |
| <i>nortriptyline oral capsule 10 mg, 25</i> (Pamelor) <i>mg, 50 mg, 75 mg</i> | 1 | |
| <i>nortriptyline oral solution 10 mg/5</i> <i>ml</i> | 4 | |
| <i>paroxetine hcl oral tablet 10 mg, 20</i> (Paxil) <i>mg, 30 mg, 40 mg</i> | 1 | |
| <i>paroxetine hcl oral tablet extended</i> (Paxil CR) <i>release 24 hr 12.5 mg, 25 mg, 37.5</i> <i>mg</i> | 4 | |
| PAXIL ORAL SUSPENSION 10 MG/5 ML | 4 | |
| <i>perphenazine-amitriptyline oral</i> <i>tablet 2-10 mg, 2-25 mg, 4-10 mg, 4-</i> <i>25 mg, 4-50 mg</i> | 2 | |
| <i>phenelzine oral tablet 15 mg</i> (Nardil) | 2 | |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 4 | |
| <i>sertraline oral concentrate 20 mg/ml</i> (Zoloft) | 2 | |
| <i>sertraline oral tablet 100 mg, 25 mg,</i> (Zoloft) <i>50 mg</i> | 1 | |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 56 MG (28 MG X 2), 84 MG (28 MG X 3) | 5 | PA NSO; NM; NDS |
| <i>tranylcypromine oral tablet 10 mg</i> (Parnate) | 4 | |
| <i>trazodone oral tablet 100 mg, 150</i> <i>mg, 50 mg</i> | 1 | |
| <i>trazodone oral tablet 300 mg</i> | 4 | |
| <i>trimipramine oral capsule 100 mg,</i> <i>25 mg, 50 mg</i> | 4 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended</i> (Effexor XR) <i>release 24hr 150 mg</i> | 2 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>venlafaxine oral capsule,extended release 24hr 37.5 mg, 75 mg</i> (Effexor XR) | 2 | QL (90 per 30 days) |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | |
| <i>venlafaxine oral tablet extended release 24hr 150 mg, 37.5 mg</i> | 4 | QL (30 per 30 days) |
| <i>venlafaxine oral tablet extended release 24hr 75 mg</i> | 4 | QL (90 per 30 days) |
| VIIBRYD ORAL TABLET 10 MG, 20 MG, 40 MG | 3 | QL (30 per 30 days) |
| VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)- 20 MG (23) | 3 | |
| ZULRESSO INTRAVENOUS SOLUTION 5 MG/ML | 5 | NM; NDS |
| Antidiabetic Agents | | |
| Antidiabetic Agents, Miscellaneous | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> (Precose) | 2 | QL (90 per 30 days) |
| FARXIGA ORAL TABLET 10 MG, 5 MG | 3 | QL (30 per 30 days) |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG | 3 | QL (30 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG | 4 | ST; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 4 | ST; QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 4 | ST; QL (30 per 30 days) |
| KORLYM ORAL TABLET 300 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| <i>metformin oral solution 500 mg/5 ml</i> (Riomet) | 4 | QL (765 per 30 days) |
| <i>metformin oral tablet 1,000 mg</i> (Glucophage) | 6 | QL (75 per 30 days) |
| <i>metformin oral tablet 500 mg</i> (Glucophage) | 6 | QL (150 per 30 days) |
| <i>metformin oral tablet 850 mg</i> (Glucophage) | 6 | QL (90 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> (Glucophage XR) | 6 | QL (120 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> (Glucophage XR) | 6 | QL (60 per 30 days) |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> (Glyset) | 4 | QL (90 per 30 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> (Starlix) | 2 | QL (90 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (2 MG/1.5 ML) | 3 | QL (3 per 28 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> (Actos) | 6 | QL (30 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg</i> | 6 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 1 mg</i> (Prandin) | 6 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> (Prandin) | 6 | QL (240 per 30 days) |
| <i>repaglinide-metformin oral tablet 1- 500 mg, 2-500 mg</i> | 4 | QL (150 per 30 days) |
| RYBELSUS ORAL TABLET 14 MG, 3 MG, 7 MG | 3 | QL (30 per 30 days) |
| SYMLINPEN 120 SUBCUTANEOUS PEN INJECTOR 2,700 MCG/2.7 ML | 5 | PA; NM; NDS; QL (10.8 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| SYMLINPEN 60 SUBCUTANEOUS PEN INJECTOR 1,500 MCG/1.5 ML | 5 | PA; NM; NDS; QL (10.8 per 28 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5- 1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 3 | QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG | 3 | QL (60 per 30 days) |
| TRADJENTA ORAL TABLET 5 MG | 4 | ST; QL (30 per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 3 | QL (2 per 28 days) |
| VICTOZA SUBCUTANEOUS PEN INJECTOR 0.6 MG/0.1 ML (18 MG/3 ML) | 3 | QL (9 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10- 1,000 MG, 10-500 MG | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5- 1,000 MG, 5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| Insulins | | |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 6 | QL (30 per 28 days) |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 6 | QL (30 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 6 | QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 6 | QL (24 per 28 days) |
| LANTUS SOLOSTAR U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 6 | QL (30 per 28 days) |
| LANTUS U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | QL (40 per 28 days) |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70- 30) | 6 | QL (40 per 28 days) |
| NOVOLIN 70-30 FLEXPEN U- 100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 6 | QL (30 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 6 | QL (30 per 28 days) |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 6 | QL (40 per 28 days) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 6 | QL (30 per 28 days) |
| NOVOLIN R REGULAR U-100 INSULIN INJECTION SOLUTION 100 UNIT/ML | 6 | QL (40 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| NOVOLOG FLEXPEN U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 6 | QL (30 per 28 days) |
| NOVOLOG MIX 70-30 U-100 INSULN SUBCUTANEOUS SOLUTION 100 UNIT/ML (70- 30) | 6 | QL (40 per 28 days) |
| NOVOLOG MIX 70- 30FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 6 | QL (30 per 28 days) |
| NOVOLOG PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML | 6 | QL (30 per 28 days) |
| NOVOLOG U-100 INSULIN ASPART SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | QL (40 per 28 days) |
| SOLIQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | 3 | QL (30 per 30 days) |
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) | 6 | QL (18 per 28 days) |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) | 6 | QL (13.5 per 28 days) |
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | 3 | QL (15 per 28 days) |
| Sulfonylureas | | |
| <i>glimepiride oral tablet 1 mg, 2 mg</i> (Amaryl) | 6 | QL (30 per 30 days) |
| <i>glimepiride oral tablet 4 mg</i> (Amaryl) | 6 | QL (60 per 30 days) |
| <i>glipizide oral tablet 10 mg</i> (Glucotrol) | 6 | QL (120 per 30 days) |
| <i>glipizide oral tablet 5 mg</i> (Glucotrol) | 6 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>glipizide oral tablet extended release</i> (Glucotrol XL) 24hr 10 mg | 6 | QL (60 per 30 days) |
| <i>glipizide oral tablet extended release</i> (Glucotrol XL) 24hr 2.5 mg, 5 mg | 6 | QL (30 per 30 days) |
| <i>glipizide-metformin oral tablet 2.5-</i> <i>250 mg</i> | 6 | QL (240 per 30 days) |
| <i>glipizide-metformin oral tablet 2.5-</i> <i>500 mg, 5-500 mg</i> | 6 | QL (120 per 30 days) |
| <i>glyburide micronized oral tablet 1.5</i> (Glynase) <i>mg, 3 mg, 6 mg</i> | 6 | |
| <i>glyburide oral tablet 1.25 mg, 2.5</i> <i>mg, 5 mg</i> | 6 | |
| <i>glyburide-metformin oral tablet</i> <i>1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 6 | |
| Antifungals | | |
| Antifungals | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | PA BvD |
| AMBISOME INTRAVENOUS SUSPENSION FOR RECONSTITUTION 50 MG | 5 | PA BvD; NM; NDS |
| <i>amphotericin b injection recon soln</i> <i>50 mg</i> | 2 | PA BvD |
| <i>caspofungin intravenous recon soln</i> (Cancidas) <i>50 mg, 70 mg</i> | 5 | NM; NDS |
| <i>ciclopirox topical cream 0.77 %</i> (Ciclodan) | 2 | QL (180 per 30 days) |
| <i>ciclopirox topical gel 0.77 %</i> | 4 | QL (300 per 30 days) |
| <i>ciclopirox topical shampoo 1 %</i> (Loprox) | 4 | |
| <i>ciclopirox topical solution 8 %</i> (Ciclodan) | 2 | QL (19.8 per 30 days) |
| <i>ciclopirox topical suspension 0.77 %</i> (Loprox (as olamine)) | 4 | QL (180 per 30 days) |
| <i>clotrimazole mucous membrane</i> <i>troche 10 mg</i> | 2 | |
| <i>clotrimazole topical cream 1 %</i> (Antifungal (clotrimazole)) | 1 | |
| <i>clotrimazole topical solution 1 %</i> | 2 | |
| <i>clotrimazole-betamethasone topical</i> <i>cream 1-0.05 %</i> | 2 | QL (90 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>clotrimazole-betamethasone topical lotion 1-0.05 %</i> | 4 | QL (90 per 30 days) |
| <i>econazole topical cream 1 %</i> | 4 | QL (170 per 30 days) |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 100 mg/50 ml, 200 mg/100 ml, 400 mg/200 ml</i> | 2 | PA BvD |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml, 40 mg/ml</i> (Diflucan) | 4 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> (Diflucan) | 2 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> (Ancobon) | 5 | NM; NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 4 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 4 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 250 mg</i> | 4 | |
| <i>itraconazole oral capsule 100 mg</i> (Sporanox) | 2 | |
| <i>itraconazole oral solution 10 mg/ml</i> (Sporanox) | 5 | NM; NDS |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | |
| <i>ketoconazole topical cream 2 %</i> | 2 | QL (180 per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> (Nizoral) | 2 | QL (360 per 30 days) |
| <i>miconazole-3 vaginal suppository 200 mg</i> | 2 | |
| NOXAFIL INTRAVENOUS SOLUTION 300 MG/16.7 ML | 5 | NM; NDS |
| NOXAFIL ORAL SUSPENSION 200 MG/5 ML (40 MG/ML) | 5 | NM; NDS |
| <i>nyamyc topical powder 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin oral suspension 100,000 unit/ml</i> | 2 | QL (900 per 30 days) |
| <i>nystatin oral tablet 500,000 unit</i> | 2 | |
| <i>nystatin topical cream 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>nystatin topical ointment 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin topical powder 100,000 unit/gram</i> (Nyamyc) | 2 | QL (60 per 30 days) |
| <i>nystatin-triamcinolone topical cream 100,000-0.1 unit/g-%</i> | 4 | |
| <i>nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-%</i> | 4 | |
| <i>nystop topical powder 100,000 unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>posaconazole oral tablet, delayed release (drlec) 100 mg</i> (Noxafil) | 5 | NM; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | |
| <i>voriconazole intravenous recon soln 200 mg</i> (Vfend IV) | 5 | PA BvD; NM; NDS |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> (Vfend) | 5 | NM; NDS |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> (Vfend) | 2 | |
| Antigout Agents | | |
| Antigout Agents, Other | | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> (Zyloprim) | 1 | |
| <i>colchicine oral tablet 0.6 mg</i> (Colcrys) | 4 | PA; QL (120 per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> (Uloric) | 2 | ST; QL (30 per 30 days) |
| MITIGARE ORAL CAPSULE 0.6 MG | 2 | QL (60 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 2 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | 2 | |
| Antihistamines | | |
| Antihistamines | | |
| <i>carbinoxamine maleate oral liquid 4 mg/5 ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>carbinoxamine maleate oral tablet 4 mg</i> | 2 | |
| <i>clemastine oral tablet 2.68 mg</i> | 2 | |
| <i>cyproheptadine oral syrup 2 mg/5 ml</i> | 2 | |
| <i>cyproheptadine oral tablet 4 mg</i> | 2 | |
| <i>diphenhydramine hcl injection solution 50 mg/ml</i> | 2 | |
| <i>diphenhydramine hcl injection syringe 50 mg/ml</i> | 4 | |
| <i>diphenhydramine hcl oral elixir 12.5 mg/5 ml</i> (Diphen) | 2 | |
| <i>hydroxyzine hcl intramuscular solution 25 mg/ml, 50 mg/ml</i> | 2 | |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | 2 | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> (Xyzal) | 4 | |
| <i>levocetirizine oral tablet 5 mg</i> (24HR Allergy Relief) | 1 | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | 1 | |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| Anti-Infectives (Skin And Mucous Membrane) | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> (Cleocin) | 2 | |
| <i>metronidazole vaginal gel 0.75 %</i> (Metrogel Vaginal) | 2 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | |
| <i>terconazole vaginal suppository 80 mg</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------|
| Antimigraine Agents | | |
| Antimigraine Agents | | |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 140 MG/ML, 70 MG/ML | 3 | PA; QL (1 per 30 days) |
| AJOVY AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 225 MG/1.5 ML | 3 | PA; QL (1.5 per 30 days) |
| AJOVY SYRINGE SUBCUTANEOUS SYRINGE 225 MG/1.5 ML | 3 | PA; QL (1.5 per 30 days) |
| <i>dihydroergotamine injection solution</i> (D.H.E.45) <i>1 mg/ml</i> | 5 | NM; NDS; QL (24 per 28 days) |
| <i>dihydroergotamine nasal spray,non- aerosol 0.5 mg/pump act. (4 mg/ml)</i> | 5 | NM; NDS; QL (8 per 28 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | 3 | PA; QL (3 per 30 days) |
| ERGOMAR SUBLINGUAL TABLET 2 MG | 5 | NM; NDS; QL (20 per 28 days) |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> (Amerge) | 4 | QL (9 per 30 days) |
| <i>rizatriptan oral tablet 10 mg</i> (Maxalt) | 2 | QL (12 per 30 days) |
| <i>rizatriptan oral tablet 5 mg</i> | 2 | QL (12 per 30 days) |
| <i>rizatriptan oral tablet,disintegrating</i> (Maxalt-MLT) <i>10 mg</i> | 2 | QL (12 per 30 days) |
| <i>rizatriptan oral tablet,disintegrating</i> <i>5 mg</i> | 2 | QL (12 per 30 days) |
| <i>sumatriptan nasal spray,non-aerosol</i> (Imitrex) <i>20 mg/actuation</i> | 4 | QL (12 per 30 days) |
| <i>sumatriptan nasal spray,non-aerosol</i> (Imitrex) <i>5 mg/actuation</i> | 4 | QL (18 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>sumatriptan succinate oral tablet 100 mg</i> (Imitrex) | 2 | QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> (Imitrex) | 2 | QL (18 per 30 days) |
| <i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i> (Imitrex STATdose Refill) | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml, 6 mg/0.5 ml</i> (Imitrex STATdose Pen) | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> (Imitrex) | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous syringe 6 mg/0.5 ml</i> | 4 | QL (4 per 28 days) |
| VYEPTI INTRAVENOUS SOLUTION 100 MG/ML | 4 | PA; QL (1 per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> (Zomig) | 4 | QL (6 per 30 days) |
| <i>zolmitriptan oral tablet, disintegrating 2.5 mg, 5 mg</i> (Zomig ZMT) | 4 | QL (6 per 30 days) |
| Antimycobacterials | | |
| Antimycobacterials | | |
| CAPASTAT INJECTION RECON SOLN 1 GRAM | 4 | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | |
| <i>ethambutol oral tablet 100 mg</i> | 2 | |
| <i>ethambutol oral tablet 400 mg</i> (Myambutol) | 2 | |
| <i>isoniazid oral solution 50 mg/5 ml</i> | 2 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | |
| PRETOMANID ORAL TABLET 200 MG | 4 | QL (30 per 30 days) |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| <i>pyrazinamide oral tablet 500 mg</i> | 2 | |
| <i>rifabutin oral capsule 150 mg</i> (Mycobutin) | 4 | |
| <i>rifampin intravenous recon soln 600 mg</i> (Rifadin) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------|
| <i>rifampin oral capsule 150 mg, 300 mg</i> (Rifadin) | 2 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | PA; NM; NDS |
| TRECTOR ORAL TABLET 250 MG | 4 | |
| Antinausea Agents | | |
| Antinausea Agents | | |
| AKYNZEO (FOSNETUPITANT) INTRAVENOUS RECON SOLN 235-0.25 MG | 4 | |
| AKYNZEO (FOSNETUPITANT) INTRAVENOUS SOLUTION 235 MG-0.25 MG /20 ML | 4 | |
| AKYNZEO (NETUPITANT) ORAL CAPSULE 300-0.5 MG | 4 | PA BvD |
| <i>aprepitant oral capsule 125 mg</i> | 4 | PA BvD; QL (2 per 28 days) |
| <i>aprepitant oral capsule 40 mg</i> (Emend) | 4 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 mg</i> (Emend) | 4 | PA BvD; QL (4 per 28 days) |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> (Emend) | 4 | PA BvD; QL (6 per 28 days) |
| CINVANTI INTRAVENOUS EMULSION 7.2 MG/ML | 4 | QL (36 per 28 days) |
| <i>compro rectal suppository 25 mg</i> | 4 | |
| <i>dimenhydrinate injection solution 50 mg/ml</i> | 2 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> (Marinol) | 4 | PA; QL (60 per 30 days) |
| <i>droperidol injection solution 2.5 mg/ml</i> | 2 | |
| EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ ML FINAL CONC.) | 4 | PA BvD; QL (6 per 28 days) |
| <i>fosaprepitant intravenous recon soln 150 mg</i> (Emend (fosaprepitant)) | 4 | QL (2 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>granisetron (pf) intravenous solution 1 mg/ml (1 ml), 100 mcg/ml</i> | 2 | |
| <i>granisetron hcl intravenous solution 1 mg/ml</i> | 2 | |
| <i>granisetron hcl oral tablet 1 mg</i> | 4 | PA BvD |
| <i>meclizine oral tablet 12.5 mg</i> | 2 | |
| <i>meclizine oral tablet 25 mg</i> (Dramamine Less Drowsy) | 2 | |
| <i>ondansetron hcl (pf) injection solution 4 mg/2 ml</i> | 1 | |
| <i>ondansetron hcl (pf) injection syringe 4 mg/2 ml</i> | 1 | |
| <i>ondansetron hcl intravenous solution 2 mg/ml</i> | 2 | |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i> | 4 | PA BvD |
| <i>ondansetron hcl oral tablet 24 mg</i> | 4 | PA BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> (Zofran) | 2 | PA BvD |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>phenadoz rectal suppository 12.5 mg, 25 mg</i> | 4 | |
| <i>prochlorperazine edisylate injection solution 10 mg/2 ml (5 mg/ml), 5 mg/ml</i> | 2 | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> (Compazine) | 2 | |
| <i>prochlorperazine rectal suppository 25 mg</i> (Compro) | 4 | |
| <i>promethazine injection solution 25 mg/ml, 50 mg/ml</i> (Phenergan) | 4 | |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>promethazine rectal suppository 12.5 mg, 25 mg, 50 mg</i> (Promethegan) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>promethegan rectal suppository 12.5 mg, 25 mg, 50 mg</i> | 4 | |
| <i>scopolamine base transdermal patch (Transderm-Scop)</i> 3 day 1 mg over 3 days | 2 | QL (10 per 30 days) |
| SYNDROS ORAL SOLUTION 5 MG/ML | 5 | PA; NM; NDS; QL (120 per 30 days) |
| Antiparasite Agents | | |
| Antiparasite Agents | | |
| <i>albendazole oral tablet 200 mg (Albenza)</i> | 5 | NM; NDS |
| ALINIA ORAL SUSPENSION FOR RECONSTITUTION 100 MG/5 ML | 5 | NM; NDS |
| ALINIA ORAL TABLET 500 MG | 5 | NM; NDS |
| <i>atovaquone oral suspension 750 mg/5 ml (Mepron)</i> | 5 | NM; NDS |
| <i>atovaquone-proguanil oral tablet 250-100 mg (Malarone)</i> | 2 | |
| <i>atovaquone-proguanil oral tablet 62.5-25 mg (Malarone Pediatric)</i> | 2 | |
| <i>chloroquine phosphate oral tablet 250 mg</i> | 2 | QL (50 per 30 days) |
| <i>chloroquine phosphate oral tablet 500 mg</i> | 2 | QL (25 per 30 days) |
| COARTEM ORAL TABLET 20-120 MG | 4 | |
| <i>hydroxychloroquine oral tablet 200 mg (Plaquenil)</i> | 2 | QL (90 per 30 days) |
| IMPAVIDO ORAL CAPSULE 50 MG | 5 | PA; NM; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg (Stromectol)</i> | 2 | |
| KRINTAFEL ORAL TABLET 150 MG | 4 | |
| <i>mefloquine oral tablet 250 mg</i> | 2 | |
| <i>paromomycin oral capsule 250 mg</i> | 4 | |
| <i>pentamidine inhalation recon soln 300 mg (Nebupent)</i> | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| <i>pentamidine injection recon soln 300 mg</i> (Pentam) | 4 | |
| PRIMAQUINE ORAL TABLET 26.3 MG | 4 | |
| <i>pyrimethamine oral tablet 25 mg</i> (Daraprim) | 5 | PA; NM; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> (Qualaquin) | 4 | PA; QL (42 per 7 days) |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 2 | |
| Antiparkinsonian Agents | | |
| Antiparkinsonian Agents | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | 2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | |
| APOKYN SUBCUTANEOUS CARTRIDGE 10 MG/ML | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>benztropine injection solution 1 mg/ml</i> (Cogentin) | 2 | |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>bromocriptine oral capsule 5 mg</i> (Parlodel) | 4 | |
| <i>bromocriptine oral tablet 2.5 mg</i> (Parlodel) | 2 | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | |
| <i>carbidopa oral tablet 25 mg</i> (Lodosyn) | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg, 25-100 mg, 25-250 mg</i> (Sinemet) | 2 | |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i> | 4 | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg</i> (Stalevo 50) | 4 | |
| <i>carbidopa-levodopa-entacapone oral tablet 18.75-75-200 mg</i> (Stalevo 75) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| <i>carbidopa-levodopa-entacapone oral</i> (Stalevo 100) <i>tablet 25-100-200 mg</i> | 4 | |
| <i>carbidopa-levodopa-entacapone oral</i> (Stalevo 125) <i>tablet 31.25-125-200 mg</i> | 4 | |
| <i>carbidopa-levodopa-entacapone oral</i> (Stalevo 150) <i>tablet 37.5-150-200 mg</i> | 4 | |
| <i>carbidopa-levodopa-entacapone oral</i> (Stalevo 200) <i>tablet 50-200-200 mg</i> | 4 | |
| <i>entacapone oral tablet 200 mg</i> (Comtan) | 2 | |
| GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 68.5 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 42 MG | 5 | PA; NM; NDS; QL (300 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NM; NDS; QL (150 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10-15-20-25-30 MG | 5 | PA; NM; NDS |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR | 3 | QL (30 per 30 days) |
| ONGENTYS ORAL CAPSULE 50 MG | 4 | PA; QL (30 per 30 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG, 258 MG | 4 | QL (30 per 30 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 322 MG/DAY(129 MG X1-193MG X1) | 4 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> (Mirapex) | 1 | |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i> (Azilect) | 4 | |
| <i>ropinirole oral tablet 0.25 mg, 3 mg, 5 mg</i> (Requip) | 2 | |
| <i>ropinirole oral tablet 0.5 mg, 1 mg, 2 mg, 4 mg</i> | 2 | |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 6 mg</i> (Requip XL) | 4 | |
| <i>ropinirole oral tablet extended release 24 hr 4 mg, 8 mg</i> | 4 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | |
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | 2 | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 1 | |
| XADAGO ORAL TABLET 100 MG, 50 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| Antipsychotic Agents | | |
| Antipsychotic Agents | | |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG | 5 | NM; NDS; QL (1 per 28 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 5 | NM; NDS; QL (1 per 28 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 4 | QL (900 per 30 days) |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg</i> (Abilify) | 4 | QL (30 per 30 days) |
| <i>aripiprazole oral tablet 2 mg</i> (Abilify) | 4 | QL (60 per 30 days) |
| <i>aripiprazole oral tablet,disintegrating 10 mg</i> | 5 | ST; NM; NDS; QL (90 per 30 days) |
| <i>aripiprazole oral tablet,disintegrating 15 mg</i> | 5 | ST; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 675 MG/2.4 ML | 5 | NM; NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML | 5 | NM; NDS; QL (3.9 per 56 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML | 5 | NM; NDS; QL (1.6 per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML | 5 | NM; NDS; QL (2.4 per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML | 5 | NM; NDS; QL (3.2 per 28 days) |
| CAPLYTA ORAL CAPSULE 42 MG | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>chlorpromazine injection solution 25 mg/ml</i> | 2 | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 4 | |
| <i>clozapine oral tablet 100 mg</i> (Clozaril) | 2 | QL (270 per 30 days) |
| <i>clozapine oral tablet 200 mg</i> (Clozaril) | 2 | QL (135 per 30 days) |
| <i>clozapine oral tablet 25 mg, 50 mg</i> (Clozaril) | 2 | QL (90 per 30 days) |
| <i>clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 25 mg</i> | 4 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet,disintegrating 150 mg</i> | 4 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet,disintegrating 200 mg</i> | 5 | ST; NM; NDS; QL (120 per 30 days) |
| FANAPT ORAL TABLET 1 MG, 2 MG | 4 | ST; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| FANAPT ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| FANAPT ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)- 4MG(2)-6MG(2) | 4 | ST |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 2 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 4 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 4 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 4 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml</i> (Haldol Decanoate) | 2 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml (1 ml)</i> | 2 | |
| <i>haloperidol decanoate intramuscular solution 50 mg/ml</i> (Haldol Decanoate) | 2 | |
| <i>haloperidol decanoate intramuscular solution 50 mg/ml(1ml)</i> | 2 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> (Haldol) | 2 | |
| <i>haloperidol lactate intramuscular syringe 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NM; NDS; QL (0.75 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NM; NDS; QL (1 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---|
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NM; NDS; QL (1.5 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 4 | QL (0.25 per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NM; NDS; QL (0.5 per 28 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.875 ML | 5 | NM; NDS; QL (0.875 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.315 ML | 5 | NM; NDS; QL (1.315 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 5 | NM; NDS; QL (1.75 per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.625 ML | 5 | NM; NDS; QL (2.625 per 84 days) |
| LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG | 3 | QL (30 per 30 days) |
| LATUDA ORAL TABLET 80 MG | 3 | QL (60 per 30 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>molindone oral tablet 10 mg</i> | 2 | QL (240 per 30 days) |
| <i>molindone oral tablet 25 mg</i> | 2 | QL (270 per 30 days) |
| <i>molindone oral tablet 5 mg</i> | 2 | QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular recon soln (Zyprexa) 10 mg</i> | 2 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, (Zyprexa) 2.5 mg, 20 mg, 5 mg, 7.5 mg</i> | 2 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>olanzapine oral tablet, disintegrating</i> (Zyprexa Zydis) 10 mg, 15 mg, 20 mg, 5 mg | 4 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr</i> (Invega) 1.5 mg, 3 mg | 4 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr</i> (Invega) 6 mg | 4 | QL (60 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr</i> (Invega) 9 mg | 5 | NM; NDS; QL (30 per 30 days) |
| <i>perphenazine oral tablet</i> 16 mg, 2 mg, 4 mg, 8 mg | 4 | |
| PERSERIS ABDOMINAL SUBCUTANEOUS SUSPENSION, EXTEND REL SYR KIT 120 MG, 90 MG | 5 | NM; NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet</i> 1 mg, 2 mg | 2 | |
| <i>quetiapine oral tablet</i> 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg (Seroquel) | 2 | QL (90 per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr</i> (Seroquel XR) 150 mg, 200 mg, 50 mg | 4 | QL (30 per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr</i> (Seroquel XR) 300 mg, 400 mg | 4 | QL (60 per 30 days) |
| REXULTI ORAL TABLET 0.25 MG | 5 | ST; NM; NDS; QL (120 per 30 days) |
| REXULTI ORAL TABLET 0.5 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| REXULTI ORAL TABLET 1 MG, 2 MG, 3 MG, 4 MG | 5 | ST; NM; NDS; QL (30 per 30 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 12.5 MG/2 ML, 25 MG/2 ML | 4 | QL (4 per 28 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 37.5 MG/2 ML, 50 MG/2 ML | 5 | NM; NDS; QL (4 per 28 days) |
| <i>risperidone oral solution</i> 1 mg/ml (Risperdal) | 2 | QL (480 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>risperidone oral tablet 0.25 mg</i> | 2 | QL (60 per 30 days) |
| <i>risperidone oral tablet 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> (Risperdal) | 2 | QL (60 per 30 days) |
| <i>risperidone oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 4 | QL (60 per 30 days) |
| <i>risperidone oral tablet, disintegrating 3 mg, 4 mg</i> | 4 | QL (120 per 30 days) |
| SAPHRIS SUBLINGUAL TABLET 10 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| SAPHRIS SUBLINGUAL TABLET 2.5 MG, 5 MG | 4 | ST; QL (60 per 30 days) |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 4 | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | ST; NM; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5 | ST; NM; NDS; QL (30 per 30 days) |
| VRAYLAR ORAL CAPSULE, DOSE PACK 1.5 MG (1)- 3 MG (6) | 4 | ST |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> (Geodon) | 2 | QL (60 per 30 days) |
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i> (Geodon) | 2 | QL (6 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | 4 | QL (2 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 300 MG | 5 | NM; NDS; QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 405 MG | 5 | NM; NDS; QL (1 per 28 days) |
| Antivirals (Systemic) | | |
| Antiretrovirals | | |
| <i>abacavir oral solution 20 mg/ml</i> (Ziagen) | 4 | |
| <i>abacavir oral tablet 300 mg</i> (Ziagen) | 2 | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> (Epzicom) | 2 | |
| <i>abacavir-lamivudine-zidovudine oral tablet 300-150-300 mg</i> (Trizivir) | 5 | NM; NDS |
| APTIVUS (WITH VITAMIN E) ORAL SOLUTION 100 MG/ML | 5 | NM; NDS |
| APTIVUS ORAL CAPSULE 250 MG | 5 | NM; NDS |
| <i>atazanavir oral capsule 150 mg, 200 mg, 300 mg</i> (Reyataz) | 2 | |
| ATRIPLA ORAL TABLET 600- 200-300 MG | 5 | NM; NDS |
| BIKTARVY ORAL TABLET 50- 200-25 MG | 5 | NM; NDS |
| CIMDUO ORAL TABLET 300- 300 MG | 5 | NM; NDS |
| COMPLERA ORAL TABLET 200-25-300 MG | 5 | NM; NDS |
| CRIXIVAN ORAL CAPSULE 200 MG, 400 MG | 4 | |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | NM; NDS |
| DESCOVY ORAL TABLET 200- 25 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>didanosine oral capsule, delayed release (drlec) 125 mg, 200 mg, 250 mg, 400 mg</i> | 2 | |
| DOVATO ORAL TABLET 50-300 MG | 5 | NM; NDS |
| EDURANT ORAL TABLET 25 MG | 5 | NM; NDS |
| <i>efavirenz oral capsule 200 mg</i> (Sustiva) | 5 | NM; NDS |
| <i>efavirenz oral capsule 50 mg</i> (Sustiva) | 2 | |
| <i>efavirenz oral tablet 600 mg</i> (Sustiva) | 2 | |
| <i>emtricitabine oral capsule 200 mg</i> (Emtriva) | 2 | |
| EMTRIVA ORAL CAPSULE 200 MG | 4 | |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | |
| EPIVIR HBV ORAL SOLUTION 25 MG/5 ML (5 MG/ML) | 4 | |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | NM; NDS |
| <i>fosamprenavir oral tablet 700 mg</i> (Lexiva) | 5 | NM; NDS |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 5 | NM; NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | NM; NDS |
| INTELENCE ORAL TABLET 100 MG, 200 MG | 5 | NM; NDS |
| INTELENCE ORAL TABLET 25 MG | 4 | |
| INVIRASE ORAL TABLET 500 MG | 5 | NM; NDS |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | NM; NDS |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 4 | |
| ISENTRESS ORAL TABLET 400 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG, 25 MG | 4 | |
| JULUCA ORAL TABLET 50-25 MG | 5 | NM; NDS |
| KALETRA ORAL TABLET 100- 25 MG | 4 | QL (300 per 30 days) |
| KALETRA ORAL TABLET 200- 50 MG | 5 | NM; NDS; QL (120 per 30 days) |
| <i>lamivudine oral solution 10 mg/ml</i> (Epivir) | 4 | |
| <i>lamivudine oral tablet 100 mg</i> (Epivir HBV) | 4 | |
| <i>lamivudine oral tablet 150 mg, 300 mg</i> (Epivir) | 2 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> (Combivir) | 2 | |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |
| <i>lopinavir-ritonavir oral solution 400- 100 mg/5 ml</i> (Kaletra) | 2 | QL (480 per 30 days) |
| <i>nevirapine oral suspension 50 mg/5 ml</i> (Viramune) | 4 | |
| <i>nevirapine oral tablet 200 mg</i> (Viramune) | 2 | |
| <i>nevirapine oral tablet extended release 24 hr 100 mg</i> | 4 | |
| <i>nevirapine oral tablet extended release 24 hr 400 mg</i> (Viramune XR) | 4 | |
| NORVIR ORAL POWDER IN PACKET 100 MG | 4 | |
| NORVIR ORAL SOLUTION 80 MG/ML | 4 | |
| ODEFSEY ORAL TABLET 200- 25-25 MG | 5 | NM; NDS |
| PIFELTRO ORAL TABLET 100 MG | 5 | NM; NDS |
| PREZCOBIX ORAL TABLET 800-150 MG-MG | 5 | NM; NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| PREZISTA ORAL TABLET 150 MG, 600 MG, 800 MG | 5 | NM; NDS |
| PREZISTA ORAL TABLET 75 MG | 4 | |
| RESCRIPTOR ORAL TABLET 200 MG | 4 | |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | 4 | |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 5 | NM; NDS |
| <i>ritonavir oral tablet 100 mg</i> (Norvir) | 2 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 5 | NM; NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 4 | |
| SELZENTRY ORAL TABLET 150 MG, 300 MG, 75 MG | 5 | NM; NDS |
| SELZENTRY ORAL TABLET 25 MG | 4 | |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | 2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | NM; NDS |
| SYMFI LO ORAL TABLET 400-300-300 MG | 5 | NM; NDS |
| SYMFI ORAL TABLET 600-300-300 MG | 5 | NM; NDS |
| SYMTUZA ORAL TABLET 800-150-200-10 MG | 5 | NM; NDS |
| TEMIXYS ORAL TABLET 300-300 MG | 5 | NM; NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> (Viread) | 2 | |
| TIVICAY ORAL TABLET 10 MG | 4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------------------|
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 4 | |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | NM; NDS |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) | 5 | NM; NDS |
| TRUVADA ORAL TABLET 100-150 MG, 133-200 MG, 167-250 MG, 200-300 MG | 5 | NM; NDS |
| VEMLIDY ORAL TABLET 25 MG | 5 | NM; NDS; QL (30 per 30 days) |
| VIDEX 2 GRAM PEDIATRIC ORAL RECON SOLN 10 MG/ML (FINAL) | 4 | |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 5 | NM; NDS |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 5 | NM; NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 5 | NM; NDS |
| <i>zidovudine oral capsule 100 mg</i> (Retrovir) | 2 | |
| <i>zidovudine oral syrup 10 mg/ml</i> (Retrovir) | 2 | |
| <i>zidovudine oral tablet 300 mg</i> | 2 | |
| Antivirals, Miscellaneous | | |
| <i>foscarnet intravenous solution 24 mg/ml</i> (Foscavir) | 4 | PA BvD |
| <i>oseltamivir oral capsule 30 mg</i> (Tamiflu) | 2 | QL (84 per 180 days) |
| <i>oseltamivir oral capsule 45 mg</i> (Tamiflu) | 2 | QL (48 per 180 days) |
| <i>oseltamivir oral capsule 75 mg</i> (Tamiflu) | 2 | QL (42 per 180 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> (Tamiflu) | 2 | QL (540 per 180 days) |
| PREVYMIS INTRAVENOUS SOLUTION 240 MG/12 ML | 5 | PA; NM; NDS; QL (336 per 28 days) |
| PREVYMIS INTRAVENOUS SOLUTION 480 MG/24 ML | 5 | PA; NM; NDS; QL (672 per 28 days) |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 4 | QL (60 per 180 days) |
| <i>rimantadine oral tablet 100 mg</i> (Flumadine) | 2 | |
| SYNAGIS INTRAMUSCULAR SOLUTION 100 MG/ML, 50 MG/0.5 ML | 5 | PA; NM; NDS |
| XOFLUZA ORAL TABLET 20 MG, 40 MG | 4 | QL (4 per 180 days) |
| Hcv Antivirals | | |
| EPCLUSA ORAL TABLET 400-100 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| HARVONI ORAL TABLET 45-200 MG, 90-400 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| <i>ledipasvir-sofosbuvir oral tablet 90-400 mg</i> (Harvoni) | 5 | PA; NM; NDS; QL (28 per 28 days) |
| MAVYRET ORAL TABLET 100-40 MG | 5 | PA; NM; NDS; QL (84 per 28 days) |
| <i>sofosbuvir-velpatasvir oral tablet 400-100 mg</i> (Epclusa) | 5 | PA; NM; NDS; QL (28 per 28 days) |
| SOVALDI ORAL PELLETS IN PACKET 150 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| SOVALDI ORAL PELLETS IN PACKET 200 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| SOVALDI ORAL TABLET 200 MG, 400 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| VIEKIRA PAK ORAL TABLETS,DOSE PACK 12.5 MG-75 MG -50 MG/250 MG | 5 | PA; NM; NDS |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| ZEPATIER ORAL TABLET 50-100 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Interferons | | |
| INTRON A INJECTION RECON SOLN 10 MILLION UNIT (1 ML), 18 MILLION UNIT (1 ML), 50 MILLION UNIT (1 ML) | 5 | PA NSO; NM; NDS |
| INTRON A INJECTION SOLUTION 10 MILLION UNIT/ML, 6 MILLION UNIT/ML | 5 | PA NSO; NM; NDS |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | NM; NDS |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 5 | NM; NDS |
| PEGINTRON SUBCUTANEOUS KIT 50 MCG/0.5 ML | 5 | NM; NDS |
| Nucleosides And Nucleotides | | |
| <i>acyclovir oral capsule 200 mg</i> | 2 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> (Zovirax) | 4 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 2 | |
| <i>acyclovir sodium intravenous recon soln 1,000 mg, 500 mg</i> | 2 | PA BvD |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 2 | PA BvD |
| <i>adefovir oral tablet 10 mg</i> (Hepsera) | 5 | NM; NDS |
| <i>cidofovir intravenous solution 75 mg/ml</i> | 5 | NM; NDS |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> (Baraclude) | 2 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | |
| <i>ganciclovir sodium intravenous recon soln 500 mg</i> (Cytovene) | 5 | PA BvD; NM; NDS |
| <i>ganciclovir sodium intravenous solution 50 mg/ml</i> | 5 | PA BvD; NM; NDS |
| <i>ribasphere oral capsule 200 mg</i> | 2 | |
| <i>ribasphere oral tablet 600 mg</i> | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ribasphere ribapak oral tablets,dose pack 600 mg (7)- 400 mg (7), 600 mg (7)- 600 mg (7)</i> | 5 | NM; NDS |
| <i>ribavirin inhalation recon soln 6 gram</i> (Virazole) | 5 | PA BvD; NM; NDS |
| <i>ribavirin oral capsule 200 mg</i> | 2 | |
| <i>ribavirin oral tablet 200 mg</i> | 2 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> (Valtrex) | 4 | |
| <i>valganciclovir oral recon soln 50 mg/ml</i> (Valcyte) | 5 | NM; NDS |
| <i>valganciclovir oral tablet 450 mg</i> (Valcyte) | 2 | |
| Blood Products/Modifiers/Volume Expanders | | |
| Anticoagulants | | |
| BEVYXXA ORAL CAPSULE 40 MG, 80 MG | 4 | QL (43 per 42 days) |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) | 3 | |
| ELIQUIS ORAL TABLET 2.5 MG, 5 MG | 3 | QL (60 per 30 days) |
| <i>enoxaparin subcutaneous solution 300 mg/3 ml</i> (Lovenox) | 2 | QL (30 per 30 days) |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i> (Lovenox) | 2 | QL (60 per 30 days) |
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i> (Lovenox) | 2 | QL (48 per 30 days) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> (Lovenox) | 2 | QL (18 per 30 days) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> (Lovenox) | 2 | QL (24 per 30 days) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> (Lovenox) | 2 | QL (36 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| <i>fondaparinux subcutaneous syringe</i> (Arixtra) 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml | 5 | NM; NDS |
| <i>fondaparinux subcutaneous syringe</i> (Arixtra) 2.5 mg/0.5 ml | 2 | |
| <i>heparin (porcine) injection cartridge</i> 5,000 unit/ml (1 ml) | 2 | |
| <i>heparin (porcine) injection solution</i> 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml | 2 | |
| <i>heparin (porcine) injection syringe</i> 5,000 unit/ml | 2 | |
| <i>heparin, porcine (pf) injection solution</i> 1,000 unit/ml | 2 | |
| <i>heparin, porcine (pf) injection syringe</i> 5,000 unit/0.5 ml | 2 | |
| <i>jantoven oral tablet</i> 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg | 1 | |
| PRADAXA ORAL CAPSULE 110 MG, 150 MG, 75 MG | 4 | ST; QL (60 per 30 days) |
| <i>warfarin oral tablet</i> 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg (Jantoven) | 1 | |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) | 3 | |
| XARELTO ORAL TABLET 10 MG, 20 MG | 3 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG | 3 | QL (60 per 30 days) |
| Blood Formation Modifiers | | |
| CINRYZE INTRAVENOUS RECON SOLN 500 UNIT (5 ML) | 5 | PA; NM; NDS; QL (20 per 30 days) |
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NM; NDS; QL (15 per 30 days) |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NM; NDS; QL (15 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| DOPTELET (30 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| FULPHILA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| GRANIX SUBCUTANEOUS SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NM; NDS |
| GRANIX SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NM; NDS |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 5 | PA; NM; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 5 | PA; NM; NDS; QL (20 per 30 days) |
| LEUKINE INJECTION RECON SOLN 250 MCG | 5 | NM; NDS |
| MOZOBIL SUBCUTANEOUS SOLUTION 24 MG/1.2 ML (20 MG/ML) | 5 | NM; NDS |
| MULPLETA ORAL TABLET 3 MG | 5 | PA; NM; NDS; QL (7 per 7 days) |
| NEULASTA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| NEUPOGEN INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NM; NDS |
| NEUPOGEN INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NM; NDS |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NM; NDS |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NM; NDS |
| NPLATE SUBCUTANEOUS RECON SOLN 125 MCG, 250 MCG, 500 MCG | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| PROMACTA ORAL TABLET 12.5 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| PROMACTA ORAL TABLET 25 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 3 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML | 3 | PA; QL (6 per 28 days) |
| UDENYCA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| ZARXIO INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | NM; NDS |
| ZIEXTENZO SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| Hematologic Agents, Miscellaneous | | |
| ADAKVEO INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA; NM; NDS |
| <i>anagrelide oral capsule 0.5 mg (Agrylin)</i> | 2 | |
| <i>anagrelide oral capsule 1 mg</i> | 2 | |
| CABLIVI INJECTION KIT 11 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| GIVLAARI SUBCUTANEOUS SOLUTION 189 MG/ML | 5 | PA; NM; NDS |
| <i>protamine intravenous solution 10 mg/ml</i> | 2 | |
| SIKLOS ORAL TABLET 1,000 MG, 100 MG | 4 | PA |
| TAVALISSE ORAL TABLET 100 MG, 150 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>tranexamic acid intravenous solution (Cyklokapron) 1,000 mg/10 ml (100 mg/ml)</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>tranexamic acid oral tablet 650 mg</i> (Lysteda) | 2 | QL (30 per 30 days) |
| Platelet-Aggregation Inhibitors | | |
| <i>aspirin-dipyridamole oral capsule, er</i> (Aggrenox) <i>multiphase 12 hr 25-200 mg</i> | 4 | QL (60 per 30 days) |
| BRILINTA ORAL TABLET 60 MG, 90 MG | 3 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | |
| <i>clopidogrel oral tablet 75 mg</i> (Plavix) | 1 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 2 | |
| <i>prasugrel oral tablet 10 mg, 5 mg</i> (Effient) | 4 | QL (30 per 30 days) |
| Caloric Agents | | |
| Caloric Agents | | |
| AMINOSYN 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| AMINOSYN 7 % WITH ELECTROLYTES INTRAVENOUS PARENTERAL SOLUTION 7 % | 4 | PA BvD |
| AMINOSYN 8.5 % INTRAVENOUS PARENTERAL SOLUTION 8.5 % | 4 | PA BvD |
| AMINOSYN 8.5 %- ELECTROLYTES INTRAVENOUS PARENTERAL SOLUTION 8.5 % | 4 | PA BvD |
| AMINOSYN II 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| AMINOSYN II 15 % INTRAVENOUS PARENTERAL SOLUTION 15 % | 4 | PA BvD |
| AMINOSYN II 7 % INTRAVENOUS PARENTERAL SOLUTION 7 % | 4 | PA BvD |
| AMINOSYN II 8.5 % INTRAVENOUS PARENTERAL SOLUTION 8.5 % | 4 | PA BvD |
| AMINOSYN II 8.5 %- ELECTROLYTES INTRAVENOUS PARENTERAL SOLUTION 8.5 % | 4 | PA BvD |
| AMINOSYN M 3.5 % INTRAVENOUS PARENTERAL SOLUTION 3.5 % | 4 | PA BvD |
| AMINOSYN-HBC 7% INTRAVENOUS PARENTERAL SOLUTION 7 % | 4 | PA BvD |
| AMINOSYN-PF 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| AMINOSYN-PF 7 % (SULFITE- FREE) INTRAVENOUS PARENTERAL SOLUTION 7 % | 4 | PA BvD |
| AMINOSYN-RF 5.2 % INTRAVENOUS PARENTERAL SOLUTION 5.2 % | 4 | PA BvD |
| CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| CLINIMIX 5%/D25W SULFITE-FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 4.25%-D25W SULF-FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX E 2.75%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 2.75 % | 4 | PA BvD |
| CLINIMIX E 4.25%/D10W SUL FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX E 4.25%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX E 5%/D15W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX E 5%/D20W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINOLIPID INTRAVENOUS EMULSION 20 % | 4 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>dextrose 10 % in water (d10w)</i> <i>intravenous parenteral solution 10 %</i> | 2 | PA BvD |
| <i>dextrose 5 % in water (d5w)</i> <i>intravenous parenteral solution</i> | 2 | |
| <i>dextrose 5 % in water (d5w)</i> <i>intravenous piggyback 5 %</i> | 2 | |
| FREAMINE HBC 6.9 % INTRAVENOUS PARENTERAL SOLUTION 6.9 % | 4 | PA BvD |
| FREAMINE III 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| HEPATAMINE 8% INTRAVENOUS PARENTERAL SOLUTION 8 % | 4 | PA BvD |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | 4 | PA BvD |
| KABIVEN INTRAVENOUS EMULSION 3.31-9.8-3.9 % | 4 | PA BvD |
| NEPHRAMINE 5.4 % INTRAVENOUS PARENTERAL SOLUTION 5.4 % | 4 | PA BvD |
| NUTRILIPID INTRAVENOUS EMULSION 20 % | 4 | PA BvD |
| PERIKABIVEN INTRAVENOUS EMULSION 2.36-6.8-3.5 % | 4 | PA BvD |
| PROCALAMINE 3% INTRAVENOUS PARENTERAL SOLUTION 3 % | 4 | PA BvD |
| PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION | 4 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| TROPHAMINE 6% INTRAVENOUS PARENTERAL SOLUTION 6 % | 4 | PA BvD |
| Cardiovascular Agents | | |
| Alpha-Adrenergic Agents | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> (Catapres) | 1 | |
| <i>clonidine transdermal patch weekly 0.1 mg/24 hr</i> (Catapres-TTS-1) | 4 | QL (4 per 28 days) |
| <i>clonidine transdermal patch weekly 0.2 mg/24 hr</i> (Catapres-TTS-2) | 4 | QL (4 per 28 days) |
| <i>clonidine transdermal patch weekly 0.3 mg/24 hr</i> (Catapres-TTS-3) | 4 | QL (8 per 28 days) |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> (Cardura) | 2 | |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>methyldopa oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>methyldopa-hydrochlorothiazide oral tablet 250-15 mg, 250-25 mg</i> | 4 | |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| NORTHERA ORAL CAPSULE 100 MG, 200 MG, 300 MG | 5 | PA; NM; NDS; QL (180 per 30 days) |
| <i>phenylephrine hcl injection solution 10 mg/ml</i> (Vazculep) | 2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> (Minipress) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Angiotensin II Receptor Antagonists | | |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> (Atacand) | 4 | |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> (Atacand HCT) | 4 | |
| EDARBI ORAL TABLET 40 MG, 80 MG | 3 | |
| EDARBYCLOR ORAL TABLET 40-12.5 MG, 40-25 MG | 3 | |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG | 3 | |
| <i>eprosartan oral tablet 600 mg</i> | 4 | |
| <i>irbesartan oral tablet 150 mg, 300 mg, 75 mg</i> (Avapro) | 6 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> (Avalide) | 6 | |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> (Cozaar) | 6 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> (Hyzaar) | 6 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> (Benicar) | 6 | |
| <i>olmesartan-amlodipin-hcthiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> (Tribenzor) | 4 | |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> (Benicar HCT) | 6 | |
| <i>telmisartan oral tablet 20 mg, 40 mg, 80 mg</i> (Micardis) | 6 | |
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> (Twynsta) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> (Micardis HCT) | 4 | |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> (Diovan) | 6 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> (Diovan HCT) | 6 | |
| Angiotensin-Converting Enzyme Inhibitors | | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg</i> (Lotensin) | 6 | |
| <i>benazepril oral tablet 5 mg</i> | 6 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Lotensin HCT) | 2 | |
| <i>benazepril-hydrochlorothiazide oral tablet 5-6.25 mg</i> | 2 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 2 | |
| <i>captopril-hydrochlorothiazide oral tablet 25-15 mg, 25-25 mg, 50-15 mg, 50-25 mg</i> | 4 | |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Vasotec) | 6 | |
| <i>enalaprilat intravenous solution 1.25 mg/ml</i> | 2 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg</i> (Vaseretic) | 6 | |
| <i>enalapril-hydrochlorothiazide oral tablet 5-12.5 mg</i> | 6 | |
| EPANED ORAL SOLUTION 1 MG/ML | 4 | ST |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 2 | |
| <i>lisinopril oral tablet 10 mg, 20 mg</i> (Prinivil) | 6 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>lisinopril oral tablet 2.5 mg, 30 mg, 40 mg, 5 mg</i> (Zestril) | 6 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Zestoretic) | 6 | |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 2 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 6 | |
| QBRELIS ORAL SOLUTION 1 MG/ML | 5 | ST; NM; NDS |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Accupril) | 6 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Accuretic) | 2 | |
| <i>ramipril oral capsule 1.25 mg, 10 mg, 2.5 mg, 5 mg</i> (Altace) | 6 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 6 | |
| Antiarrhythmic Agents | | |
| <i>amiodarone oral tablet 100 mg, 400 mg</i> (Pacerone) | 4 | |
| <i>amiodarone oral tablet 200 mg</i> (Pacerone) | 1 | |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> (Norpace) | 2 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> (Tikosyn) | 4 | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | |
| <i>lidocaine (pf) intravenous syringe 100 mg/5 ml (2%), 50 mg/5 ml (1%)</i> | 1 | |
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i> | 2 | |
| MULTAQ ORAL TABLET 400 MG | 3 | |
| <i>pacerone oral tablet 100 mg, 400 mg</i> | 4 | |
| <i>pacerone oral tablet 200 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>procainamide injection solution 100 mg/ml, 500 mg/ml</i> | 2 | |
| <i>procainamide intravenous syringe 100 mg/ml</i> | 2 | |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> (Rythmol SR) | 4 | |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | |
| <i>quinidine gluconate oral tablet extended release 324 mg</i> | 4 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 2 | |
| Beta-Adrenergic Blocking Agents | | |
| <i>acebutolol oral capsule 200 mg, 400 mg</i> | 2 | |
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> (Tenormin) | 1 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg</i> (Tenoretic 100) | 2 | |
| <i>atenolol-chlorthalidone oral tablet 50-25 mg</i> (Tenoretic 50) | 2 | |
| <i>betaxolol oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> (Ziac) | 2 | |
| BYSTOLIC ORAL TABLET 10 MG, 2.5 MG, 20 MG, 5 MG | 3 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> (Coreg) | 1 | |
| <i>labetalol intravenous solution 5 mg/ml</i> | 2 | |
| <i>labetalol intravenous syringe 20 mg/4 ml (5 mg/ml)</i> | 2 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>metoprolol succinate oral tablet</i> (Toprol XL) <i>extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg</i> | 2 | |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 50-25 mg</i> (Lopressor HCT) | 2 | |
| <i>metoprolol tartrate intravenous solution 5 mg/5 ml</i> (Lopressor) | 2 | |
| <i>metoprolol tartrate intravenous syringe 5 mg/5 ml</i> | 2 | |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> (Lopressor) | 1 | |
| <i>metoprolol tartrate oral tablet 25 mg</i> | 1 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> (Corgard) | 2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 4 | |
| <i>propranolol intravenous solution 1 mg/ml</i> | 2 | |
| <i>propranolol oral capsule, extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> (Inderal LA) | 4 | |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | 2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>propranolol-hydrochlorothiazid oral tablet 40-25 mg, 80-25 mg</i> | 2 | |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> | 2 | |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> | 2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> (Sorine) | 2 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Calcium-Channel Blocking Agents | | |
| <i>cartia xt oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | 2 | |
| <i>diltiazem hcl intravenous solution 5 mg/ml</i> | 2 | |
| <i>diltiazem hcl oral capsule,extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 2 | |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg</i> (Taztia XT) | 4 | |
| <i>diltiazem hcl oral capsule,extended release 24 hr 420 mg</i> (Tiadylt ER) | 2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (Cartia XT) | 2 | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg</i> (Cardizem) | 2 | |
| <i>diltiazem hcl oral tablet 90 mg</i> | 2 | |
| <i>dilt-xr oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 4 | |
| <i>taztia xt oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> | 2 | |
| <i>tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> | 2 | |
| <i>verapamil intravenous syringe 2.5 mg/ml</i> | 2 | |
| <i>verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg</i> (Verelan PM) | 2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg</i> (Verelan) | 2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 360 mg</i> (Verelan) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------------------|
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg, 240 mg</i> (Calan SR) | 1 | |
| Cardiovascular Agents, Miscellaneous | | |
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 3 | |
| CORLANOR ORAL TABLET 5 MG, 7.5 MG | 3 | |
| DEMSER ORAL CAPSULE 250 MG | 5 | NM; NDS |
| <i>digitek oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 2 | |
| <i>digox oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 2 | |
| <i>digoxin injection syringe 250 mcg/ml (0.25 mg/ml)</i> | 2 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> (Digitek) | 2 | |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml</i> (EpiPen Jr) | 2 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.3 mg/0.3 ml</i> (Auvi-Q) | 2 | QL (4 per 30 days) |
| <i>hydralazine injection solution 20 mg/ml</i> | 2 | |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> (Firazyr) | 5 | PA; NM; NDS; QL (18 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> (Demser) | 5 | NM; NDS |
| <i>milrinone intravenous solution 1 mg/ml</i> | 5 | PA BvD; NM; NDS |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg, 500 mg</i> (Ranexa) | 4 | |
| SYMJEPI INJECTION SYRINGE 0.15 MG/0.3 ML, 0.3 MG/0.3 ML | 3 | QL (4 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| VYNDAMAX ORAL CAPSULE 61 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| VYNDAQEL ORAL CAPSULE 20 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| Dihydropyridines | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> (Norvasc) | 1 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 5-10 mg, 5-20 mg, 5-40 mg</i> (Lotrel) | 6 | |
| <i>amlodipine-benazepril oral capsule 2.5-10 mg</i> | 6 | |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> (Azor) | 2 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> (Exforge) | 6 | |
| <i>amlodipine-valsartan-hcthiiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> (Exforge HCT) | 4 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>isradipine oral capsule 2.5 mg, 5 mg</i> | 4 | |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 4 | ST; QL (300 per 30 days) |
| <i>nicardipine oral capsule 20 mg, 30 mg</i> | 4 | |
| <i>nifedipine oral capsule 10 mg</i> (Procardia) | 4 | |
| <i>nifedipine oral capsule 20 mg</i> | 4 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg, 60 mg, 90 mg</i> (Procardia XL) | 2 | |
| <i>nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg</i> (Adalat CC) | 2 | |
| Diuretics | | |
| <i>amiloride oral tablet 5 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 2 | |
| <i>bumetanide injection solution 0.25 mg/ml</i> | 4 | |
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>chlorothiazide oral tablet 500 mg</i> | 2 | |
| <i>chlorothiazide sodium intravenous recon soln 500 mg</i> (Diuril IV) | 2 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>furosemide injection solution 10 mg/ml</i> | 1 | |
| <i>furosemide injection syringe 10 mg/ml</i> | 2 | |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 1 | |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> (Lasix) | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| JYNARQUE ORAL TABLET 15 MG, 30 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| JYNARQUE ORAL TABLETS, SEQUENTIAL 15 MG (AM)/ 15 MG (PM), 30 MG (AM)/ 15 MG (PM), 45 MG (AM)/ 15 MG (PM), 60 MG (AM)/ 30 MG (PM), 90 MG (AM)/ 30 MG (PM) | 5 | PA; NM; NDS; QL (56 per 28 days) |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> (Aldactone) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> (Aldactazide) | 2 | |
| <i>toremide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 2 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> (Dyazide) | 1 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg</i> (Maxzide-25mg) | 1 | |
| <i>triamterene-hydrochlorothiazid oral tablet 75-50 mg</i> (Maxzide) | 1 | |
| Dyslipidemics | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 10-20 mg, 10-40 mg, 10-80 mg, 5-10 mg, 5-20 mg, 5-40 mg, 5-80 mg</i> (Caduet) | 4 | |
| <i>amlodipine-atorvastatin oral tablet 2.5-10 mg, 2.5-20 mg, 2.5-40 mg</i> | 4 | |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> (Lipitor) | 6 | |
| <i>cholestyramine (with sugar) oral powder in packet 4 gram</i> (Questran) | 2 | |
| <i>cholestyramine light oral powder 4 gram</i> | 2 | |
| <i>cholestyramine light packet 4 gram</i> | 2 | |
| <i>colesevelam oral tablet 625 mg</i> (WelChol) | 2 | |
| <i>colestipol oral packet 5 gram</i> (Colestid) | 2 | |
| <i>colestipol oral tablet 1 gram</i> (Colestid) | 2 | |
| EZALLOR SPRINKLE ORAL CAPSULE, SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG | 4 | ST; QL (30 per 30 days) |
| <i>ezetimibe oral tablet 10 mg</i> (Zetia) | 2 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg</i> (Vytorin 10-10) | 2 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-20 mg</i> (Vytorin 10-20) | 2 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-40 mg</i> (Vytorin 10-40) | 2 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>ezetimibe-simvastatin oral tablet 10-80 mg</i> (Vytorin 10-80) | 2 | QL (30 per 30 days) |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 67 mg</i> | 4 | |
| <i>fenofibrate micronized oral capsule 43 mg</i> | 2 | |
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i> (Tricor) | 2 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | 2 | |
| <i>fenofibric acid (choline) oral capsule, delayed release (drlec) 135 mg, 45 mg</i> (Trilipix) | 4 | |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> (Lescol) | 4 | |
| <i>gemfibrozil oral tablet 600 mg</i> (Lopid) | 1 | |
| JUXTAPID ORAL CAPSULE 10 MG, 30 MG, 40 MG, 60 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| JUXTAPID ORAL CAPSULE 20 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| JUXTAPID ORAL CAPSULE 5 MG | 5 | PA; NM; NDS; QL (45 per 30 days) |
| LIVALO ORAL TABLET 1 MG, 2 MG, 4 MG | 3 | QL (30 per 30 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | |
| NEXLETOL ORAL TABLET 180 MG | 4 | PA; QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | 3 | PA; QL (30 per 30 days) |
| <i>niacin oral tablet 500 mg</i> (Niacor) | 4 | |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 750 mg</i> (Niaspan Extended-Release) | 4 | |
| <i>niacin oral tablet extended release 24 hr 500 mg</i> (Niaspan Extended-Release) | 2 | |
| <i>niacor oral tablet 500 mg</i> | 2 | |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> (Lovaza) | 2 | QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| PRALUENT PEN SUBCUTANEOUS PEN INJECTOR 150 MG/ML, 75 MG/ML | 4 | PA; QL (2 per 28 days) |
| <i>pravastatin oral tablet 10 mg, 80 mg</i> | 6 | |
| <i>pravastatin oral tablet 20 mg, 40 mg</i> (Pravachol) | 6 | |
| <i>prevalite oral powder in packet 4 gram</i> | 2 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML | 4 | PA; QL (3.5 per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML | 4 | PA; QL (3 per 28 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML | 4 | PA; QL (3 per 28 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Crestor) | 6 | QL (30 per 30 days) |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> (Zocor) | 6 | QL (30 per 30 days) |
| <i>simvastatin oral tablet 5 mg</i> | 6 | QL (30 per 30 days) |
| VASCEPA ORAL CAPSULE 0.5 GRAM | 3 | QL (240 per 30 days) |
| VASCEPA ORAL CAPSULE 1 GRAM | 3 | QL (120 per 30 days) |
| WELCHOL ORAL POWDER IN PACKET 3.75 GRAM | 2 | |
| Renin-Angiotensin-Aldosterone System Inhibitors | | |
| <i>aliskiren oral tablet 150 mg, 300 mg</i> (Tekturna) | 4 | |
| CAROSPIR ORAL SUSPENSION 25 MG/5 ML | 4 | ST |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> (Inspra) | 4 | |
| Vasodilators | | |
| BIDIL ORAL TABLET 20-37.5 MG | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg</i> | 2 | |
| <i>isosorbide dinitrate oral tablet 5 mg</i> (Isordil Titradose) | 2 | |
| <i>isosorbide dinitrate oral tablet extended release 40 mg</i> (ISOCHRON) | 2 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | |
| <i>minitran transdermal patch 24 hour 0.1 mg/1hr, 0.2 mg/1hr, 0.4 mg/1hr, 0.6 mg/1hr</i> | 2 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 2 | |
| <i>nitroglycerin intravenous solution 50 mg/10 ml (5 mg/ml)</i> | 2 | |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> (Nitrostat) | 2 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/1hr, 0.2 mg/1hr, 0.4 mg/1hr, 0.6 mg/1hr</i> (Minitran) | 2 | |
| Central Nervous System Agents | | |
| Central Nervous System Agents | | |
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> (Strattera) | 2 | QL (60 per 30 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> (Strattera) | 2 | QL (30 per 30 days) |
| AUBAGIO ORAL TABLET 14 MG, 7 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| AVONEX INTRAMUSCULAR PEN INJECTOR 30 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NM; NDS; QL (15 per 30 days) |
| <i>caffeine citrate intravenous solution</i> (Cafcit) 60 mg/3 ml (20 mg/ml) | 2 | PA BvD |
| <i>caffeine citrate oral solution</i> 60 mg/3 ml (20 mg/ml) | 2 | |
| <i>clonidine hcl oral tablet extended release</i> 12 hr 0.1 mg (Kapvay) | 4 | |
| COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML | 5 | PA; NM; NDS; QL (30 per 30 days) |
| COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML | 5 | PA; NM; NDS; QL (12 per 28 days) |
| <i>dalfampridine oral tablet extended release</i> 12 hr 10 mg (Ampyra) | 2 | PA; QL (60 per 30 days) |
| <i>dexmethylphenidate oral tablet</i> 10 mg, 2.5 mg, 5 mg (Focalin) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine oral capsule, extended release</i> 10 mg, 15 mg, 5 mg (Dexedrine Spansule) | 4 | QL (120 per 30 days) |
| <i>dextroamphetamine oral tablet</i> 10 mg, 5 mg (Zenedi) | 4 | QL (180 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release</i> 24hr 10 mg, 15 mg, 5 mg (Adderall XR) | 4 | QL (30 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release</i> 24hr 20 mg, 25 mg, 30 mg (Adderall XR) | 4 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral tablet</i> 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg (Adderall) | 2 | QL (60 per 30 days) |
| ENSPRYNG SUBCUTANEOUS SYRINGE 120 MG/ML | 5 | PA; NM; NDS |
| EXTAVIA SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NM; NDS; QL (15 per 30 days) |
| <i>flumazenil intravenous solution</i> 0.1 mg/ml | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---|
| GILENYA ORAL CAPSULE 0.25 MG, 0.5 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> (Copaxone) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> (Copaxone) | 5 | PA; NM; NDS; QL (12 per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> | 5 | PA; NM; NDS; QL (12 per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> (Intuniv ER) | 2 | |
| INGREZZA INITIATION PACK ORAL CAPSULE,DOSE PACK 40 MG (7)- 80 MG (21) | 5 | PA NSO; NM; NDS |
| INGREZZA ORAL CAPSULE 40 MG, 80 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML | 5 | PA; NM; NDS; QL (1.2 per 28 days) |
| LEMTRADA INTRAVENOUS SOLUTION 12 MG/1.2 ML | 5 | PA; NM; NDS; QL (6 per 365 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | |
| <i>lithium carbonate oral tablet 300 mg</i> | 2 | |
| <i>lithium carbonate oral tablet extended release 300 mg</i> (Lithobid) | 2 | |
| <i>lithium carbonate oral tablet extended release 450 mg</i> | 2 | |
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| MAYZENT ORAL TABLET 2 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>metadate er oral tablet extended release 20 mg</i> | 4 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 40 mg, 50 mg, 60 mg</i> | 4 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 30 mg</i> | 4 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 50-50 10 mg, 20 mg, 40 mg</i> (Ritalin LA) | 4 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 50-50 30 mg</i> (Ritalin LA) | 4 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 50-50 60 mg</i> | 4 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml</i> (Methylin) | 2 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> (Ritalin) | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 10 mg</i> | 4 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 20 mg</i> (Metadate ER) | 4 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg (bx rating), 27 mg (bx rating), 54 mg (bx rating)</i> | 4 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 54 mg</i> (Concerta) | 4 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| <i>methylphenidate hcl oral tablet</i> (Concerta) <i>extended release 24hr 36 mg</i> | 4 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral tablet</i> <i>extended release 24hr 36 mg (bx</i> <i>rating)</i> | 4 | QL (60 per 30 days) |
| NUEDEXTA ORAL CAPSULE 20-10 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| OCREVUS INTRAVENOUS SOLUTION 30 MG/ML | 5 | PA; NM; NDS; QL (20 per 180 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NM; NDS |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NM; NDS |
| RADICAVA INTRAVENOUS PIGGYBACK 30 MG/100 ML | 5 | PA; NM; NDS; QL (2800 per 28 days) |
| REBIF (WITH ALBUMIN) SUBCUTANEOUS SYRINGE 22 MCG/0.5 ML, 44 MCG/0.5 ML | 5 | PA; NM; NDS; QL (6 per 28 days) |
| REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML | 5 | PA; NM; NDS; QL (6 per 28 days) |
| REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 8.8MCG/0.2ML-22 MCG/0.5ML (6) | 5 | PA; NM; NDS |
| REBIF TITRATION PACK SUBCUTANEOUS SYRINGE 8.8MCG/0.2ML-22 MCG/0.5ML (6) | 5 | PA; NM; NDS |
| <i>riluzole oral tablet 50 mg</i> (Rilutek) | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | 3 | QL (60 per 30 days) |
| SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) | 3 | |
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG | 5 | PA; NM; NDS; QL (14 per 7 days) |
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG (14)-240 MG (46) | 5 | PA; NM; NDS |
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 240 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> (Xenazine) | 5 | PA; NM; NDS; QL (112 per 28 days) |
| VUMERITY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| ZEPOSIA ORAL CAPSULE 0.92 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| ZEPOSIA STARTER KIT ORAL CAPSULE,DOSE PACK 0.23-0.46-0.92 MG | 5 | PA; NM; NDS |
| ZEPOSIA STARTER PACK ORAL CAPSULE,DOSE PACK 0.23 MG (4)- 0.46 MG (3) | 5 | PA; NM; NDS |
| Contraceptives | | |
| Contraceptives | | |
| <i>afirmelle oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg-35 mcg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>amethia lo oral tablets, dose pack, 3 month 0.10 mg-20 mcg (84)/10 mcg (7)</i> | 2 | QL (91 per 84 days) |
| <i>amethia oral tablets, dose pack, 3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 2 | QL (91 per 84 days) |
| <i>apri oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i> | 2 | |
| <i>ashlyna oral tablets, dose pack, 3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 2 | QL (91 per 84 days) |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>aurovela 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>aurovela 1/20 (21) oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>aurovela 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 2 | |
| <i>aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | |
| <i>aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>ayuna oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>balziva (28) oral tablet 0.4-35 mg-mcg</i> | 2 | |
| <i>bekyree (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 2 | |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | |
| <i>blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>camila oral tablet 0.35 mg</i> | 1 | |
| <i>caziant (28) oral tablet 0.11.125/1.15-25 mg-mcg</i> | 2 | |
| <i>chateal eq (28) oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>cryselle (28) oral tablet 0.3-30 mg- mcg</i> | 2 | |
| <i>cyclafem 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>cyclafem 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>dasetta 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>daysee oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 2 | QL (91 per 84 days) |
| <i>deblitane oral tablet 0.35 mg</i> | 1 | |
| <i>desog-e.estradiolle.estradiol oral (Azurette (28)) tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>desogestrel-ethinyl estradiol oral (Apri) tablet 0.15-0.03 mg</i> | 2 | |
| <i>drospirenone-ethinyl estradiol oral (Jasmiel (28)) tablet 3-0.02 mg</i> | 2 | |
| <i>drospirenone-ethinyl estradiol oral (Syeda) tablet 3-0.03 mg</i> | 2 | |
| <i>elinest oral tablet 0.3-30 mg-mcg</i> | 2 | |
| ELLA ORAL TABLET 30 MG | 4 | QL (6 per 365 days) |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | 4 | QL (1 per 28 days) |
| <i>emoquette oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 2 | |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>errin oral tablet 0.35 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>estarylla oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg</i> (Kelnor 1/35 (28)) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg</i> (Kelnor 1-50) | 2 | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> (EluRyng) | 4 | QL (1 per 28 days) |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>femynor oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 2 | |
| <i>hailey fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | |
| <i>hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 2 | |
| <i>hailey oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>heather oral tablet 0.35 mg</i> | 1 | |
| <i>incassia oral tablet 0.35 mg</i> | 1 | |
| <i>introvale oral tablets, dose pack, 3 month 0.15 mg-30 mcg (91)</i> | 2 | QL (91 per 84 days) |
| <i>isibloom oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>jaimiess oral tablets, dose pack, 3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | 2 | QL (91 per 84 days) |
| <i>jasmiel (28) oral tablet 3-0.02 mg</i> | 2 | |
| <i>jencycla oral tablet 0.35 mg</i> | 1 | |
| <i>juleber oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 2 | |
| <i>kalliga oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>kelnor 1-50 oral tablet 1-50 mg-mcg</i> | 2 | |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>l norgestle.estradiol-e.estradiol oral tablets,dose pack,3 month 0.10 mg-20 mcg (84)/10 mcg (7)</i> (Amethia Lo) | 2 | QL (91 per 84 days) |
| <i>l norgestle.estradiol-e.estradiol oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> (Amethia) | 2 | QL (91 per 84 days) |
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | 2 | |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | 2 | |
| <i>larin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | 2 | |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | 2 | |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>larissia oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 2 | |
| <i>levonorgestrel-ethinyl estradiol oral tablet 0.1-20 mg-mcg</i> (Afirmelle) | 2 | |
| <i>levonorgestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> (Altavera (28)) | 2 | |
| <i>levonorgestrel-ethinyl estradiol oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> (Introvale) | 2 | QL (91 per 84 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> (Enpresse) | 2 | |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>lillow (28) oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>lojaimiess oral tablets, dose pack, 3 month 0.10 mg-20 mcg (84)/10 mcg (7)</i> | 2 | QL (91 per 84 days) |
| <i>loryna (28) oral tablet 3-0.02 mg</i> | 2 | |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | 2 | |
| <i>lo-zumandimine (28) oral tablet 3-0.02 mg</i> | 2 | |
| <i>luteru (28) oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>lyza oral tablet 0.35 mg</i> | 1 | |
| <i>marlissa (28) oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | 1 | |
| <i>mili oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>mono-linyah oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>necon 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | 2 | |
| <i>nikki (28) oral tablet 3-0.02 mg</i> | 2 | |
| <i>norethindrone (contraceptive) oral tablet 0.35 mg</i> (Camila) | 1 | |
| <i>norethindrone ac-eth estradiol oral tablet 1.5-30 mg-mcg</i> (Aurovela 1.5/30 (21)) | 2 | |
| <i>norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg</i> (Aurovela 1/20 (21)) | 2 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> (Aurovela Fe 1-20 (28)) | 1 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> (Aurovela Fe 1.5/30 (28)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-25 mcg</i> (Tri-Lo-Estarylla) | 1 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-35 mcg</i> (28) (Tri Femynor) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.25-35 mg-mcg</i> (Estarylla) | 2 | |
| <i>norlyda oral tablet 0.35 mg</i> | 1 | |
| <i>nortrel 0.5/35 (28) oral tablet 0.5-35 mg-mcg</i> | 2 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg</i> (21) | 2 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>ogestrel (28) oral tablet 0.5-50 mg-mcg</i> | 2 | |
| <i>orsythia oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>philith oral tablet 0.4-35 mg-mcg</i> | 2 | |
| <i>pimtreea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>pirmella oral tablet 0.5/0.75/1 mg-35 mcg, 1-35 mg-mcg</i> | 2 | |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>previfem oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | 2 | |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg</i> (91) | 2 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | 1 | |
| <i>simliya (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>simpesse oral tablets,dose pack,3 month 0.15 mg-30 mcg</i> (84)/10 mcg (7) | 2 | QL (91 per 84 days) |
| SLYND ORAL TABLET 4 MG (28) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>sprintec (28) oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>syeda oral tablet 3-0.03 mg</i> | 2 | |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/175 mg (4)</i> | 2 | |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/175 mg (7)</i> | 1 | |
| <i>tri femynor oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | 2 | |
| <i>tri-lynyah oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | |
| <i>tri-previfem (28) oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | |
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | 2 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-25 mcg</i> | 1 | |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | 2 | |
| <i>tulana oral tablet 0.35 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>velivet triphasic regimen (28) oral tablet 0.11.125/1.15-25 mg-mcg</i> | 2 | |
| <i>vienva oral tablet 0.1-20 mg-mcg</i> | 2 | |
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>volnea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | 2 | |
| <i>vyfemla (28) oral tablet 0.4-35 mg-mcg</i> | 2 | |
| <i>vylibra oral tablet 0.25-35 mg-mcg</i> | 2 | |
| <i>wera (28) oral tablet 0.5-35 mg-mcg</i> | 2 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | 4 | QL (3 per 28 days) |
| <i>zarah oral tablet 3-0.03 mg</i> | 2 | |
| <i>zovia 1/35e (28) oral tablet 1-35 mg-mcg</i> | 2 | |
| <i>zumandimine (28) oral tablet 3-0.03 mg</i> | 2 | |
| Dental And Oral Agents | | |
| Dental And Oral Agents | | |
| <i>cevimeline oral capsule 30 mg (Evoxac)</i> | 4 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 % (Paroex Oral Rinse)</i> | 1 | |
| <i>oralone dental paste 0.1 %</i> | 2 | |
| <i>paroex oral rinse mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>periogard mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg (Salagen (pilocarpine))</i> | 2 | |
| <i>triamcinolone acetonide dental paste 0.1 % (Oralene)</i> | 2 | |
| Dermatological Agents | | |
| Dermatological Agents, Other | | |
| <i>acitretin oral capsule 10 mg, 25 mg (Soriatane)</i> | 2 | |
| <i>acitretin oral capsule 17.5 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>acyclovir topical cream 5 %</i> (Zovirax) | 4 | QL (5 per 4 days) |
| <i>acyclovir topical ointment 5 %</i> (Zovirax) | 4 | QL (30 per 30 days) |
| ALCOHOL PADS TOPICAL PADS, MEDICATED | 1 | |
| <i>ammonium lactate topical cream 12 %</i> (Geri-Hydrolac) | 2 | |
| <i>ammonium lactate topical lotion 12 %</i> (Geri-Hydrolac) | 2 | |
| <i>calcipotriene scalp solution 0.005 %</i> | 4 | QL (120 per 30 days) |
| <i>calcipotriene topical cream 0.005 %</i> (Dovonex) | 4 | QL (120 per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | 4 | QL (120 per 30 days) |
| DENAVIR TOPICAL CREAM 1 % | 5 | NM; NDS |
| <i>fluorouracil topical cream 0.5 %</i> (Carac) | 5 | NM; NDS |
| <i>fluorouracil topical cream 5 %</i> (Efudex) | 2 | |
| <i>fluorouracil topical solution 2 %, 5 %</i> | 2 | |
| <i>imiquimod topical cream in packet 5 %</i> (Aldara) | 2 | QL (24 per 30 days) |
| <i>methoxsalen oral capsule, liqd-filled, rapid rel 10 mg</i> (Oxsoralen Ultra) | 5 | NM; NDS |
| PANRETIN TOPICAL GEL 0.1 % | 5 | NM; NDS |
| PICATO TOPICAL GEL 0.015 % | 3 | QL (3 per 56 days) |
| PICATO TOPICAL GEL 0.05 % | 3 | QL (2 per 56 days) |
| <i>podofilox topical solution 0.5 %</i> | 2 | |
| REGRANEX TOPICAL GEL 0.01 % | 5 | PA; NM; NDS; QL (30 per 30 days) |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 4 | QL (180 per 30 days) |
| TOLAK TOPICAL CREAM 4 % | 4 | |
| VALCHLOR TOPICAL GEL 0.016 % | 5 | NM; NDS |
| VEREGEN TOPICAL OINTMENT 15 % | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg | 2 | |
| Dermatological Antibacterials | | |
| clindamycin phosphate topical foam 1% (Evoclin) | 4 | QL (100 per 30 days) |
| clindamycin phosphate topical solution 1% (Cleocin T) | 2 | QL (180 per 30 days) |
| clindamycin phosphate topical swab 1% (Clindacin ETZ) | 2 | |
| clindamycin-benzoyl peroxide topical gel 1.2%(1% base) -5% (Neuac) | 4 | |
| clindamycin-benzoyl peroxide topical gel 1-5% (Benzaclin) | 4 | |
| ery pads topical swab 2% | 2 | |
| erythromycin with ethanol topical gel 2% (Erygel) | 4 | QL (180 per 30 days) |
| erythromycin with ethanol topical solution 2% | 2 | QL (180 per 30 days) |
| erythromycin-benzoyl peroxide topical gel 3-5% (Benzamycin) | 4 | |
| gentamicin topical cream 0.1% | 2 | QL (120 per 30 days) |
| gentamicin topical ointment 0.1% | 2 | QL (120 per 30 days) |
| metronidazole topical cream 0.75% (Rosadan) | 4 | |
| metronidazole topical gel 0.75% (Rosadan) | 2 | |
| metronidazole topical gel 1% (Metrogel) | 4 | |
| metronidazole topical lotion 0.75% (MetroLotion) | 4 | |
| mupirocin topical ointment 2% (Centany) | 1 | QL (220 per 30 days) |
| neomycin-polymyxin b gu irrigation solution 40 mg-200,000 unit/ml | 2 | |
| rosadan topical cream 0.75% | 4 | |
| selenium sulfide topical lotion 2.5% | 2 | |
| silver sulfadiazine topical cream 1% (SSD) | 2 | |
| ssd topical cream 1% | 4 | |
| sulfacetamide sodium (acne) topical suspension 10% (Klaron) | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------|
| Dermatological Anti-Inflammatory Agents | | |
| <i>ala-cort topical cream 1 %</i> | 1 | |
| <i>ala-scalp topical lotion 2 %</i> | 4 | |
| <i>alclometasone topical cream 0.05 %</i> | 2 | |
| <i>alclometasone topical ointment 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 2 | |
| <i>betamethasone valerate topical cream 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical foam (Luxiq) 0.12 %</i> | 4 | |
| <i>betamethasone valerate topical lotion 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 2 | |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical ointment 0.05 % (Diprolene)</i> | 2 | |
| <i>clobetasol scalp solution 0.05 %</i> | 2 | |
| <i>clobetasol topical cream 0.05 % (Temovate)</i> | 2 | |
| <i>clobetasol topical foam 0.05 % (Olux)</i> | 4 | |
| <i>clobetasol topical gel 0.05 %</i> | 4 | |
| <i>clobetasol topical lotion 0.05 % (Clobex)</i> | 4 | |
| <i>clobetasol topical ointment 0.05 % (Temovate)</i> | 4 | |
| <i>clobetasol topical shampoo 0.05 % (Clobex)</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>clobetasol-emollient topical cream 0.05 %</i> | 2 | |
| <i>clobetasol-emollient topical foam 0.05 %</i> (Olux-E) | 4 | |
| <i>cormax scalp solution 0.05 %</i> | 2 | |
| <i>desonide topical cream 0.05 %</i> (DesOwen) | 4 | |
| <i>desonide topical lotion 0.05 %</i> (DesOwen) | 4 | |
| <i>desonide topical ointment 0.05 %</i> | 4 | |
| <i>desoximetasone topical cream 0.05 %</i> (Topicort) | 4 | QL (120 per 30 days) |
| <i>desoximetasone topical cream 0.25 %</i> (Topicort) | 2 | QL (120 per 30 days) |
| <i>desoximetasone topical gel 0.05 %</i> (Topicort) | 4 | QL (120 per 30 days) |
| <i>desoximetasone topical ointment 0.05 %, 0.25 %</i> (Topicort) | 4 | QL (120 per 30 days) |
| <i>diflorasone topical ointment 0.05 %</i> | 4 | QL (60 per 30 days) |
| EUCRISA TOPICAL OINTMENT 2 % | 3 | |
| <i>fluocinolone topical cream 0.01 %</i> | 2 | |
| <i>fluocinolone topical cream 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinolone topical ointment 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinonide topical cream 0.05 %</i> | 2 | |
| <i>fluocinonide topical gel 0.05 %</i> | 2 | |
| <i>fluocinonide topical ointment 0.05 %</i> | 2 | |
| <i>fluocinonide topical solution 0.05 %</i> | 2 | |
| <i>fluocinonide-e topical cream 0.05 %</i> | 4 | |
| <i>fluticasone propionate topical cream 0.05 %</i> (Cutivate) | 2 | |
| <i>fluticasone propionate topical ointment 0.005 %</i> | 2 | |
| <i>halobetasol propionate topical cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 2 | |
| <i>hydrocortisone butyrate topical cream 0.1 %</i> | 4 | QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>hydrocortisone butyrate topical lotion 0.1 %</i> (Locoid) | 4 | QL (118 per 30 days) |
| <i>hydrocortisone butyrate topical ointment 0.1 %</i> | 4 | QL (120 per 30 days) |
| <i>hydrocortisone butyrate topical solution 0.1 %</i> | 4 | QL (120 per 30 days) |
| <i>hydrocortisone topical cream 1 %</i> (Ala-Cort) | 1 | |
| <i>hydrocortisone topical cream 2.5 %</i> | 1 | |
| <i>hydrocortisone topical lotion 2.5 %</i> | 2 | |
| <i>hydrocortisone topical ointment 1 %</i> (Anti-Itch (HC)) | 1 | |
| <i>hydrocortisone topical ointment 2.5 %</i> | 1 | |
| <i>hydrocortisone valerate topical cream 0.2 %</i> | 4 | |
| <i>hydrocortisone valerate topical ointment 0.2 %</i> | 4 | |
| <i>mometasone topical cream 0.1 %</i> | 2 | |
| <i>mometasone topical ointment 0.1 %</i> | 2 | |
| <i>mometasone topical solution 0.1 %</i> | 2 | |
| <i>pimecrolimus topical cream 1 %</i> (Elidel) | 4 | QL (100 per 30 days) |
| <i>prednicarbate topical ointment 0.1 %</i> | 2 | |
| <i>procto-med hc topical cream with perineal applicator 2.5 %</i> | 2 | |
| <i>procto-pak topical cream with perineal applicator 1 %</i> | 2 | |
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i> | 2 | |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> | 2 | |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> (Protopic) | 4 | QL (100 per 30 days) |
| <i>triamcinolone acetonide topical cream 0.025 %</i> | 1 | |
| <i>triamcinolone acetonide topical cream 0.1 %, 0.5 %</i> (Triderm) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | 2 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | 2 | |
| <i>triamcinolone acetonide topical ointment 0.05 %</i> (Trianex) | 2 | |
| Dermatological Retinoids | | |
| <i>adapalene topical cream 0.1 %</i> (Differin) | 4 | |
| <i>adapalene topical gel 0.1 %</i> (Differin) | 2 | |
| ALTRENO TOPICAL LOTION 0.05 % | 4 | PA |
| <i>tazarotene topical cream 0.1 %</i> (Tazorac) | 4 | |
| TAZORAC TOPICAL CREAM 0.05 % | 4 | |
| <i>tretinoin topical cream 0.025 %</i> (Avita) | 4 | PA |
| <i>tretinoin topical cream 0.05 %, 0.1 %</i> (Retin-A) | 4 | PA |
| <i>tretinoin topical gel 0.01 %</i> (Retin-A) | 4 | PA |
| <i>tretinoin topical gel 0.025 %</i> (Avita) | 4 | PA |
| <i>tretinoin topical gel 0.05 %</i> (Atralin) | 4 | PA |
| Scabicides And Pediculicides | | |
| <i>malathion topical lotion 0.5 %</i> (Ovide) | 4 | |
| <i>permethrin topical cream 5 %</i> (Elimite) | 2 | |
| Devices | | |
| Devices | | |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 2 | |
| BD UF NANO PEN NEEDLE 4MMX32G 32 GAUGE X 5/32" | 2 | |
| BD VEO INS 0.3 ML 6MMX31G (1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | |
| BD VEO INS SYRING 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| BD VEO INS SYRN 0.5 ML 6MMX31G 1/2 ML 31 GAUGE X 15/64" | 2 | |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " | 1 | |
| INSULIN SYRINGE-NEEDLE (Ultilet Insulin Syringe) U-100 SYRINGE 0.3 ML 29 GAUGE | 2 | |
| INSULIN SYRINGE-NEEDLE (Advocate Syringes) U-100 SYRINGE 1 ML 29 GAUGE X 1/2" | 2 | |
| INSULIN SYRINGE-NEEDLE (Lite Touch Insulin Syringe) U-100 SYRINGE 1/2 ML 28 GAUGE | 2 | |
| OMNIPOD DASH 5 PACK POD | 2 | |
| PEN NEEDLE, DIABETIC (1st Tier Unifine NEEDLE 29 GAUGE X 1/2" Pentips) | 2 | |
| SM STERILE PADS 2" X 2" 2"X2", STERILE 2 X 2 " | 1 | |
| Enzyme Replacement/Modifiers | | |
| Enzyme Replacement/Modifiers | | |
| ALDURAZYME INTRAVENOUS SOLUTION 2.9 MG/5 ML | 5 | NM; NDS |
| CERDELGA ORAL CAPSULE 84 MG | 5 | PA; NM; NDS |
| CEREZYME INTRAVENOUS RECON SOLN 400 UNIT | 5 | NM; NDS |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 -60,000 UNIT, 24,000-76,000 - 120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT | 3 | |
| ELAPRASE INTRAVENOUS SOLUTION 6 MG/3 ML | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| ELITEK INTRAVENOUS RECON SOLN 1.5 MG, 7.5 MG | 5 | NM; NDS |
| FABRAZYME INTRAVENOUS RECON SOLN 35 MG, 5 MG | 5 | PA; NM; NDS |
| GALAFOLD ORAL CAPSULE 123 MG | 5 | PA; NM; NDS; QL (14 per 28 days) |
| KANUMA INTRAVENOUS SOLUTION 2 MG/ML | 5 | PA; NM; NDS |
| KRYSTEXXA INTRAVENOUS SOLUTION 8 MG/ML | 5 | PA BvD; NM; NDS |
| KUVAN ORAL TABLET,SOLUBLE 100 MG | 5 | NM; NDS |
| MEPSEVII INTRAVENOUS SOLUTION 2 MG/ML | 5 | PA; NM; NDS |
| <i>miglustat oral capsule 100 mg</i> (Zavesca) | 5 | PA; NM; NDS; QL (90 per 30 days) |
| NAGLAZYME INTRAVENOUS SOLUTION 5 MG/5 ML | 5 | NM; NDS |
| <i>nitisinone oral capsule 10 mg, 2 mg, 5 mg</i> (Orfadin) | 5 | PA; NM; NDS |
| NITYR ORAL TABLET 10 MG, 2 MG, 5 MG | 5 | PA; NM; NDS |
| ORFADIN ORAL CAPSULE 20 MG | 5 | PA; NM; NDS |
| ORFADIN ORAL SUSPENSION 4 MG/ML | 5 | PA; NM; NDS |
| PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML | 5 | PA; NM; NDS |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 5 | PA BvD; NM; NDS |
| REVCovi INTRAMUSCULAR SOLUTION 2.4 MG/1.5 ML (1.6 MG/ML) | 5 | PA; NM; NDS |
| <i>sapropterin oral tablet,soluble 100 mg</i> (Kuvan) | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML | 5 | PA; NM; LA; NDS |
| VIMIZIM INTRAVENOUS SOLUTION 5 MG/5 ML (1 MG/ML) | 5 | PA; NM; NDS |
| VPRIV INTRAVENOUS RECON SOLN 400 UNIT | 5 | NM; NDS |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000-84,000 UNIT, 25,000-79,000-105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000-168,000 UNIT, 5,000-17,000-24,000 UNIT | 3 | |
| Eye, Ear, Nose, Throat Agents | | |
| Eye, Ear, Nose, Throat Agents, Miscellaneous | | |
| <i>alcaine ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>atropine ophthalmic (eye) drops 1 %</i> (Isopto Atropine) | 4 | |
| <i>azelastine nasal aerosol,spray 137 mcg (0.1 %)</i> | 2 | QL (30 per 25 days) |
| <i>azelastine nasal spray,non-aerosol 0.15 % (205.5 mcg)</i> | 4 | QL (30 per 25 days) |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| BEPREVE OPHTHALMIC (EYE) DROPS 1.5 % | 4 | ST |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>cyclopentolate ophthalmic (eye) drops 0.5 %, 1 %, 2 %</i> (Cyclogyl) | 2 | |
| CYSTADROPS OPHTHALMIC (EYE) DROPS 0.37 % | 5 | NM; NDS |
| CYSTARAN OPHTHALMIC (EYE) DROPS 0.44 % | 5 | NM; NDS |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>ipratropium bromide nasal spray,non-aerosol 0.03 %</i> | 2 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i> | 2 | QL (15 per 10 days) |
| <i>olopatadine nasal spray,non-aerosol 0.6 %</i> (Patanase) | 4 | QL (30.5 per 30 days) |
| <i>olopatadine ophthalmic (eye) drops 0.1 %</i> (Pataday) | 2 | |
| <i>olopatadine ophthalmic (eye) drops 0.2 %</i> (Pataday) | 4 | |
| <i>proparacaine ophthalmic (eye) drops 0.5 %</i> (Alcaine) | 2 | |
| TEPEZZA INTRAVENOUS RECON SOLN 500 MG | 5 | PA; NM; NDS |
| Eye, Ear, Nose, Throat Anti-Infectives Agents | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 2 | |
| <i>acetic acid-aluminum acetate otic (ear) drops 2 %</i> | 2 | |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> (Baciguent) | 4 | |
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i> (Polycin) | 2 | |
| BESIVANCE OPHTHALMIC (EYE) DROPS,SUSPENSION 0.6 % | 3 | ST |
| <i>bleph-10 ophthalmic (eye) drops 10 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> (Ciloxan) | 1 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops,suspension 0.3-0.1 %</i> (Ciprodex) | 2 | |
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | 2 | QL (3.5 per 4 days) |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> (Zymaxid) | 4 | |
| <i>gentak ophthalmic (eye) ointment 0.3 % (3 mg/gram)</i> | 2 | |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | 4 | |
| <i>levofloxacin ophthalmic (eye) drops 0.5 %</i> | 4 | |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> (Vigamox) | 2 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | 4 | |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> (Neo-Polycin HC) | 2 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> (Neo-Polycin) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> (Maxitrol) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> (Maxitrol) | 2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml</i> | 2 | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |
| <i>neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | 2 | |
| <i>neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | 2 | |
| <i>ofloxacin ophthalmic (eye) drops (Ocuflox) 0.3 %</i> | 2 | |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | 2 | |
| <i>polycin ophthalmic (eye) ointment 500-10,000 unit/gram</i> | 2 | |
| <i>polymyxin b sulf-trimethoprim (Polytrim) ophthalmic (eye) drops 10,000 unit-1 mg/ml</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic (Bleph-10) (eye) drops 10 %</i> | 2 | |
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | 2 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | 2 | |
| <i>tobramycin ophthalmic (eye) drops (Tobrex) 0.3 %</i> | 1 | |
| <i>tobramycin-dexamethasone (TobraDex) ophthalmic (eye) drops,suspension 0.3-0.1 %</i> | 2 | |
| <i>trifluridine ophthalmic (eye) drops 1 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| ZIRGAN OPHTHALMIC (EYE) GEL 0.15 % | 4 | |
| ZYLET OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % | 3 | |
| Eye, Ear, Nose, Throat Anti-Inflammatory Agents | | |
| ALREX OPHTHALMIC (EYE) DROPS,SUSPENSION 0.2 % | 3 | ST |
| <i>bromfenac ophthalmic (eye) drops</i> 0.09 % | 4 | |
| BROMSITE OPHTHALMIC (EYE) DROPS 0.075 % | 3 | |
| <i>dexamethasone sodium phosphate</i> <i>ophthalmic (eye) drops 0.1 %</i> | 2 | |
| <i>diclofenac sodium ophthalmic (eye)</i> <i>drops 0.1 %</i> | 2 | |
| DUREZOL OPHTHALMIC (EYE) DROPS 0.05 % | 3 | |
| <i>flunisolide nasal spray,non-aerosol</i> 25 mcg (0.025 %) | 2 | QL (50 per 25 days) |
| <i>fluocinolone acetonide oil otic (ear)</i> (DermOtic Oil) <i>drops 0.01 %</i> | 4 | |
| <i>fluorometholone ophthalmic (eye)</i> (FML Liquifilm) <i>drops,suspension 0.1 %</i> | 4 | |
| <i>flurbiprofen sodium ophthalmic</i> <i>(eye) drops 0.03 %</i> | 2 | |
| <i>fluticasone propionate nasal</i> (24 Hour Allergy <i>spray,suspension 50 mcg/actuation</i> Relief) | 1 | QL (16 per 30 days) |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | 3 | |
| INVELTYS OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | 3 | |
| <i>ketorolac ophthalmic (eye) drops</i> (Acular) 0.5 % | 2 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC (EYE) DROPS,GEL 0.5 % | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-------------------------|
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | 3 | |
| LOTEMAX SM OPHTHALMIC (EYE) DROPS,GEL 0.38 % | 3 | |
| <i>loteprednol etabonate ophthalmic</i> (Lotemax) (eye) drops,suspension 0.5 % | 2 | |
| <i>mometasone nasal spray,non-aerosol</i> (Nasonex) 50 mcg/actuation | 2 | QL (34 per 28 days) |
| <i>prednisolone acetate ophthalmic</i> (Pred Forte) (eye) drops,suspension 1 % | 4 | |
| <i>prednisolone sodium phosphate</i> <i>ophthalmic (eye) drops 1 %</i> | 2 | |
| PROLENSA OPHTHALMIC (EYE) DROPS 0.07 % | 3 | |
| RESTASIS OPHTHALMIC (EYE) DROPPERETTE 0.05 % | 3 | QL (60 per 30 days) |
| XHANCE NASAL AEROSOL BREATH ACTIVATED 93 MCG/ACTUATION | 3 | ST; QL (32 per 30 days) |
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % | 3 | QL (60 per 30 days) |
| Gastrointestinal Agents | | |
| Antiulcer Agents And Acid Suppressants | | |
| <i>amoxicil-clarithromy-lansopraz oral</i> <i>combo pack 500-500-30 mg</i> | 4 | |
| <i>cimetidine hcl oral solution 300 mg/5</i> <i>ml</i> | 2 | |
| <i>cimetidine oral tablet 200 mg</i> (Acid Reducer (cimetidine)) | 2 | |
| <i>cimetidine oral tablet 300 mg, 400</i> <i>mg, 800 mg</i> | 2 | |
| DEXILANT ORAL CAPSULE,BIPHASE DELAYED RELEAS 30 MG, 60 MG | 3 | ST; QL (30 per 30 days) |
| <i>esomeprazole sodium intravenous</i> <i>recon soln 20 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>esomeprazole sodium intravenous recon soln 40 mg</i> (Nexium IV) | 2 | |
| <i>famotidine (pf) intravenous solution 20 mg/2 ml</i> | 1 | |
| <i>famotidine (pf)-nacl (iso-os) intravenous piggyback 20 mg/50 ml</i> | 2 | |
| <i>famotidine intravenous solution 10 mg/ml</i> | 2 | |
| <i>famotidine oral suspension 40 mg/5 ml (8 mg/ml)</i> | 4 | |
| <i>famotidine oral tablet 20 mg</i> (Acid Controller) | 1 | |
| <i>famotidine oral tablet 40 mg</i> (Pepcid) | 1 | |
| <i>lansoprazole oral capsule, delayed release (drlec) 15 mg</i> (Heartburn Treatment 24 Hour) | 4 | QL (30 per 30 days) |
| <i>lansoprazole oral capsule, delayed release (drlec) 30 mg</i> (Prevacid) | 4 | QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> (Cytotec) | 2 | |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | 2 | |
| <i>nizatidine oral solution 150 mg/10 ml</i> | 2 | |
| <i>omeprazole oral capsule, delayed release (drlec) 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>omeprazole-sodium bicarbonate oral capsule 20-1.1 mg-gram, 40-1.1 mg-gram</i> (Zegerid) | 4 | ST; QL (30 per 30 days) |
| <i>pantoprazole intravenous recon soln 40 mg</i> (Protonix) | 2 | |
| <i>pantoprazole oral tablet, delayed release (drlec) 20 mg</i> (Protonix) | 1 | QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (drlec) 40 mg</i> (Protonix) | 1 | QL (60 per 30 days) |
| <i>rabeprazole oral tablet, delayed release (drlec) 20 mg</i> (AcipHex) | 2 | ST; QL (30 per 30 days) |
| <i>ranitidine hcl injection solution 25 mg/ml, 50 mg/2 ml (25 mg/ml)</i> | 2 | |
| <i>ranitidine hcl oral syrup 15 mg/ml</i> | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ranitidine hcl oral tablet 150 mg, 300 mg</i> | 1 | |
| <i>sucralfate oral tablet 1 gram</i> (Carafate) | 2 | |
| Gastrointestinal Agents, Other | | |
| AMITIZA ORAL CAPSULE 24 MCG, 8 MCG | 3 | QL (60 per 30 days) |
| CARBAGLU ORAL TABLET, DISPERSIBLE 200 MG | 5 | NM; NDS |
| <i>constulose oral solution 10 gram/15 ml</i> | 2 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> (Gastrocrom) | 4 | |
| <i>dicyclomine oral capsule 10 mg</i> | 2 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 4 | |
| <i>dicyclomine oral tablet 20 mg</i> | 2 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | 4 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> (Lomotil) | 4 | |
| <i>enulose oral solution 10 gram/15 ml</i> | 2 | |
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG | 5 | PA; NM; NDS |
| <i>generlac oral solution 10 gram/15 ml</i> | 2 | |
| <i>glycopyrrolate injection solution 0.2 mg/ml</i> | 4 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>kionex (with sorbitol) oral suspension 15-19.3 gram/60 ml</i> | 2 | |
| <i>lactulose oral solution 10 gram/15 ml</i> (Constulose) | 2 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | QL (30 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM | 3 | QL (90 per 30 days) |
| <i>loperamide oral capsule 2 mg</i> (Anti-Diarrheal (loperamide)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------------|
| <i>methscopolamine oral tablet 2.5 mg, 5 mg</i> | 4 | |
| <i>metoclopramide hcl injection solution 5 mg/ml</i> | 2 | |
| <i>metoclopramide hcl injection syringe 5 mg/ml</i> | 2 | |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | 2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> (Reglan) | 1 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | QL (30 per 30 days) |
| OICALIVA ORAL TABLET 10 MG, 5 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>propantheline oral tablet 15 mg</i> | 4 | |
| RAVICTI ORAL LIQUID 1.1 GRAM/ML | 5 | PA; NM; NDS |
| RELISTOR ORAL TABLET 150 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML | 5 | PA; NM; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML | 5 | PA; NM; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML | 5 | PA; NM; NDS; QL (11.2 per 28 days) |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> (Buphenyl) | 5 | NM; NDS |
| <i>sodium polystyrene (sorb free) oral suspension 15 gram/60 ml</i> | 2 | |
| <i>sodium polystyrene sulfonate oral powder</i> | 2 | |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 2 | |
| TRULANCE ORAL TABLET 3 MG | 4 | QL (30 per 30 days) |
| <i>ursodiol oral capsule 300 mg</i> (Actigall) | 2 | |
| <i>ursodiol oral tablet 250 mg</i> (URSO 250) | 2 | |
| <i>ursodiol oral tablet 500 mg</i> (URSO Forte) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|----------------------------------|
| VIBERZI ORAL TABLET 100 MG, 75 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| XERMELO ORAL TABLET 250 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| Laxatives | | |
| CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM -12 GRAM/160 ML | 3 | |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 -5.84 gram</i> | 2 | |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 -5.86 gram</i> | 2 | |
| <i>gavilyte-n oral recon soln 420 gram</i> | 2 | |
| SUPREP BOWEL PREP KIT ORAL RECON SOLN 17.5-3.13-1.6 GRAM | 3 | |
| <i>trilyte with flavor packets oral recon soln 420 gram</i> | 2 | |
| Phosphate Binders | | |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 2 | |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | 2 | |
| <i>lanthanum oral tablet, chewable</i> (Fosrenol) <i>1,000 mg, 500 mg, 750 mg</i> | 5 | NM; NDS |
| PHOSLYRA ORAL SOLUTION 667 MG (169 MG CALCIUM)/5 ML | 4 | |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> (Renvela) | 5 | NM; NDS |
| <i>sevelamer carbonate oral tablet 800 mg</i> (Renvela) | 4 | |
| <i>sevelamer hcl oral tablet 400 mg</i> | 2 | |
| <i>sevelamer hcl oral tablet 800 mg</i> (Renagel) | 2 | |
| VELPHORO ORAL TABLET,CHEWABLE 500 MG | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| Genitourinary Agents | | |
| Antispasmodics, Urinary | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>flavoxate oral tablet 100 mg</i> | 2 | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG | 3 | |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | 2 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg</i> (Ditropan XL) | 2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 15 mg</i> | 2 | |
| <i>tolterodine oral capsule, extended release 24hr 2 mg, 4 mg</i> (Detrol LA) | 2 | |
| <i>tolterodine oral tablet 1 mg, 2 mg</i> (Detrol) | 2 | |
| TOVIAZ ORAL TABLET EXTENDED RELEASE 24 HR 4 MG, 8 MG | 3 | |
| <i>trospium oral capsule, extended release 24hr 60 mg</i> | 4 | |
| <i>trospium oral tablet 20 mg</i> | 4 | |
| Genitourinary Agents, Miscellaneous | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg</i> (Uroxatral) | 1 | QL (30 per 30 days) |
| <i>dutasteride oral capsule 0.5 mg</i> (Avodart) | 2 | |
| <i>dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg</i> (Jalyn) | 4 | |
| <i>finasteride oral tablet 5 mg</i> (Proscar) | 1 | |
| <i>tamsulosin oral capsule 0.4 mg</i> (Flomax) | 1 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| THIOLA EC ORAL TABLET, DELAYED RELEASE (DR/EC) 100 MG, 300 MG | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------------------|
| THIOLA ORAL TABLET 100 MG | 5 | NM; NDS |
| Heavy Metal Antagonists | | |
| Heavy Metal Antagonists | | |
| <i>clovique oral capsule 250 mg</i> | 5 | PA; NM; NDS; QL (240 per 30 days) |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> (Jadenu Sprinkle) | 5 | PA; NM; NDS |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> (Jadenu) | 5 | PA; NM; NDS |
| <i>deferasirox oral tablet, dispersible 125 mg</i> (Exjade) | 2 | PA |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> (Exjade) | 5 | PA; NM; NDS |
| <i>deferoxamine injection recon soln 2 gram, 500 mg</i> (Desferal) | 2 | PA |
| FERRIPROX ORAL SOLUTION 100 MG/ML | 5 | PA; NM; NDS |
| FERRIPROX ORAL TABLET 1,000 MG, 500 MG | 5 | PA; NM; NDS |
| <i>penicillamine oral capsule 250 mg</i> (Cuprimine) | 5 | PA; NM; NDS |
| <i>penicillamine oral tablet 250 mg</i> (Depen Titratabs) | 5 | PA; NM; NDS |
| <i>trientine oral capsule 250 mg</i> (Clovique) | 5 | PA; NM; NDS; QL (240 per 30 days) |
| Hormonal Agents, Stimulant/Replacement/Modifying | | |
| Androgens | | |
| ANADROL-50 ORAL TABLET 50 MG | 5 | PA; NM; NDS |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | |
| <i>oxandrolone oral tablet 10 mg</i> (Oxandrin) | 5 | NM; NDS |
| <i>oxandrolone oral tablet 2.5 mg</i> (Oxandrin) | 4 | |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml</i> (Depo-Testosterone) | 2 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>testosterone cypionate intramuscular oil 200 mg/ml (1 ml)</i> | 2 | PA |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | 2 | PA; QL (5 per 28 days) |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/1.25 gram (1%)</i> (Vogelxo) | 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62%)</i> (AndroGel) | 2 | PA; QL (150 per 30 days) |
| <i>testosterone transdermal gel in packet 1% (25 mg/2.5gram), 1% (50 mg/5 gram)</i> (AndroGel) | 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal solution in metered pump w/app 30 mg/lactuation (1.5 ml)</i> | 2 | PA; QL (180 per 30 days) |
| XYOSTED SUBCUTANEOUS AUTO-INJECTOR 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| Estrogens And Antiestrogens | | |
| <i>amabelz oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | 2 | |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | 2 | QL (8 per 28 days) |
| DUAVEE ORAL TABLET 0.45-20 MG | 3 | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> (Estrace) | 1 | |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (Dotti) | 2 | QL (8 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>estradiol transdermal patch weekly</i> (Climara) 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr | 2 | QL (4 per 28 days) |
| <i>estradiol vaginal cream 0.01 % (0.1</i> (Estrace) <i>mg/gram)</i> | 2 | |
| <i>estradiol vaginal tablet 10 mcg</i> (Yuvafem) | 2 | QL (18 per 28 days) |
| <i>estradiol valerate intramuscular oil</i> (Delestrogen) 20 mg/ml, 40 mg/ml | 2 | |
| <i>estradiol-norethindrone acet oral</i> (Amabelz) <i>tablet 0.5-0.1 mg</i> | 2 | |
| FEMRING VAGINAL RING 0.05 MG/24 HR, 0.1 MG/24 HR | 4 | QL (1 per 84 days) |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg,</i> <i>1-5 mg-mcg</i> | 2 | |
| <i>jinteli oral tablet 1-5 mg-mcg</i> | 2 | |
| <i>mimvey oral tablet 1-0.5 mg</i> | 2 | |
| <i>norethindrone ac-eth estradiol oral</i> (Fyavolv) <i>tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | 2 | |
| PREMARIN INJECTION RECON SOLN 25 MG | 3 | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.625 MG, 0.9 MG, 1.25 MG | 3 | |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | 3 | |
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG- 5MG(14) | 3 | |
| PREMPRO ORAL TABLET 0.3- 1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | |
| <i>raloxifene oral tablet 60 mg</i> (Evista) | 2 | |
| <i>yuvafem vaginal tablet 10 mcg</i> | 2 | QL (18 per 28 days) |
| Glucocorticoids/Mineralocorticoids | | |
| <i>a-hydrocort injection recon soln 100</i> <i>mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| <i>betamethasone acet,sod phos</i> (Celestone Soluspan) <i>injection suspension 6 mg/ml</i> | 2 | |
| <i>cortisone oral tablet 25 mg</i> | 2 | |
| <i>dexamethasone oral elixir 0.5 mg/5 ml</i> | 2 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 4 mg, 6 mg</i> (Decadron) | 2 | |
| <i>dexamethasone oral tablet 1 mg, 1.5 mg, 2 mg</i> | 2 | |
| <i>dexamethasone sodium phos (pf) injection solution 10 mg/ml</i> | 1 | |
| <i>dexamethasone sodium phos (pf) injection syringe 10 mg/ml</i> | 1 | |
| <i>dexamethasone sodium phosphate injection solution 10 mg/ml, 4 mg/ml</i> | 1 | |
| <i>dexamethasone sodium phosphate injection syringe 4 mg/ml</i> | 1 | |
| EMFLAZA ORAL SUSPENSION 22.75 MG/ML | 5 | PA; NM; NDS; QL (91 per 28 days) |
| EMFLAZA ORAL TABLET 18 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| EMFLAZA ORAL TABLET 30 MG, 36 MG, 6 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>fludrocortisone oral tablet 0.1 mg</i> | 2 | |
| HEMADY ORAL TABLET 20 MG | 4 | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> (Cortef) | 2 | |
| <i>methylprednisolone acetate injection suspension 40 mg/ml, 80 mg/ml</i> (Depo-Medrol) | 2 | |
| <i>methylprednisolone oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> (Medrol) | 2 | |
| <i>methylprednisolone oral tablets,dose pack 4 mg</i> (Medrol (Pak)) | 2 | |
| <i>methylprednisolone sodium succ injection recon soln 125 mg, 40 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------------|
| <i>methylprednisolone sodium succ</i> (Solu-Medrol) <i>intravenous recon soln 1,000 mg,</i> <i>500 mg</i> | 2 | |
| <i>prednisolone 15 mg/5 ml soln alf, dlf</i> <i>15 mg/5 ml (3 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone oral solution 15 mg/5</i> <i>ml</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral</i> <i>solution 25 mg/5 ml (5 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral</i> (Pediapred) <i>solution 5 mg base/5 ml (6.7 mg/5</i> <i>ml)</i> | 2 | PA BvD |
| <i>prednisone oral solution 5 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg,</i> <i>2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD |
| <i>prednisone oral tablets,dose pack 10</i> <i>mg, 10 mg (48 pack), 5 mg, 5 mg</i> <i>(48 pack)</i> | 2 | |
| SOLU-CORTEF ACT-O-VIAL (PF) INJECTION RECON SOLN 1,000 MG/8 ML, 100 MG/2 ML, 250 MG/2 ML, 500 MG/4 ML | 4 | |
| <i>triamcinolone acetonide injection</i> (Kenalog) <i>suspension 40 mg/ml</i> | 2 | |
| Pituitary | | |
| BYNFEZIA SUBCUTANEOUS PEN INJECTOR 2,500 MCG/ML | 5 | NM; NDS |
| <i>desmopressin 10 mcg/0.1 ml spr 10</i> <i>mcg/spray (0.1 ml)</i> | 4 | |
| <i>desmopressin injection solution 4</i> (DDAVP) <i>mcg/ml</i> | 4 | |
| <i>desmopressin nasal spray,non-</i> <i>aerosol 10 mcg/spray (0.1 ml)</i> | 4 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2</i> (DDAVP) <i>mg</i> | 2 | |
| EGRIFTA SUBCUTANEOUS RECON SOLN 1 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| EGRIFTA SV SUBCUTANEOUS RECON SOLN 2 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.2 MG/0.25 ML, 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML | 5 | PA; NM; NDS |
| GENOTROPIN SUBCUTANEOUS CARTRIDGE 12 MG/ML (36 UNIT/ML), 5 MG/ML (15 UNIT/ML) | 5 | PA; NM; NDS |
| HUMATROPE INJECTION CARTRIDGE 12 MG (36 UNIT), 24 MG (72 UNIT), 6 MG (18 UNIT) | 5 | PA; NM; NDS |
| HUMATROPE INJECTION RECON SOLN 5 (15 UNIT) MG | 5 | PA; NM; NDS |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 5 | NM; NDS |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 5 | NM; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG | 5 | NM; NDS |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 5 | NM; NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG | 5 | NM; NDS |
| MYCAPSSA ORAL CAPSULE, DELAYED RELEASE (DR/EC) 20 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------------|
| NOCDURNA (MEN) SUBLINGUAL TABLET,DISINTEGRATING 55.3 MCG | 3 | QL (30 per 30 days) |
| NOCDURNA (WOMEN) SUBLINGUAL TABLET,DISINTEGRATING 27.7 MCG | 3 | QL (30 per 30 days) |
| NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 5 | PA; NM; NDS |
| NUTROPIN AQ NUSPIN SUBCUTANEOUS PEN INJECTOR 10 MG/2 ML (5 MG/ML), 20 MG/2 ML (10 MG/ML), 5 MG/2 ML (2.5 MG/ML) | 5 | PA; NM; NDS |
| <i>octreotide acetate injection solution</i> <i>1,000 mcg/ml, 200 mcg/ml</i> | 2 | |
| <i>octreotide acetate injection solution</i> (Sandostatin) <i>100 mcg/ml, 50 mcg/ml, 500 mcg/ml</i> | 2 | |
| <i>octreotide acetate injection syringe</i> <i>100 mcg/ml (1 ml), 50 mcg/ml (1 ml), 500 mcg/ml (1 ml)</i> | 2 | |
| OMNITROPE SUBCUTANEOUS CARTRIDGE 10 MG/1.5 ML (6.7 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 5 | PA; NM; NDS |
| OMNITROPE SUBCUTANEOUS RECON SOLN 5.8 MG | 4 | PA |
| ORILISSA ORAL TABLET 150 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------------|
| ORILISSA ORAL TABLET 200 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| SAIZEN SAIZENPREP SUBCUTANEOUS CARTRIDGE 8.8 MG/1.51 ML (FINAL CONC.) | 5 | PA; NM; NDS |
| SAIZEN SUBCUTANEOUS RECON SOLN 5 MG, 8.8 MG | 5 | PA; NM; NDS |
| SANDOSTATIN LAR DEPOT INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 10 MG, 20 MG, 30 MG | 5 | NM; NDS |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | 5 | PA; NM; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 120 MG/0.5 ML | 5 | PA NSO; NM; NDS; QL (1 per 28 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 60 MG/0.2 ML, 90 MG/0.3 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NM; NDS |
| STIMATE NASAL SPRAY, NON-AEROSOL 150 MCG/SPRAY (0.1 ML) | 3 | |
| SUPPRELIN LA IMPLANT KIT 50 MG (65 MCG/DAY) | 5 | NM; NDS; QL (1 per 360 days) |
| SYNAREL NASAL SPRAY, NON-AEROSOL 2 MG/ML | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|---------------------------------|
| TRIPTODUR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG | 5 | NM; NDS; QL (1 per 168 days) |
| ZOMACTON SUBCUTANEOUS RECON SOLN 10 MG | 5 | PA; NM; NDS |
| ZOMACTON SUBCUTANEOUS RECON SOLN 5 MG | 4 | PA |
| ZORBTIVE SUBCUTANEOUS RECON SOLN 8.8 MG | 5 | PA; NM; NDS |
| Progestins | | |
| DEPO-PROVERA INTRAMUSCULAR SUSPENSION 400 MG/ML | 4 | QL (10 per 28 days) |
| <i>hydroxyprogesterone cap(ppres)</i> (Makena) <i>intramuscular oil 250 mg/ml</i> | 5 | NM; NDS |
| <i>medroxyprogesterone intramuscular</i> (Depo-Provera) <i>suspension 150 mg/ml</i> | 2 | QL (1 per 84 days) |
| <i>medroxyprogesterone intramuscular</i> (Depo-Provera) <i>syringe 150 mg/ml</i> | 2 | QL (1 per 84 days) |
| <i>medroxyprogesterone oral tablet 10</i> (Provera) <i>mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>megestrol oral suspension 400 mg/10</i> <i>ml (40 mg/ml)</i> | 2 | |
| <i>norethindrone acetate oral tablet 5</i> (Aygestin) <i>mg</i> | 2 | |
| <i>progesterone intramuscular oil 50</i> <i>mg/ml</i> | 2 | |
| <i>progesterone micronized oral</i> (Prometrium) <i>capsule 100 mg, 200 mg</i> | 2 | |
| Thyroid And Antithyroid Agents | | |
| <i>levothyroxine oral tablet 100 mcg,</i> (Euthyrox) <i>112 mcg, 125 mcg, 137 mcg, 150</i> <i>mcg, 175 mcg, 200 mcg, 25 mcg, 50</i> <i>mcg, 75 mcg, 88 mcg</i> | 1 | |
| <i>levothyroxine oral tablet 300 mcg</i> (Levo-T) | 1 | |
| <i>liothyronine oral tablet 25 mcg, 5</i> (Cytomel) <i>mcg, 50 mcg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| <i>methimazole oral tablet 10 mg, 5 mg</i> (Tapazole) | 1 | |
| <i>propylthiouracil oral tablet 50 mg</i> | 2 | |
| Immunological Agents | | |
| Immunological Agents | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 5 | PA; NM; NDS |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) | 5 | PA; NM; NDS |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 5 | PA; NM; NDS |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 5 | NM; NDS |
| AVSOLA INTRAVENOUS RECON SOLN 100 MG | 5 | PA; NM; NDS |
| <i>azathioprine oral tablet 50 mg</i> (Imuran) | 2 | PA BvD |
| <i>azathioprine sodium injection recon soln 100 mg</i> | 2 | PA BvD |
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) | 5 | PA; NM; NDS |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 5 | PA; NM; NDS |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NM; NDS |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NM; NDS |
| <i>cyclosporine intravenous solution</i> (Sandimmune) <i>250 mg/5 ml</i> | 2 | PA BvD |
| <i>cyclosporine modified oral capsule</i> (Gengraf) <i>100 mg, 25 mg</i> | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>cyclosporine modified oral capsule</i> 50 mg | 2 | PA BvD |
| <i>cyclosporine modified oral solution</i> (Gengraf) 100 mg/ml | 2 | PA BvD |
| <i>cyclosporine oral capsule</i> 100 mg, 25 mg (Sandimmune) | 2 | PA BvD |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | 5 | PA; NM; NDS |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NM; NDS |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| <i>everolimus (immunosuppressive)</i> (Zortress) <i>oral tablet</i> 0.25 mg | 4 | PA BvD |
| <i>everolimus (immunosuppressive)</i> (Zortress) <i>oral tablet</i> 0.5 mg, 0.75 mg | 5 | PA BvD; NM; NDS |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %, 5 % | 5 | PA BvD; NM; NDS |
| GAMASTAN INTRAMUSCULAR SOLUTION 15-18 % RANGE | 4 | PA BvD |
| GAMMAGARD LIQUID INJECTION SOLUTION 10 % | 5 | PA BvD; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM | 5 | PA BvD; NM; NDS |
| GAMMAPLEX (WITH SORBITOL) INTRAVENOUS SOLUTION 5 % | 5 | PA BvD; NM; NDS |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML) | 5 | PA BvD; NM; NDS |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %), 10 GRAM/100 ML (10 %), 2.5 GRAM/25 ML (10 %), 20 GRAM/200 ML (10 %), 40 GRAM/400 ML (10 %), 5 GRAM/50 ML (10 %) | 5 | PA BvD; NM; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg</i> | 2 | PA BvD |
| <i>gengraf oral solution 100 mg/ml</i> | 2 | PA BvD |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.8 ML | 5 | PA; NM; NDS |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NM; NDS |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NM; NDS |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML | 5 | PA; NM; NDS |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NM; NDS |
| HYPERRAB (PF) INTRAMUSCULAR SOLUTION 300 UNIT/ML | 4 | |
| HYPERRAB S/D (PF) INTRAMUSCULAR SOLUTION 150 UNIT/ML | 4 | |
| HYQVIA SUBCUTANEOUS SOLUTION 10 GRAM /100 ML (10 %), 2.5 GRAM /25 ML (10 %), 20 GRAM /200 ML (10 %), 30 GRAM /300 ML (10 %), 5 GRAM /50 ML (10 %) | 5 | PA BvD; NM; NDS |
| ILARIS (PF) SUBCUTANEOUS SOLUTION 150 MG/ML | 5 | PA; NM; NDS |
| ILUMYA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; NM; NDS |
| IMOGAM RABIES-HT (PF) INTRAMUSCULAR SOLUTION 150 UNIT/ML | 4 | |
| INFLECTRA INTRAVENOUS RECON SOLN 100 MG | 5 | PA; NM; NDS |
| KEDRAB (PF) INTRAMUSCULAR SOLUTION 150 UNIT/ML | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| KEVZARA SUBCUTANEOUS PEN INJECTOR 150 MG/1.14 ML, 200 MG/1.14 ML | 5 | PA; NM; NDS |
| KEVZARA SUBCUTANEOUS SYRINGE 150 MG/1.14 ML, 200 MG/1.14 ML | 5 | PA; NM; NDS |
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 5 | PA; NM; NDS |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> (Arava) | 2 | |
| <i>mycophenolate mofetil (hcl)</i> (CellCept Intravenous) <i>intravenous recon soln 500 mg</i> | 2 | PA BvD |
| <i>mycophenolate mofetil oral capsule</i> (CellCept) <i>250 mg</i> | 2 | PA BvD |
| <i>mycophenolate mofetil oral</i> (CellCept) <i>suspension for reconstitution 200</i> <i>mg/ml</i> | 5 | PA BvD; NM; NDS |
| <i>mycophenolate mofetil oral tablet</i> (CellCept) <i>500 mg</i> | 2 | PA BvD |
| NULOJIX INTRAVENOUS RECON SOLN 250 MG | 5 | PA BvD; NM; NDS |
| OCTAGAM INTRAVENOUS SOLUTION 10 %, 5 % | 5 | PA BvD; NM; NDS |
| OLUMIANT ORAL TABLET 1 MG, 2 MG | 5 | PA; NM; NDS |
| ORENCIA (WITH MALTOSE) INTRAVENOUS RECON SOLN 250 MG | 5 | PA; NM; NDS |
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO- INJECTOR 125 MG/ML | 5 | PA; NM; NDS |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML | 5 | PA; NM; NDS |
| OTEZLA ORAL TABLET 30 MG | 5 | PA; NM; NDS |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG(19) | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| PRIVIGEN INTRAVENOUS SOLUTION 10 % | 5 | PA BvD; NM; NDS |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML | 4 | PA BvD |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 4 | PA BvD |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML | 3 | |
| REMICADE INTRAVENOUS RECON SOLN 100 MG | 5 | PA; NM; NDS |
| RENFLEXIS INTRAVENOUS RECON SOLN 100 MG | 5 | PA; NM; NDS |
| RIDAURA ORAL CAPSULE 3 MG | 5 | NM; NDS |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG | 5 | PA; NM; NDS |
| SILIQ SUBCUTANEOUS SYRINGE 210 MG/1.5 ML | 5 | PA; NM; NDS |
| SIMPONI ARIA INTRAVENOUS SOLUTION 12.5 MG/ML | 5 | PA; NM; NDS |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML | 5 | PA; NM; NDS |
| SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML | 5 | PA; NM; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> (Rapamune) | 5 | PA BvD; NM; NDS |
| <i>sirolimus oral tablet 0.5 mg, 1 mg</i> (Rapamune) | 4 | PA BvD |
| <i>sirolimus oral tablet 2 mg</i> (Rapamune) | 5 | PA BvD; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| SKYRIZI SUBCUTANEOUS SYRINGE KIT 150MG/1.66ML(75 MG/0.83 ML X2) | 5 | PA; NM; NDS |
| STELARA INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NM; NDS |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 5 | PA; NM; NDS |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML | 5 | PA; NM; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> (Prograf) | 2 | PA BvD |
| TALTZ AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 80 MG/ML | 5 | PA; NM; NDS |
| TALTZ SYRINGE SUBCUTANEOUS SYRINGE 80 MG/ML | 5 | PA; NM; NDS |
| TREMFYA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NM; NDS |
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; NM; NDS |
| TYSABRI INTRAVENOUS SOLUTION 300 MG/15 ML | 5 | PA; NM; LA; NDS |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5 | PA; NM; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 5 | PA; NM; NDS |
| ZORTRESS ORAL TABLET 1 MG | 5 | PA BvD; NM; NDS |
| Vaccines | | |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 6 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 6 | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 6 | |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 6 | PA BvD |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 6 | |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG- LF/0.5ML | 6 | |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML | 6 | |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG- LF/0.5ML | 6 | |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 6 | PA BvD |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 6 | PA BvD |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 6 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 6 | QL (1.5 per 365 days) |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 6 | QL (1.5 per 365 days) |
| HAVRIX (PF) INTRAMUSCULAR SUSPENSION 1,440 ELISA UNIT/ML | 6 | |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML, 720 ELISA UNIT/0.5 ML | 6 | |
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 6 | |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 6 | PA BvD |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SUSPENSION 25-58-10 LF- MCG-LF/0.5ML | 6 | |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25-58-10 LF-MCG-LF/0.5ML | 6 | |
| IPOL INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 6 | |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 6 | |
| KINRIX (PF) INTRAMUSCULAR SUSPENSION 25 LF-58 MCG-10 LF/0.5 ML | 6 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 6 | |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 6 | |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 6 | |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 6 | |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 6 | |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 6 | |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 6 | |
| PENTACEL (PF) INTRAMUSCULAR KIT 15 LF UNIT-20 MCG-5 LF/0.5 ML | 6 | |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3- 4.3-3- 3.99 TCID50/0.5 | 6 | |
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML | 6 | |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 6 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 6 | PA BvD |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 6 | PA BvD |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 6 | |
| ROTATEQ VACCINE ORAL SOLUTION 2 ML | 6 | |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 6 | QL (2 per 365 days) |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML | 6 | |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 6 | |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 6 | |
| TETANUS,DIPHThERIA TOX PED(PF) INTRAMUSCULAR SUSPENSION 5-25 LF UNIT/0.5 ML | 6 | |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 6 | |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 6 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------|
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 6 | |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML | 6 | |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML, 50 UNIT/ML | 6 | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML, 50 UNIT/ML | 6 | |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 6 | QL (2 per 365 days) |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML | 6 | |
| ZOSTAVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 19,400 UNIT/0.65 ML | 6 | QL (1 per 365 days) |
| Inflammatory Bowel Disease | | |
| Agents | | |
| Inflammatory Bowel Disease Agents | | |
| <i>alosetron oral tablet 0.5 mg</i> (Lotronex) | 2 | |
| <i>alosetron oral tablet 1 mg</i> (Lotronex) | 5 | NM; NDS |
| <i>balsalazide oral capsule 750 mg</i> (Colazal) | 2 | |
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> (Entocort EC) | 4 | |
| <i>colocort rectal enema 100 mg/60 ml</i> | 2 | |
| DIPENTUM ORAL CAPSULE 250 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>hydrocortisone rectal enema 100 mg/60 ml</i> (Cortenema) | 4 | |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> (Delzicol) | 4 | |
| <i>mesalamine oral capsule,extended release 24hr 0.375 gram</i> (Apriso) | 4 | |
| <i>mesalamine oral tablet,delayed release (drlec) 1.2 gram</i> (Lialda) | 4 | |
| <i>mesalamine oral tablet,delayed release (drlec) 800 mg</i> (Asacol HD) | 4 | |
| <i>mesalamine rectal suppository 1,000 mg</i> (Canasa) | 5 | NM; NDS |
| <i>sulfasalazine oral tablet 500 mg</i> (Azulfidine) | 2 | |
| <i>sulfasalazine oral tablet,delayed release (drlec) 500 mg</i> (Azulfidine EN-tabs) | 2 | |
| UCERIS RECTAL FOAM 2 MG/ACTUATION | 3 | |
| Irrigating Solutions | | |
| Irrigating Solutions | | |
| LACTATED RINGERS IRRIGATION SOLUTION | 4 | |
| Metabolic Bone Disease Agents | | |
| Metabolic Bone Disease Agents | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | 4 | QL (300 per 28 days) |
| <i>alendronate oral tablet 10 mg, 5 mg</i> | 1 | QL (30 per 30 days) |
| <i>alendronate oral tablet 35 mg</i> | 1 | QL (4 per 28 days) |
| <i>alendronate oral tablet 70 mg</i> (Fosamax) | 1 | QL (4 per 28 days) |
| <i>calcitonin (salmon) nasal spray,non-aerosol 200 unit/lactuation</i> | 2 | QL (3.7 per 28 days) |
| <i>calcitriol intravenous solution 1 mcg/ml</i> | 2 | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> (Rocaltrol) | 2 | |
| <i>calcitriol oral solution 1 mcg/ml</i> (Rocaltrol) | 4 | |
| <i>cinacalcet oral tablet 30 mg</i> (Sensipar) | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------------|
| <i>cinacalcet oral tablet 60 mg</i> (Sensipar) | 5 | NM; NDS; QL (60 per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> (Sensipar) | 5 | NM; NDS; QL (120 per 30 days) |
| <i>doxercalciferol intravenous solution 4 mcg/2 ml</i> (Hectorol) | 2 | |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | 4 | |
| EVENITY SUBCUTANEOUS SYRINGE 105 MG/1.17 ML, 210MG/2.34ML (105MG/1.17MLX2) | 5 | PA; NM; NDS; QL (2.34 per 30 days) |
| FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE - 600 MCG/2.4 ML | 3 | PA; QL (2.4 per 28 days) |
| <i>ibandronate intravenous solution 3 mg/3 ml</i> | 4 | QL (3 per 84 days) |
| <i>ibandronate intravenous syringe 3 mg/3 ml</i> (Boniva) | 4 | QL (3 per 84 days) |
| <i>ibandronate oral tablet 150 mg</i> (Boniva) | 2 | QL (1 per 28 days) |
| MIACALCIN INJECTION SOLUTION 200 UNIT/ML | 5 | NM; NDS |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE | 5 | PA; NM; NDS; QL (2 per 28 days) |
| <i>pamidronate intravenous recon soln 30 mg, 90 mg</i> | 2 | |
| <i>pamidronate intravenous solution 30 mg/10 ml (3 mg/ml), 60 mg/10 ml (6 mg/ml), 90 mg/10 ml (9 mg/ml)</i> | 2 | |
| <i>paricalcitol hemodialysis port injection solution 2 mcg/ml</i> | 4 | |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg</i> (Zemplar) | 4 | |
| <i>paricalcitol oral capsule 4 mcg</i> | 4 | |
| PROLIA SUBCUTANEOUS SYRINGE 60 MG/ML | 3 | ST; QL (1 per 180 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| <i>risedronate oral tablet 150 mg</i> (Actonel) | 4 | QL (1 per 28 days) |
| <i>risedronate oral tablet 30 mg</i> | 4 | QL (30 per 30 days) |
| <i>risedronate oral tablet 35 mg</i> (Actonel) | 4 | QL (4 per 28 days) |
| <i>risedronate oral tablet 35 mg (12 pack), 35 mg (4 pack)</i> | 4 | QL (4 per 28 days) |
| <i>risedronate oral tablet 5 mg</i> (Actonel) | 4 | QL (30 per 30 days) |
| <i>risedronate oral tablet, delayed release (drlec) 35 mg</i> | 4 | QL (4 per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 3 | PA; QL (1.56 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 5 | PA; NM; NDS |
| <i>zoledronic acid intravenous recon soln 4 mg</i> | 4 | |
| <i>zoledronic acid intravenous solution 4 mg/5 ml</i> | 4 | |
| <i>zoledronic acid-mannitol-water intravenous piggyback 5 mg/100 ml</i> (Reclast) | 4 | QL (100 per 300 days) |
| Miscellaneous Therapeutic Agents | | |
| Miscellaneous Therapeutic Agents | | |
| ACTHAR INJECTION GEL 80 UNIT/ML | 5 | PA; NM; NDS; QL (35 per 28 days) |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 5 | PA; NM; NDS |
| BENLYSTA INTRAVENOUS RECON SOLN 120 MG, 400 MG | 5 | PA; NM; NDS |
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML | 5 | PA; NM; NDS; QL (4 per 28 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 5 | PA; NM; NDS; QL (4 per 28 days) |
| CYSTADANE ORAL POWDER 1 GRAM/1.7 ML | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>dexrazoxane hcl intravenous recon soln 250 mg, 500 mg</i> | 5 | NM; NDS |
| <i>diazoxide oral suspension 50 mg/ml</i> (Proglycem) | 2 | |
| ELMIRON ORAL CAPSULE 100 MG | 5 | NM; NDS; QL (90 per 30 days) |
| ENDARI ORAL POWDER IN PACKET 5 GRAM | 5 | PA; NM; NDS; QL (180 per 30 days) |
| EVRYSDI ORAL RECON SOLN 0.75 MG/ML | 5 | PA; NM; NDS |
| EXONDYS-51 INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA; NM; LA; NDS |
| <i>fomepizole intravenous solution 1 gram/ml</i> | 5 | NM; NDS |
| GVOKE HYPOPEN 1PK 0.5 MG/0.1 ML 0.5 MG/0.1 ML | 3 | |
| GVOKE HYPOPEN 1-PK 1 MG/0.2 ML 1 MG/0.2 ML | 3 | |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE PFS 1PK 0.5 MG/0.1 ML SYR 0.5 MG/0.1 ML | 3 | |
| GVOKE PFS 1-PK 1 MG/0.2 ML SYR 1 MG/0.2 ML | 3 | |
| GVOKE PFS 2-PACK SYRINGE SUBCUTANEOUS SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| <i>hydroxyzine pamoate oral capsule 100 mg</i> | 2 | |
| <i>hydroxyzine pamoate oral capsule 25 mg, 50 mg</i> (Vistaril) | 2 | |
| KEVEYIS ORAL TABLET 50 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| <i>leucovorin calcium injection recon soln 100 mg, 200 mg, 350 mg, 50 mg, 500 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| <i>leucovorin calcium injection solution 10 mg/ml</i> | 2 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> (Carnitor) | 2 | |
| <i>levocarnitine oral tablet 330 mg</i> (Carnitor) | 2 | |
| <i>levoleucovorin calcium intravenous recon soln 50 mg</i> (Fusilev) | 5 | NM; NDS |
| <i>mesna intravenous solution 100 mg/ml</i> (Mesnex) | 2 | |
| MESNEX ORAL TABLET 400 MG | 5 | NM; NDS |
| <i>pyridostigmine bromide oral syrup 60 mg/5 ml</i> (Mestinon) | 4 | |
| <i>pyridostigmine bromide oral tablet 30 mg</i> | 4 | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> (Mestinon) | 2 | |
| <i>pyridostigmine bromide oral tablet extended release 180 mg</i> (Mestinon Timespan) | 4 | |
| RECTIV RECTAL OINTMENT 0.4 % (W/W) | 4 | QL (30 per 30 days) |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2 ML (150 MG/ML) | 5 | PA; NM; NDS; QL (4 per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| TOTECT INTRAVENOUS RECON SOLN 500 MG | 5 | NM; NDS |
| TYBOST ORAL TABLET 150 MG | 3 | QL (30 per 30 days) |
| VISTOGARD ORAL GRANULES IN PACKET 10 GRAM | 5 | NM; NDS; QL (24 per 14 days) |
| XURIDEN ORAL GRANULES IN PACKET 2 GRAM | 5 | PA; NM; NDS; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------|
| Ophthalmic Agents | | |
| Antiglaucoma Agents | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | |
| <i>acetazolamide sodium injection recon soln 500 mg</i> | 2 | |
| ALPHAGAN P OPHTHALMIC (EYE) DROPS 0.1 % | 3 | |
| AZOPT OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | 3 | |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>bimatoprost ophthalmic (eye) drops 0.03 %</i> | 4 | QL (2.5 per 25 days) |
| <i>brimonidine ophthalmic (eye) drops (Alphagan P) 0.15 %</i> | 4 | |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | 1 | |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 1 | |
| COMBIGAN OPHTHALMIC (EYE) DROPS 0.2-0.5 % | 3 | |
| <i>dorzolamide ophthalmic (eye) drops (Trusopt) 2 %</i> | 2 | |
| <i>dorzolamide-timolol ophthalmic (eye) drops 22.3-6.8 mg/ml (Cosopt)</i> | 2 | |
| <i>latanoprost ophthalmic (eye) drops (Xalatan) 0.005 %</i> | 1 | QL (2.5 per 25 days) |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | 1 | |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | 3 | QL (2.5 per 25 days) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 4 | |
| <i>metipranolol ophthalmic (eye) drops 0.3 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| <i>pilocarpine hcl ophthalmic (eye)</i> (Isopto Carpine) <i>drops 1 %, 2 %, 4 %</i> | 2 | |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 3 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 3 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1- 0.2 % | 3 | |
| <i>timolol maleate ophthalmic (eye)</i> (Timoptic) <i>drops 0.25 %, 0.5 %</i> | 1 | |
| <i>timolol maleate ophthalmic (eye)</i> (Timoptic-XE) <i>gel forming solution 0.25 %, 0.5 %</i> | 4 | |
| <i>travoprost ophthalmic (eye) drops</i> (Travatan Z) <i>0.004 %</i> | 4 | QL (2.5 per 25 days) |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 4 | QL (5 per 30 days) |
| XELPROS OPHTHALMIC (EYE) DROPS, EMULSION 0.005 % | 4 | ST; QL (2.5 per 25 days) |
| ZIOPTAN (PF) OPHTHALMIC (EYE) DROPPERETTE 0.0015 % | 4 | QL (30 per 30 days) |
| Replacement Preparations | | |
| Replacement Preparations | | |
| <i>calcium chloride intravenous syringe</i> <i>100 mg/ml (10 %)</i> | 2 | |
| IONOSOL-B IN D5W INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | |
| IONOSOL-MB IN D5W INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | |
| ISOLYTE-S INTRAVENOUS PARENTERAL SOLUTION | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> | 2 | |
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> | 2 | |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> | 2 | |
| <i>magnesium sulfate in d5w intravenous piggyback 1 gram/100 ml</i> | 2 | |
| <i>magnesium sulfate in water intravenous parenteral solution 20 gram/500 ml (4%), 40 gram/1,000 ml (4%)</i> | 2 | PA BvD |
| <i>magnesium sulfate in water intravenous piggyback 2 gram/50 ml (4%), 4 gram/100 ml (4%), 4 gram/50 ml (8%)</i> | 2 | PA BvD |
| <i>magnesium sulfate injection solution 4 meq/ml (50%)</i> | 2 | PA BvD |
| <i>magnesium sulfate injection syringe 4 meq/ml</i> | 2 | PA BvD |
| NORMOSOL-M IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| NORMOSOL-R PH 7.4 INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| PLASMA-LYTE 148 INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| PLASMA-LYTE A INTRAVENOUS PARENTERAL SOLUTION | 4 | |
| <i>potassium chloride intravenous solution 2 meq/ml</i> | 2 | PA BvD |
| <i>potassium chloride intravenous solution 2 meq/ml (20 ml)</i> | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | 2 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | 4 | |
| <i>potassium chloride oral tablet extended release 10 meq, 8 meq</i> (K-Tab) | 2 | |
| <i>potassium chloride oral tablet, er particles/crystals 10 meq</i> (Klor-Con M10) | 2 | |
| <i>potassium chloride oral tablet, er particles/crystals 20 meq</i> (Klor-Con M20) | 2 | |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i> | 2 | |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg)</i> (Urocit-K 10) | 2 | |
| <i>potassium citrate oral tablet extended release 15 meq</i> (Urocit-K 15) | 2 | |
| <i>potassium citrate oral tablet extended release 5 meq (540 mg)</i> (Urocit-K 5) | 2 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | 2 | |
| Respiratory Tract Agents | | |
| Anti-Inflammatories, Inhaled Corticosteroids | | |
| ADVAIR DISKUS INHALATION BLISTER WITH DEVICE 100-50 MCG/DOSE, 250-50 MCG/DOSE, 500-50 MCG/DOSE | 2 | QL (60 per 30 days) |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION | 3 | QL (12 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|-----------------------|
| ARNUIITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION | 3 | QL (30 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE | 3 | QL (60 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml</i> (Pulmicort) | 2 | PA BvD |
| FLOVENT 100 MCG DISKUS 100 MCG/ACTUATION | 3 | QL (60 per 30 days) |
| FLOVENT 250 MCG DISKUS 250 MCG/ACTUATION | 3 | QL (120 per 30 days) |
| FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 50 MCG/ACTUATION | 3 | QL (60 per 30 days) |
| FLOVENT DISKUS INHALATION BLISTER WITH DEVICE 250 MCG/ACTUATION | 3 | QL (120 per 30 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION | 3 | QL (12 per 28 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 220 MCG/ACTUATION | 3 | QL (24 per 28 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 44 MCG/ACTUATION | 3 | QL (21.2 per 28 days) |
| Antileukotrienes | | |
| <i>montelukast oral tablet 10 mg</i> (Singulair) | 1 | |
| <i>montelukast oral tablet, chewable 4 mg, 5 mg</i> (Singulair) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| <i>zafirlukast oral tablet 10 mg, 20 mg (Accolate)</i> | 4 | |
| Bronchodilators | | |
| <i>albuterol 5 mg/ml solution 5 mg/ml</i> | 2 | PA BvD; QL (120 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (ProAir HFA)</i> | 2 | QL (17 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | 2 | QL (13.4 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i> | 2 | QL (36 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %)</i> | 2 | PA BvD; QL (360 per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 2.5 mg/0.5 ml</i> | 2 | PA BvD; QL (120 per 30 days) |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | 2 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 2 | |
| <i>albuterol sulfate oral tablet extended release 12 hr 4 mg, 8 mg</i> | 2 | |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION | 3 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 3 | QL (25.8 per 28 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 3 | QL (8 per 30 days) |
| <i>elixophyllin oral elixir 80 mg/15 ml</i> | 4 | |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | PA BvD; QL (312.5 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | 2 | PA BvD; QL (540 per 30 days) |
| <i>metaproterenol oral syrup 10 mg/5 ml</i> | 1 | |
| PROAIR RESPICLICK INHALATION AEROSOL POWDR BREATH ACTIVATED 90 MCG/ACTUATION | 3 | QL (2 per 30 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 3 | QL (60 per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| SPIRIVA WITH HANDIHALER INHALATION CAPSULE, W/INHALATION DEVICE 18 MCG | 3 | QL (30 per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION | 3 | QL (4 per 28 days) |
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 3 | QL (4 per 28 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | 4 | |
| <i>terbutaline subcutaneous solution 1 mg/ml</i> | 5 | NM; NDS |
| <i>theophylline oral solution 80 mg/15 ml</i> | 4 | |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg</i> | 2 | |
| <i>theophylline oral tablet extended release 12 hr 300 mg, 450 mg</i> | 4 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------------|
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG | 3 | QL (60 per 30 days) |
| Respiratory Tract Agents, Other | | |
| <i>acetylcysteine intravenous solution (Acetadote) 200 mg/ml (20 %)</i> | 2 | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 2 | PA BvD |
| CINQAIR INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA; NM; NDS |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 2 | PA BvD |
| DALIRESP ORAL TABLET 250 MCG | 3 | QL (28 per 28 days) |
| DALIRESP ORAL TABLET 500 MCG | 3 | QL (30 per 30 days) |
| ESBRIET ORAL CAPSULE 267 MG | 5 | PA; NM; NDS; QL (270 per 30 days) |
| ESBRIET ORAL TABLET 267 MG | 5 | PA; NM; NDS; QL (270 per 30 days) |
| ESBRIET ORAL TABLET 801 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| FASENRA SUBCUTANEOUS SYRINGE 30 MG/ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 25 MG, 50 MG, 75 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| PROLASTIN C 1,000 MG/20 ML VL PRICE/ONE MG,L/F,SUV 1,000 MG (+/-)/20 ML | 5 | PA BvD; NM; NDS |
| PROLASTIN-C INTRAVENOUS RECON SOLN 1,000 MG | 5 | PA BvD; NM; NDS |
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) | 5 | PA; NM; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N) | 5 | PA; NM; NDS; QL (84 per 28 days) |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 5 | PA; NM; NDS |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.5 ML | 5 | PA; NM; NDS |
| Skeletal Muscle Relaxants | | |
| Skeletal Muscle Relaxants | | |
| <i>baclofen oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>chlorzoxazone oral tablet 250 mg</i> | 5 | NM; NDS |
| <i>chlorzoxazone oral tablet 500 mg</i> | 2 | |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>dantrolene oral capsule 100 mg</i> | 2 | |
| <i>dantrolene oral capsule 25 mg, 50 mg</i> (Dantrium) | 2 | |
| <i>methocarbamol oral tablet 500 mg</i> | 2 | |
| <i>methocarbamol oral tablet 750 mg</i> (Robaxin-750) | 2 | |
| <i>revonto intravenous recon soln 20 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|---------------------------------------|
| <i>tizanidine oral tablet 2 mg</i> | 2 | |
| <i>tizanidine oral tablet 4 mg</i> (Zanaflex) | 2 | |
| Sleep Disorder Agents | | |
| Sleep Disorder Agents | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> (Nuvigil) | 2 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> (Lunesta) | 4 | QL (30 per 30 days) |
| HETLIOZ ORAL CAPSULE 20 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| SUNOSI ORAL TABLET 150 MG, 75 MG | 4 | PA; QL (30 per 30 days) |
| XYREM ORAL SOLUTION 500 MG/ML | 5 | PA; NM; LA; NDS; QL (540 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 4 | QL (30 per 30 days) |
| <i>zolpidem oral tablet 10 mg, 5 mg</i> (Ambien) | 1 | QL (30 per 30 days) |
| <i>zolpidem oral tablet, ext release multiphase 12.5 mg, 6.25 mg</i> (Ambien CR) | 2 | QL (30 per 30 days) |
| Vasodilating Agents | | |
| Vasodilating Agents | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> (Letairis) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>epoprostenol (glycine) intravenous recon soln 0.5 mg</i> (Flolan) | 2 | PA |
| <i>epoprostenol (glycine) intravenous recon soln 1.5 mg</i> (Flolan) | 5 | PA; NM; NDS |
| OPSUMIT ORAL TABLET 10 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>sildenafil (pulm.hypertension) intravenous solution 10 mg/12.5 ml</i> (Revatio) | 5 | PA; NM; NDS; QL (37.5 per 1 day) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> (Revatio) | 2 | PA; QL (90 per 30 days) |
| <i>tadalafil (pulm. hypertension) oral tablet 20 mg</i> (Alyq) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>tadalafil oral tablet 2.5 mg, 5 mg</i> (Cialis) | 2 | PA; QL (30 per 30 days) |
| TRACLEER ORAL TABLET 125 MG, 62.5 MG | 5 | PA; NM; LA; NDS; QL (60 per 30 days) |
| TRACLEER ORAL TABLET FOR SUSPENSION 32 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| <i>treprostinil sodium injection solution 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml</i> (Remodulin) | 5 | PA; NM; NDS |
| TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) | 5 | PA; NM; NDS |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 5 | PA; NM; NDS; QL (240 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) | 5 | PA; NM; NDS |
| Vitamins And Minerals | | |
| Vitamins And Minerals | | |
| SE-NATAL-19 ORAL TABLET 29 MG IRON- 1 MG | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

Effective Date: 01/01/2021

Formulary ID: 21045.000

INDEX

| | | | | | |
|--|---------|---------------------------------|-----|--|--------|
| <i>abacavir</i> | 71 | <i>a-hydrocort</i> | 134 | <i>ambrisentan</i> | 167 |
| <i>abacavir-lamivudine</i> | 71 | AIMOVIG | | <i>amethia</i> | 105 |
| <i>abacavir-lamivudine-</i> | | AUTOINJECTOR..... | 58 | <i>amethia lo</i> | 105 |
| <i>zidovudine</i> | 71 | AJOVY AUTOINJECTOR.... | 58 | <i>amiloride</i> | 94 |
| ABELCET..... | 54 | AJOVY SYRINGE..... | 58 | <i>amiloride-hydrochlorothiazide</i> .. | 95 |
| ABILIFY MAINTENA..... | 65 | AKYNZEO | | AMINOSYN 10 %..... | 82 |
| ABRAXANE..... | 22 | (FOSNETUPITANT)..... | 60 | AMINOSYN 7 % WITH | |
| <i>acamprosate</i> | 10 | AKYNZEO | | ELECTROLYTES..... | 82 |
| <i>acarbose</i> | 49 | (NETUPITANT)..... | 60 | AMINOSYN 8.5 %..... | 82 |
| <i>acebutolol</i> | 90 | <i>ala-cort</i> | 115 | AMINOSYN 8.5 %- | |
| <i>acetaminophen-codeine</i> | 3 | <i>ala-scalp</i> | 115 | ELECTROLYTES..... | 82 |
| <i>acetazolamide</i> | 158 | <i>albendazole</i> | 62 | AMINOSYN II 10 %..... | 82 |
| <i>acetazolamide sodium</i> | 158 | <i>albuterol sulfate</i> | 163 | AMINOSYN II 15 %..... | 83 |
| <i>acetic acid</i> | 122 | <i>alcaine</i> | 121 | AMINOSYN II 7 %..... | 83 |
| <i>acetic acid-aluminum acetate</i> .. | 122 | <i>alclometasone</i> | 115 | AMINOSYN II 8.5 %..... | 83 |
| <i>acetylcysteine</i> | 165 | ALCOHOL PADS..... | 113 | AMINOSYN II 8.5 %- | |
| <i>acitretin</i> | 112 | ALDURAZYME..... | 119 | ELECTROLYTES..... | 83 |
| ACTEMRA..... | 141 | ALECENSA..... | 23 | AMINOSYN M 3.5 %..... | 83 |
| ACTEMRA ACTPEN..... | 141 | <i>alendronate</i> | 153 | AMINOSYN-HBC 7%..... | 83 |
| ACTHAR..... | 155 | <i>alfuzosin</i> | 131 | AMINOSYN-PF 10 %..... | 83 |
| ACTHIB (PF)..... | 147 | ALIMTA..... | 23 | AMINOSYN-PF 7 % | |
| ACTIMMUNE..... | 155 | ALINIA..... | 62 | (SULFITE-FREE)..... | 83 |
| <i>acyclovir</i> | 77, 113 | ALIQOPA..... | 23 | AMINOSYN-RF 5.2 %..... | 83 |
| <i>acyclovir sodium</i> | 77 | <i>aliskiren</i> | 98 | <i>amiodarone</i> | 89 |
| ADACEL(TDAP | | <i>allopurinol</i> | 56 | AMITIZA..... | 128 |
| ADOLESN/ADULT)(PF).... | 148 | <i>alosetron</i> | 152 | <i>amitriptyline</i> | 46 |
| ADAKVEO..... | 81 | ALPHAGAN P..... | 158 | <i>amitriptyline-chlordiazepoxide</i> .. | 46 |
| <i>adapalene</i> | 118 | <i>alprazolam</i> | 12 | <i>amlodipine</i> | 94 |
| ADCETRIS..... | 22 | ALREX..... | 125 | <i>amlodipine-atorvastatin</i> | 96 |
| <i>adefovir</i> | 77 | <i>altavera (28)</i> | 104 | <i>amlodipine-benazepril</i> | 94 |
| ADEMPAS..... | 167 | ALTRENO..... | 118 | <i>amlodipine-olmesartan</i> | 94 |
| <i>adriamycin</i> | 23 | ALUNBRIG..... | 23 | <i>amlodipine-valsartan</i> | 94 |
| <i>adrucil</i> | 23 | <i>alyacen 1/35 (28)</i> | 104 | <i>amlodipine-valsartan-hcthiazid</i> .. | 94 |
| ADVAIR DISKUS..... | 161 | <i>alyacen 7/7/7 (28)</i> | 104 | <i>ammonium lactate</i> | 113 |
| ADVAIR HFA..... | 161 | <i>alyq</i> | 167 | <i>amoxapine</i> | 46 |
| AFINITOR..... | 23 | <i>amabelz</i> | 133 | <i>amoxicil-clarithromy-</i> | |
| AFINITOR DISPERZ..... | 23 | <i>amantadine hcl</i> | 63 | <i>lansopraz</i> | 126 |
| <i>afirmelle</i> | 104 | AMBISOME..... | 54 | <i>amoxicillin</i> | 18, 19 |

| | | | | | |
|--|-----|---------------------------------------|----------|---|---------|
| <i>amoxicillin-pot clavulanate</i> | 19 | AUBAGIO..... | 99 | BELSOMRA..... | 167 |
| <i>amphotericin b</i> | 54 | <i>aubra eq</i> | 105 | <i>benazepril</i> | 88 |
| <i>ampicillin</i> | 19 | <i>aurovela 1.5/30 (21)</i> | 105 | <i>benazepril-hydrochlorothiazide</i> | 88 |
| <i>ampicillin sodium</i> | 19 | <i>aurovela 1/20 (21)</i> | 105 | BENDEKA..... | 24 |
| <i>ampicillin-sulbactam</i> | 19 | <i>aurovela 24 fe</i> | 105 | BENLYSTA..... | 155 |
| ANADROL-50..... | 132 | <i>aurovela fe 1.5/30 (28)</i> | 105 | <i>benztropine</i> | 63 |
| <i>anagrelide</i> | 81 | <i>aurovela fe 1-20 (28)</i> | 105 | BEPREVE..... | 121 |
| <i>anastrozole</i> | 23 | AUSTEDO..... | 99 | BESIVANCE..... | 122 |
| ANORO ELLIPTA..... | 163 | AVASTIN..... | 23 | BESPONSA..... | 24 |
| APOKYN..... | 63 | <i>aviane</i> | 105 | <i>betamethasone acet,sod phos.</i> | 135 |
| <i>apraclonidine</i> | 121 | AVONEX..... | 99, 100 | <i>betamethasone dipropionate</i> | 115 |
| <i>aprepitant</i> | 60 | AVSOLA..... | 141 | <i>betamethasone valerate</i> | 115 |
| <i>apri</i> | 105 | <i>ayuna</i> | 105 | <i>betamethasone, augmented</i> | 115 |
| APTIOM..... | 39 | AYVAKIT..... | 23 | BETASERON..... | 100 |
| APTIVUS..... | 71 | <i>azacitidine</i> | 23 | <i>betaxolol</i> | 90, 158 |
| APTIVUS (WITH VITAMIN E)..... | 71 | <i>azathioprine</i> | 141 | <i>bethanechol chloride</i> | 131 |
| <i>aranelle (28)</i> | 105 | <i>azathioprine sodium</i> | 141 | BETHKIS..... | 13 |
| ARCALYST..... | 141 | <i>azelastine</i> | 121 | BEVYXXA..... | 78 |
| <i>aripiprazole</i> | 65 | <i>azithromycin</i> | 17, 18 | <i>bexarotene</i> | 24 |
| ARISTADA..... | 66 | AZOPT..... | 158 | BEXSERO..... | 148 |
| ARISTADA INITIO..... | 66 | <i>aztreonam</i> | 18 | <i>bicalutamide</i> | 24 |
| <i>armodafinil</i> | 167 | <i>azurette (28)</i> | 105 | BICILLIN L-A..... | 19 |
| ARNUITY ELLIPTA..... | 162 | <i>bacitracin</i> | 14, 122 | BIDIL..... | 98 |
| <i>arsenic trioxide</i> | 23 | <i>bacitracin-polymyxin b</i> | 122 | BIKTARVY..... | 71 |
| <i>ascomp with codeine</i> | 3 | <i>baclofen</i> | 166 | <i>bimatoprost</i> | 158 |
| <i>ashlyna</i> | 105 | <i>balsalazide</i> | 152 | <i>bisoprolol fumarate</i> | 90 |
| <i>aspirin-dipyridamole</i> | 82 | BALVERSA..... | 23, 24 | <i>bisoprolol-hydrochlorothiazide</i> | 90 |
| ASSURE ID INSULIN SAFETY..... | 118 | <i>balziva (28)</i> | 105 | BLENREP..... | 24 |
| <i>atazanavir</i> | 71 | BANZEL..... | 39 | <i>bleomycin</i> | 24 |
| <i>atenolol</i> | 90 | BAVENCIO..... | 24 | <i>bleph-10</i> | 122 |
| <i>atenolol-chlorthalidone</i> | 90 | BAXDELA..... | 20 | BLINCYTO..... | 24 |
| <i>atomoxetine</i> | 99 | BCG VACCINE, LIVE (PF)..... | 148 | <i>blisovi 24 fe</i> | 105 |
| <i>atorvastatin</i> | 96 | BD ULTRA-FINE NANO PEN NEEDLE..... | 118 | <i>blisovi fe 1.5/30 (28)</i> | 105 |
| <i>atovaquone</i> | 62 | BD VEO INSULIN SYR HALF UNIT..... | 118 | <i>blisovi fe 1/20 (28)</i> | 105 |
| <i>atovaquone-proguanil</i> | 62 | BD VEO INSULIN SYRINGE UF..... | 118, 119 | BOOSTRIX TDAP..... | 148 |
| ATRIPLA..... | 71 | <i>bekyree (28)</i> | 105 | BORTEZOMIB..... | 24 |
| <i>atropine</i> | 121 | BELEODAQ..... | 24 | BOSULIF..... | 24 |
| ATROVENT HFA..... | 163 | | | BRAFTOVI..... | 24 |
| | | | | BREO ELLIPTA..... | 162 |
| | | | | <i>briellyn</i> | 105 |

| | | | | | |
|---|----------|--|--------|--|----------|
| BRILINTA..... | 82 | CAPLYTA..... | 66 | CHANTIX CONTINUING | |
| <i>brimonidine</i> | 158 | CAPRELSA..... | 25 | MONTH BOX..... | 11 |
| BRIVIACT..... | 39, 40 | <i>captopril</i> | 88 | CHANTIX STARTING | |
| <i>bromfenac</i> | 125 | <i>captopril-hydrochlorothiazide</i> ...88 | | MONTH BOX..... | 11 |
| <i>bromocriptine</i> | 63 | CARBAGLU..... | 128 | <i>chateal eq (28)</i> | 106 |
| BROMSITE..... | 125 | <i>carbamazepine</i> | 40 | <i>chloramphenicol sod succinate</i> .. | 14 |
| BRUKINSA..... | 24 | <i>carbidopa</i> | 63 | <i>chlordiazepoxide hcl</i> | 12 |
| <i>budesonide</i> | 152, 162 | <i>carbidopa-levodopa</i> | 63 | <i>chlorhexidine gluconate</i> | 112 |
| <i>bumetanide</i> | 95 | <i>carbidopa-levodopa-</i> | | <i>chloroquine phosphate</i> | 62 |
| <i>buprenorphine</i> | 3 | <i>entacapone</i> | 63, 64 | <i>chlorothiazide</i> | 95 |
| <i>buprenorphine hcl</i> | 3, 10 | <i>carbinoxamine maleate</i> | 56, 57 | <i>chlorothiazide sodium</i> | 95 |
| <i>buprenorphine-naloxone</i> | 11 | <i>carboplatin</i> | 25 | <i>chlorpromazine</i> | 66 |
| <i>bupropion hcl</i> | 46 | CAROSPIR..... | 98 | <i>chlorthalidone</i> | 95 |
| <i>bupropion hcl (smoking deter)</i> . | 11 | <i>carteolol</i> | 158 | <i>chlorzoxazone</i> | 166 |
| <i>buspirone</i> | 12 | <i>cartia xt</i> | 92 | <i>cholestyramine (with sugar)</i> | 96 |
| <i>butalbital compound w/codeine</i> ...3 | | <i>carvedilol</i> | 90 | <i>cholestyramine light</i> | 96 |
| <i>butalbital-acetaminop-caf-cod</i> ...3 | | <i>caspofungin</i> | 54 | <i>ciclopirox</i> | 54 |
| <i>butalbital-acetaminophen</i> | 3 | CAYSTON..... | 18 | <i>cidofovir</i> | 77 |
| <i>butalbital-acetaminophen-caff</i> ...3 | | <i>caziant (28)</i> | 106 | <i>cilostazol</i> | 82 |
| <i>butalbital-aspirin-caffeine</i> | 3 | <i>cefaclor</i> | 16 | CIMDUO..... | 71 |
| <i>butorphanol</i> | 3 | <i>cefadroxil</i> | 16 | <i>cimetidine</i> | 126 |
| BYNFEZIA..... | 136 | <i>cefazolin</i> | 16 | <i>cimetidine hcl</i> | 126 |
| BYSTOLIC..... | 90 | <i>cefdinir</i> | 16 | CIMZIA..... | 141 |
| <i>cabergoline</i> | 63 | <i>cefepime</i> | 16 | CIMZIA POWDER FOR | |
| CABLIVI..... | 81 | <i>cefixime</i> | 16 | RECONST..... | 141 |
| CABOMETYX..... | 24 | <i>cefotaxime</i> | 16 | <i>cinacalcet</i> | 153, 154 |
| <i>caffeine citrate</i> | 100 | <i>cefoxitin</i> | 16 | CINQAIR..... | 165 |
| <i>calcipotriene</i> | 113 | <i>cefpodoxime</i> | 17 | CINRYZE..... | 79 |
| <i>calcitonin (salmon)</i> | 153 | <i>cefprozil</i> | 17 | CINVANTI..... | 60 |
| <i>calcitriol</i> | 153 | <i>ceftazidime</i> | 17 | <i>ciprofloxacin</i> | 21 |
| <i>calcium acetate (phosphat</i> | | <i>ceftriaxone</i> | 17 | <i>ciprofloxacin hcl</i> | 20, 123 |
| <i>bind)</i> | 130 | <i>cefuroxime axetil</i> | 17 | <i>ciprofloxacin in 5% dextrose</i> ... 20 | |
| <i>calcium chloride</i> | 159 | <i>cefuroxime sodium</i> | 17 | <i>ciprofloxacin-dexamethasone</i> . | 123 |
| CALDOLOR..... | 7 | <i>celecoxib</i> | 7 | <i>citalopram</i> | 46 |
| CALQUENCE..... | 24 | CELONTIN..... | 40 | <i>cladribine</i> | 25 |
| <i>camila</i> | 106 | <i>cephalexin</i> | 17 | <i>clarithromycin</i> | 18 |
| <i>candesartan</i> | 87 | CERDELGA..... | 119 | <i>clemastine</i> | 57 |
| <i>candesartan-</i> | | CEREZYME..... | 119 | CLENPIQ..... | 130 |
| <i>hydrochlorothiazid</i> | 87 | <i>cevimeline</i> | 112 | <i>clindamycin hcl</i> | 14 |
| CAPASTAT..... | 59 | CHANTIX..... | 11 | | |

| | | | | |
|--|---|---------------|---|-----|
| CLINDAMYCIN IN 0.9 % | <i>clopidogrel</i> | 82 | <i>cypheptadine</i> | 57 |
| SOD CHLOR..... | <i>clorazepate dipotassium</i> | 12 | CYRAMZA..... | 25 |
| <i>clindamycin in 5 % dextrose</i> | <i>clotrimazole</i> | 54 | <i>cyred eq</i> | 106 |
| CLINDAMYCIN IN 5 % | <i>clotrimazole-betamethasone</i> 54, 55 | | CYSTADANE..... | 155 |
| DEXTROSE..... | <i>clovique</i> | 132 | CYSTADROPS..... | 122 |
| <i>clindamycin palmitate hcl</i> | <i>clozapine</i> | 66 | CYSTARAN..... | 122 |
| <i>clindamycin pediatric</i> | COARTEM..... | 62 | <i>dalfampridine</i> | 100 |
| <i>clindamycin phosphate</i> 15, 57, 114 | <i>codeine sulfate</i> | 3 | DALIRESP..... | 165 |
| <i>clindamycin-benzoyl peroxide</i> 114 | <i>colchicine</i> | 56 | <i>danazol</i> | 132 |
| CLINIMIX 5%/D15W | <i>colesevelam</i> | 96 | <i>dantrolene</i> | 166 |
| SULFITE FREE..... | <i>colestipol</i> | 96 | <i>dapsone</i> | 59 |
| CLINIMIX 5%/D25W | <i>colistin (colistimethate na)</i> | 15 | DAPTACEL (DTAP | |
| SULFITE-FREE..... | <i>colocort</i> | 152 | PEDIATRIC) (PF)..... | 148 |
| CLINIMIX 4.25%/D10W | COMBIGAN..... | 158 | <i>daptomycin</i> | 15 |
| SULF FREE..... | COMBIVENT RESPIMAT.. | 163 | DARZALEX..... | 25 |
| CLINIMIX 4.25%/D5W | COMETRIQ..... | 25 | DARZALEX FASPRO..... | 25 |
| SULFIT FREE..... | COMPLERA..... | 71 | <i>dasetta 1/35 (28)</i> | 106 |
| CLINIMIX 4.25%-D25W | <i>compro</i> | 60 | <i>dasetta 7/7/7 (28)</i> | 106 |
| SULF-FREE..... | <i>constulose</i> | 128 | DAURISMO..... | 25 |
| CLINIMIX 5%- | COPAXONE..... | 100 | <i>daysee</i> | 106 |
| D20W(SULFITE-FREE)..... | COPIKTRA..... | 25 | <i>deblitane</i> | 106 |
| CLINIMIX E 2.75%/D5W | CORLANOR..... | 93 | <i>decitabine</i> | 26 |
| SULF FREE..... | <i>cormax</i> | 116 | <i>deferasirox</i> | 132 |
| CLINIMIX E 4.25%/D10W | <i>cortisone</i> | 135 | <i>deferoxamine</i> | 132 |
| SUL FREE..... | COSENTYX (2 SYRINGES) | | DELSTRIGO..... | 71 |
| CLINIMIX E 4.25%/D5W | | 141 | <i>demeclocycline</i> | 21 |
| SULF FREE..... | COSENTYX PEN (2 PENS) | 141 | DEM SER..... | 93 |
| CLINIMIX E 5%/D15W | COTELLIC..... | 25 | DENAVIR..... | 113 |
| SULFIT FREE..... | CREON..... | 119 | DEPO-PROVERA..... | 140 |
| CLINIMIX E 5%/D20W | CRIXIVAN..... | 71 | DESCOVY..... | 71 |
| SULFIT FREE..... | <i>cromolyn</i> | 121, 128, 165 | <i>desipramine</i> | 46 |
| CLINOLIPID..... | <i>cryselle (28)</i> | 106 | <i>desmopressin</i> | 136 |
| <i>clobazam</i> | <i>cyclafem 1/35 (28)</i> | 106 | <i>desog-e.estradiolle.estradiol</i> | 106 |
| <i>clobetasol</i> | <i>cyclafem 7/7/7 (28)</i> | 106 | <i>desogestrel-ethinyl estradiol</i> | 106 |
| <i>clobetasol-emollient</i> | <i>cyclobenzaprine</i> | 166 | <i>desonide</i> | 116 |
| <i>clofarabine</i> | <i>cyclopentolate</i> | 122 | <i>desoximetasone</i> | 116 |
| <i>clomipramine</i> | <i>cyclophosphamide</i> | 25 | <i>desvenlafaxine succinate</i> | 46 |
| <i>clonazepam</i> | CYCLOPHOSPHAMIDE..... | 25 | <i>dexamethasone</i> | 135 |
| <i>clonidine</i> | <i>cyclosporine</i> | 141, 142 | <i>dexamethasone sodium phos</i> | |
| <i>clonidine hcl</i> | <i>cyclosporine modified</i> | 141, 142 | (<i>pf</i>)..... | 135 |

| | | | | | |
|---|-----------|---|--------|--|-----|
| <i>dexamethasone sodium phosphate</i> | 125, 135 | DOPTELET (10 TAB PACK) | 79 | <i>elinest</i> | 106 |
| DEXILANT..... | 126 | DOPTELET (15 TAB PACK) | 79 | ELIQUIS..... | 78 |
| <i>dexmethylphenidate</i> | 100 | DOPTELET (30 TAB PACK) | 80 | ELIQUIS DVT-PE TREAT | |
| <i>dextrazoxane hcl</i> | 156 | <i>dorzolamide</i> | 158 | 30D START..... | 78 |
| <i>dextroamphetamine</i> | 100 | <i>dorzolamide-timolol</i> | 158 | ELITEK..... | 120 |
| <i>dextroamphetamine-amphetamine</i> | 100 | <i>dotti</i> | 133 | <i>elixophyllin</i> | 163 |
| <i>dextrose 10 % in water (d10w)</i> | 85 | DOVATO..... | 72 | ELLA..... | 106 |
| <i>dextrose 5 % in water (d5w)</i> | 85 | <i>doxazosin</i> | 86 | ELMIRON..... | 156 |
| <i>diazepam</i> | 12, 40 | <i>doxepin</i> | 46 | <i>eluryng</i> | 106 |
| <i>diazepam intensol</i> | 12 | <i>doxercalciferol</i> | 154 | EMCYT..... | 26 |
| <i>diazoxide</i> | 156 | <i>doxorubicin</i> | 26 | EMEND..... | 60 |
| <i>diclofenac epolamine</i> | 7 | <i>doxorubicin, peg-liposomal</i> | 26 | EMFLAZA..... | 135 |
| <i>diclofenac potassium</i> | 7 | <i>doxy-100</i> | 21 | EMGALITY PEN..... | 58 |
| <i>diclofenac sodium</i> | 7, 8, 125 | <i>doxycycline hyclate</i> | 21, 22 | EMGALITY SYRINGE..... | 58 |
| <i>diclofenac-misoprostol</i> | 8 | <i>doxycycline monohydrate</i> | 22 | <i>emoquette</i> | 106 |
| <i>dicloxacillin</i> | 20 | DRIZALMA SPRINKLE..... | 46 | EMPLICITI..... | 26 |
| <i>dicyclomine</i> | 128 | <i>dronabinol</i> | 60 | EMSAM..... | 47 |
| <i>didanosine</i> | 72 | <i>droperidol</i> | 60 | <i>emtricitabine</i> | 72 |
| DIFICID..... | 18 | <i>drospirenone-ethinyl estradiol</i> | 106 | EMTRIVA..... | 72 |
| <i>diflorasone</i> | 116 | DROXIA..... | 26 | <i>enalapril maleate</i> | 88 |
| <i>diflunisal</i> | 8 | DUAVEE..... | 133 | <i>enalaprilat</i> | 88 |
| <i>digitek</i> | 93 | DUEXIS..... | 8 | <i>enalapril-hydrochlorothiazide</i> | 88 |
| <i>digox</i> | 93 | <i>duloxetine</i> | 47 | ENBREL..... | 142 |
| <i>digoxin</i> | 93 | DUPIXENT PEN..... | 142 | ENBREL MINI..... | 142 |
| <i>dihydroergotamine</i> | 58 | DUPIXENT SYRINGE..... | 142 | ENBREL SURECLICK..... | 142 |
| <i>diltiazem hcl</i> | 92 | DUREZOL..... | 125 | ENDARI..... | 156 |
| <i>dilt-xr</i> | 92 | <i>dutasteride</i> | 131 | <i>endocet</i> | 4 |
| <i>dimenhydrinate</i> | 60 | <i>dutasteride-tamsulosin</i> | 131 | ENGERIX-B (PF)..... | 148 |
| DIPENTUM..... | 152 | <i>econazole</i> | 55 | ENGERIX-B PEDIATRIC | |
| <i>diphenhydramine hcl</i> | 57 | EDARBI..... | 87 | (PF)..... | 148 |
| <i>diphenoxylate-atropine</i> | 128 | EDARBYCLOR..... | 87 | ENHERTU..... | 26 |
| <i>dipyridamole</i> | 82 | EDURANT..... | 72 | <i>enoxaparin</i> | 78 |
| <i>disopyramide phosphate</i> | 89 | <i>efavirenz</i> | 72 | <i>enpresse</i> | 106 |
| <i>disulfiram</i> | 11 | EGRIFTA..... | 136 | <i>enskyce</i> | 106 |
| <i>divalproex</i> | 40 | EGRIFTA SV..... | 137 | ENSPRYNG..... | 100 |
| <i>docetaxel</i> | 26 | ELAPRASE..... | 119 | <i>entacapone</i> | 64 |
| <i>dofetilide</i> | 89 | ELIGARD..... | 26 | <i>entecavir</i> | 77 |
| <i>donepezil</i> | 45 | ELIGARD (3 MONTH)..... | 26 | ENTRESTO..... | 87 |
| | | ELIGARD (4 MONTH)..... | 26 | <i>enulose</i> | 128 |
| | | ELIGARD (6 MONTH)..... | 26 | EPANED..... | 88 |

| | | | | | |
|--|----------|---|--------|--|----------|
| EPCLUSA..... | 76 | <i>everolimus</i> | | <i>finasteride</i> | 131 |
| EPIDIOLEX..... | 40 | (<i>immunosuppressive</i>) | 142 | FINTEPLA..... | 41 |
| <i>epinastine</i> | 122 | EVOTAZ..... | 72 | FIRVANQ..... | 15 |
| <i>epinephrine</i> | 93 | EVRYSDI..... | 156 | <i>flavoxate</i> | 131 |
| <i>epitol</i> | 40 | <i>exemestane</i> | 27 | FLEBOGAMMA DIF | 142 |
| EPIVIR HBV | 72 | EXONDYS-51 | 156 | <i>flecainide</i> | 89 |
| <i>eplerenone</i> | 98 | EXTAVIA..... | 100 | FLOVENT DISKUS..... | 162 |
| <i>epoprostenol (glycine)</i> | 167 | EZALLOR SPRINKLE..... | 96 | FLOVENT HFA..... | 162 |
| <i>eprosartan</i> | 87 | <i>ezetimibe</i> | 96 | <i>floxuridine</i> | 27 |
| <i>ergoloid</i> | 45 | <i>ezetimibe-simvastatin</i> | 96, 97 | <i>fluconazole</i> | 55 |
| ERGOMAR..... | 58 | FABRAZYME..... | 120 | <i>fluconazole in nacl (iso-osm)</i> ... | 55 |
| ERIVEDGE..... | 26 | <i>falmina (28)</i> | 107 | <i>flucytosine</i> | 55 |
| ERLEADA..... | 26 | <i>famciclovir</i> | 77 | <i>fludrocortisone</i> | 135 |
| <i>erlotinib</i> | 26, 27 | <i>famotidine</i> | 127 | <i>flumazenil</i> | 100 |
| <i>errin</i> | 106 | <i>famotidine (pf)</i> | 127 | <i>flunisolide</i> | 125 |
| <i>ertapenem</i> | 18 | <i>famotidine (pf)-nacl (iso-os)</i> | 127 | <i>fluocinolone</i> | 116 |
| <i>ery pads</i> | 114 | FANAPT..... | 66, 67 | <i>fluocinolone acetonide oil</i> | 125 |
| <i>erythromycin</i> | 18, 123 | FARXIGA..... | 49 | <i>fluocinonide</i> | 116 |
| <i>erythromycin ethylsuccinate</i> | 18 | FARYDAK..... | 27 | <i>fluocinonide-e</i> | 116 |
| <i>erythromycin with ethanol</i> | 114 | FASENRA..... | 165 | <i>fluorometholone</i> | 125 |
| <i>erythromycin-benzoyl peroxide</i> | | FASENRA PEN..... | 165 | <i>fluorouracil</i> | 27, 113 |
| | 114 | <i>febuxostat</i> | 56 | <i>fluoxetine</i> | 47 |
| ESBRIET..... | 165 | <i>felbamate</i> | 40, 41 | <i>fluphenazine decanoate</i> | 67 |
| <i>escitalopram oxalate</i> | 47 | <i>felodipine</i> | 94 | <i>fluphenazine hcl</i> | 67 |
| <i>esomeprazole sodium</i> | 126, 127 | FEMRING..... | 134 | <i>flurazepam</i> | 13 |
| <i>estarylla</i> | 107 | <i>femynor</i> | 107 | <i>flurbiprofen</i> | 8 |
| <i>estazolam</i> | 13 | <i>fenofibrate</i> | 97 | <i>flurbiprofen sodium</i> | 125 |
| <i>estradiol</i> | 133, 134 | <i>fenofibrate micronized</i> | 97 | <i>flutamide</i> | 27 |
| <i>estradiol valerate</i> | 134 | <i>fenofibrate nanocrystallized</i> | 97 | <i>fluticasone propionate</i> | 116, 125 |
| <i>estradiol-norethindrone acet</i> ... | 134 | <i>fenofibric acid (choline)</i> | 97 | <i>fluvastatin</i> | 97 |
| <i>eszopiclone</i> | 167 | <i>fenopropfen</i> | 8 | <i>fluvoxamine</i> | 47 |
| <i>ethambutol</i> | 59 | <i>fentanyl</i> | 4 | <i>fomepizole</i> | 156 |
| <i>ethosuximide</i> | 40 | <i>fentanyl citrate</i> | 4 | <i>fondaparinux</i> | 79 |
| <i>ethynodiol diac-eth estradiol</i> ... | 107 | FERRIPROX..... | 132 | FORTEO..... | 154 |
| <i>etodolac</i> | 8 | FETZIMA..... | 47 | <i>fosamprenavir</i> | 72 |
| <i>etonogestrel-ethinyl estradiol</i> .. | 107 | FIASP FLEXTOUCH U-100 | | <i>fosaprepitant</i> | 60 |
| ETOPOPHOS..... | 27 | INSULIN..... | 51 | <i>foscarnet</i> | 75 |
| <i>etoposide</i> | 27 | FIASP PENFILL U-100 | | <i>fosinopril</i> | 88 |
| EUCRISA..... | 116 | INSULIN..... | 51 | <i>fosinopril-hydrochlorothiazide</i> .. | 88 |
| EVENITY..... | 154 | FIASP U-100 INSULIN..... | 52 | <i>fosphenytoin</i> | 41 |

| | | | | | |
|--|--------------|--|---------|---|---------------|
| FREAMINE HBC 6.9 %..... | 85 | GENVOYA..... | 72 | <i>haloperidol lactate</i> | 67 |
| FREAMINE III 10 %..... | 85 | GILENYA..... | 101 | HARVONI..... | 76 |
| FULPHILA..... | 80 | GILOTRIF..... | 27 | HAVRIX (PF)..... | 149 |
| <i>fulvestrant</i> | 27 | GIVLAARI..... | 81 | <i>heather</i> | 107 |
| <i>furosemide</i> | 95 | <i>glatiramer</i> | 101 | HEMADY..... | 135 |
| FUZEON..... | 72 | <i>glatopa</i> | 101 | <i>heparin (porcine)</i> | 79 |
| <i>fyavolv</i> | 134 | <i>glimepiride</i> | 53 | <i>heparin, porcine (pf)</i> | 79 |
| FYCOMPA..... | 41 | <i>glipizide</i> | 53, 54 | HEPATAMINE 8%..... | 85 |
| <i>gabapentin</i> | 41 | <i>glipizide-metformin</i> | 54 | HERCEPTIN..... | 27 |
| GALAFOLD..... | 120 | <i>glyburide</i> | 54 | HERCEPTIN HYLECTA..... | 27 |
| <i>galantamine</i> | 45 | <i>glyburide micronized</i> | 54 | HERZUMA..... | 27 |
| GAMASTAN..... | 142 | <i>glyburide-metformin</i> | 54 | HETLIOZ..... | 167 |
| GAMMAGARD LIQUID... 142 | | <i>glycopyrrolate</i> | 128 | HIBERIX (PF)..... | 149 |
| GAMMAGARD S-D (IGA < | | <i>glydo</i> | 10 | HUMATROPE..... | 137 |
| 1 MCG/ML)..... | 143 | GOCOVRI..... | 64 | HUMIRA..... | 143 |
| GAMMAPLEX..... | 143 | GRALISE..... | 41 | HUMIRA PEN..... | 143 |
| GAMMAPLEX (WITH | | GRALISE 30-DAY | | HUMIRA PEN CROHNS- | |
| SORBITOL)..... | 143 | STARTER PACK..... | 41 | UC-HS START..... | 143 |
| GAMUNEX-C..... | 143 | <i>granisetron (pf)</i> | 61 | HUMIRA PEN PSOR- | |
| <i>ganciclovir sodium</i> | 77 | <i>granisetron hcl</i> | 61 | UVEITS-ADOL HS..... | 143 |
| GARDASIL 9 (PF)..... | 149 | GRANIX..... | 80 | HUMIRA(CF)..... | 144 |
| <i>gatifloxacin</i> | 123 | <i>griseofulvin microsize</i> | 55 | HUMIRA(CF) PEDI | |
| GATTEX 30-VIAL..... | 128 | <i>griseofulvin ultramicrosize</i> | 55 | CROHNS STARTER..... | 143 |
| GAUZE PAD..... | 119 | <i>guanfacine</i> | 86, 101 | HUMIRA(CF) PEN..... | 144 |
| <i>gavilyte-c</i> | 130 | GVOKE HYPOPEN 1- | | HUMIRA(CF) PEN | |
| <i>gavilyte-g</i> | 130 | PACK..... | 156 | CROHNS-UC-HS..... | 144 |
| <i>gavilyte-n</i> | 130 | GVOKE HYPOPEN 2- | | HUMIRA(CF) PEN PSOR- | |
| GAVRETO..... | 27 | PACK..... | 156 | UV-ADOL HS..... | 144 |
| GAZYVA..... | 27 | GVOKE PFS 1-PACK | | HUMULIN R U-500 | |
| <i>gemcitabine</i> | 27 | SYRINGE..... | 156 | (CONC) INSULIN..... | 52 |
| <i>gemfibrozil</i> | 97 | GVOKE PFS 2-PACK | | HUMULIN R U-500 | |
| <i>generlac</i> | 128 | SYRINGE..... | 156 | (CONC) KWIKPEN..... | 52 |
| <i>gengraf</i> | 143 | HAEGARDA..... | 80 | <i>hydralazine</i> | 93 |
| GENOTROPIN..... | 137 | <i>hailey</i> | 107 | <i>hydrochlorothiazide</i> | 95 |
| GENOTROPIN | | <i>hailey 24 fe</i> | 107 | <i>hydrocodone-acetaminophen</i> | 4 |
| MINIQUICK..... | 137 | <i>hailey fe 1.5/30 (28)</i> | 107 | <i>hydrocodone-ibuprofen</i> | 4 |
| <i>gentak</i> | 123 | <i>hailey fe 1/20 (28)</i> | 107 | <i>hydrocortisone</i> | 117, 135, 153 |
| <i>gentamicin</i> | 13, 114, 123 | <i>halobetasol propionate</i> | 116 | <i>hydrocortisone butyrate</i> .. | 116, 117 |
| <i>gentamicin sulfate (ped) (pf)</i> ...14 | | <i>haloperidol</i> | 67 | <i>hydrocortisone valerate</i> | 117 |
| <i>gentamicin sulfate (pf)</i> | 14 | <i>haloperidol decanoate</i> | 67 | <i>hydrocortisone-acetic acid</i> | 123 |

| | | | | | |
|----------------------------------|-----|---|----------|-----------------------------------|--------|
| <i>hydromorphone</i> | 5 | INFANRIX (DTAP) (PF).... | 149 | IXEMPRA..... | 29 |
| <i>hydromorphone (pf)</i> | 4 | INFLECTRA..... | 144 | IXIARO (PF)..... | 149 |
| <i>hydroxychloroquine</i> | 62 | INFUGEM..... | 29 | <i>jaimiess</i> | 107 |
| <i>hydroxyprogesterone</i> | | INGREZZA..... | 101 | JAKAFI..... | 29 |
| <i>cap(ppres)</i> | 140 | INGREZZA INITIATION | | <i>jantoven</i> | 79 |
| <i>hydroxyurea</i> | 28 | PACK..... | 101 | JANUMET..... | 49 |
| <i>hydroxyzine hcl</i> | 57 | INLYTA..... | 29 | JANUMET XR..... | 49 |
| <i>hydroxyzine pamoate</i> | 156 | INQOVI..... | 29 | JANUVIA..... | 49 |
| HYPERRAB (PF)..... | 144 | INREBIC..... | 29 | JARDIANCE..... | 49 |
| HYPERRAB S/D (PF)..... | 144 | INSULIN SYRINGE- | | <i>jasmiel (28)</i> | 107 |
| HYQVIA..... | 144 | NEEDLE U-100..... | 119 | <i>jencycla</i> | 107 |
| <i>ibandronate</i> | 154 | INTELENCE..... | 72 | JENTADUETO..... | 49 |
| IBRANCE..... | 28 | INTRALIPID..... | 85 | JENTADUETO XR..... | 50 |
| <i>ibu</i> | 8 | INTRON A..... | 77 | <i>jinteli</i> | 134 |
| <i>ibuprofen</i> | 8 | <i>introvale</i> | 107 | <i>juleber</i> | 107 |
| <i>icatibant</i> | 93 | INVEGA SUSTENNA..... | 67, 68 | JULUCA..... | 73 |
| ICLUSIG..... | 28 | INVEGA TRINZA..... | 68 | <i>junel 1.5/30 (21)</i> | 107 |
| IDHIFA..... | 28 | INVELTYS..... | 125 | <i>junel 1/20 (21)</i> | 107 |
| <i>ifosfamide</i> | 28 | INVIRASE..... | 72 | <i>junel fe 1.5/30 (28)</i> | 107 |
| ILARIS (PF)..... | 144 | IONOSOL-B IN D5W..... | 159 | <i>junel fe 1/20 (28)</i> | 107 |
| ILEVRO..... | 125 | IONOSOL-MB IN D5W..... | 159 | <i>junel fe 24</i> | 108 |
| ILUMYA..... | 144 | IPOL..... | 149 | JUXTAPID..... | 97 |
| <i>imatinib</i> | 28 | <i>ipratropium bromide</i> | 122, 163 | JYNARQUE..... | 95 |
| IMBRUVICA..... | 28 | <i>ipratropium-albuterol</i> | 164 | KABIVEN..... | 85 |
| IMFINZI..... | 28 | <i>irbesartan</i> | 87 | KALETRA..... | 73 |
| <i>imipenem-cilastatin</i> | 18 | <i>irbesartan-hydrochlorothiazide</i> | 87 | <i>kalliga</i> | 108 |
| <i>imipramine hcl</i> | 47 | IRESSA..... | 29 | KALYDECO..... | 165 |
| <i>imipramine pamoate</i> | 47 | <i>irinotecan</i> | 29 | KANJINTI..... | 29 |
| <i>imiquimod</i> | 113 | ISENTRESS..... | 72, 73 | KANUMA..... | 120 |
| IMLYGIC..... | 28 | ISENTRESS HD..... | 72 | <i>kariva (28)</i> | 108 |
| IMOGAM RABIES-HT (PF) | | <i>isibloom</i> | 107 | KATERZIA..... | 94 |
| | 144 | ISOLYTE-P IN 5 % | | KEDRAB (PF)..... | 144 |
| IMOVAX RABIES | | DEXTROSE..... | 159 | <i>kelnor 1/35 (28)</i> | 108 |
| VACCINE (PF)..... | 149 | ISOLYTE-S..... | 159 | <i>kelnor 1-50</i> | 108 |
| IMPAVIDO..... | 62 | <i>isoniazid</i> | 59 | KESIMPTA PEN..... | 101 |
| INBRIJA..... | 64 | <i>isosorbide dinitrate</i> | 99 | <i>ketoconazole</i> | 55 |
| <i>incassia</i> | 107 | <i>isosorbide mononitrate</i> | 99 | <i>ketoprofen</i> | 8 |
| INCRELEX..... | 137 | <i>isradipine</i> | 94 | <i>ketorolac</i> | 9, 125 |
| <i>indapamide</i> | 95 | <i>itraconazole</i> | 55 | KEVEYIS..... | 156 |
| <i>indomethacin</i> | 8 | <i>ivermectin</i> | 62 | KEVZARA..... | 145 |

| | | | | | |
|---|----------|--|----------|--|----------|
| KEYTRUDA..... | 29 | <i>leflunomide</i> | 145 | LONSURF..... | 30 |
| KINERET..... | 145 | LEMTRADA..... | 101 | <i>loperamide</i> | 128 |
| KINRIX (PF)..... | 149, 150 | LENVIMA..... | 30 | <i>lopinavir-ritonavir</i> | 73 |
| <i>kionex (with sorbitol)</i> | 128 | <i>lessina</i> | 108 | <i>lorazepam</i> | 13 |
| KISQALI..... | 30 | <i>letrozole</i> | 30 | <i>lorazepam intensol</i> | 13 |
| KISQALI FEMARA CO- PACK..... | 29, 30 | <i>leucovorin calcium</i> | 156, 157 | LOBRENA..... | 31 |
| <i>klor-con m10</i> | 160 | LEUKERAN..... | 30 | <i>lorcet (hydrocodone)</i> | 5 |
| <i>klor-con m15</i> | 160 | LEUKINE..... | 80 | <i>lorcet hd</i> | 5 |
| <i>klor-con m20</i> | 160 | <i>leuprolide</i> | 30 | <i>lorcet plus</i> | 5 |
| KORLYM..... | 50 | <i>levetiracetam</i> | 42 | <i>loryna (28)</i> | 109 |
| KOSELUGO..... | 30 | <i>levobunolol</i> | 158 | <i>losartan</i> | 87 |
| KRINTAFEL..... | 62 | <i>levocarnitine</i> | 157 | <i>losartan-hydrochlorothiazide</i> | 87 |
| KRYSTEXXA..... | 120 | <i>levocarnitine (with sugar)</i> | 157 | LOTEMAX..... | 125, 126 |
| <i>kurvelo (28)</i> | 108 | <i>levocetirizine</i> | 57 | LOTEMAX SM..... | 126 |
| KUVAN..... | 120 | <i>levofloxacin</i> | 21, 123 | <i>loteprednol etabonate</i> | 126 |
| KYNMOBI..... | 64 | <i>levofloxacin in d5w</i> | 21 | <i>lovastatin</i> | 97 |
| KYPROLIS..... | 30 | <i>levoleucovorin calcium</i> | 157 | <i>low-ogestrel (28)</i> | 109 |
| <i>l norgestle.estradiol-e.estrad</i> ... 108 | | <i>levonest (28)</i> | 108 | <i>loxapine succinate</i> | 68 |
| <i>labetalol</i> | 90 | <i>levonorgestrel-ethinyl estrad</i> ... 108 | | <i>lo-zumandimine (28)</i> | 109 |
| LACTATED RINGERS..... | 153 | <i>levonorg-eth estrad triphasic</i> ... 109 | | LUCEMYRA..... | 11 |
| <i>lactulose</i> | 128 | <i>levora-28</i> | 109 | LUMIGAN..... | 158 |
| <i>lamivudine</i> | 73 | <i>levothyroxine</i> | 140 | LUMOXITI..... | 31 |
| <i>lamivudine-zidovudine</i> | 73 | LEXIVA..... | 73 | LUPRON DEPOT..... | 31, 137 |
| <i>lamotrigine</i> | 41, 42 | LIBTAYO..... | 30 | LUPRON DEPOT (3 MONTH)..... | 31, 137 |
| <i>lansoprazole</i> | 127 | <i>lidocaine</i> | 10 | LUPRON DEPOT (4 MONTH)..... | 31 |
| <i>lanthanum</i> | 130 | <i>lidocaine (pf)</i> | 10, 89 | LUPRON DEPOT (6 MONTH)..... | 31 |
| LANTUS SOLOSTAR U-100 INSULIN..... | 52 | <i>lidocaine hcl</i> | 10 | LUPRON DEPOT (6 MONTH)..... | 31 |
| LANTUS U-100 INSULIN... 52 | | <i>lidocaine viscous</i> | 10 | LUPRON DEPOT-PED..... | 137 |
| <i>larin 1.5/30 (21)</i> | 108 | <i>lidocaine-prilocaine</i> | 10 | LUPRON DEPOT-PED (3 MONTH)..... | 137 |
| <i>larin 1/20 (21)</i> | 108 | <i>lillow (28)</i> | 109 | <i>lutera (28)</i> | 109 |
| <i>larin 24 fe</i> | 108 | <i>linezolid</i> | 15 | LYNPARZA..... | 31 |
| <i>larin fe 1.5/30 (28)</i> | 108 | <i>linezolid in dextrose 5%</i> | 15 | LYSODREN..... | 31 |
| <i>larin fe 1/20 (28)</i> | 108 | LINZESS..... | 128 | <i>lyza</i> | 109 |
| <i>larissia</i> | 108 | <i>liothyronine</i> | 140 | <i>magnesium sulfate</i> | 160 |
| <i>latanoprost</i> | 158 | <i>lisinopril</i> | 88, 89 | <i>magnesium sulfate in d5w</i> | 160 |
| LATUDA..... | 68 | <i>lisinopril-hydrochlorothiazide</i> ... 89 | | <i>magnesium sulfate in water</i> | 160 |
| LAZANDA..... | 5 | <i>lithium carbonate</i> | 101 | <i>malathion</i> | 118 |
| <i>ledipasvir-sofosbuvir</i> | 76 | LIVALO..... | 97 | | |
| | | <i>lojaimiess</i> | 109 | | |
| | | LOKELMA..... | 128 | | |

| | | | | | |
|--------------------------------------|---------|--|-------------|--|----------|
| <i>maprotiline</i> | 47 | <i>mesna</i> | 157 | <i>mili</i> | 109 |
| <i>marlissa (28)</i> | 109 | MESNEX..... | 157 | <i>milrinone</i> | 93 |
| MARPLAN..... | 47 | <i>metadate er</i> | 102 | <i>mimvey</i> | 134 |
| MARQIBO..... | 31 | <i>metaproterenol</i> | 164 | <i>minitran</i> | 99 |
| MATULANE..... | 31 | <i>metformin</i> | 50 | <i>minocycline</i> | 22 |
| <i>matzim la</i> | 92 | <i>methadone</i> | 5 | <i>minoxidil</i> | 99 |
| MAVENCLAD (10 TABLET PACK)..... | 101 | <i>methadose</i> | 5 | <i>mirtazapine</i> | 47, 48 |
| MAVENCLAD (4 TABLET PACK)..... | 101 | <i>methazolamide</i> | 158 | <i>misoprostol</i> | 127 |
| MAVENCLAD (5 TABLET PACK)..... | 101 | <i>methenamine hippurate</i> | 15 | MITIGARE..... | 56 |
| MAVENCLAD (6 TABLET PACK)..... | 101 | <i>methimazole</i> | 141 | <i>mitoxantrone</i> | 32 |
| MAVENCLAD (7 TABLET PACK)..... | 101 | <i>methocarbamol</i> | 166 | M-M-R II (PF)..... | 150 |
| MAVENCLAD (8 TABLET PACK)..... | 102 | <i>methotrexate sodium</i> | 32 | <i>moexipril</i> | 89 |
| MAVENCLAD (9 TABLET PACK)..... | 102 | <i>methotrexate sodium (pf)</i> | 32 | <i>molindone</i> | 68 |
| MAVYRET..... | 76 | <i>methoxsalen</i> | 113 | <i>mometasone</i> | 117, 126 |
| MAYZENT..... | 102 | <i>methscopolamine</i> | 129 | <i>mondoxyne nl</i> | 22 |
| <i>meclizine</i> | 61 | <i>methyldopa</i> | 86 | MONJUVI..... | 32 |
| <i>medroxyprogesterone</i> | 140 | <i>methyldopa-</i> <i>hydrochlorothiazide</i> | 86 | <i>mono-lynyah</i> | 109 |
| <i>mefenamic acid</i> | 9 | <i>methylphenidate hcl</i> | 102, 103 | <i>montelukast</i> | 162 |
| <i>mefloquine</i> | 62 | <i>methylprednisolone</i> | 135 | <i>morphine</i> | 5, 6 |
| <i>megestrol</i> | 31, 140 | <i>methylprednisolone acetate</i> | 135 | MORPHINE..... | 5 |
| MEKINIST..... | 31 | <i>methylprednisolone sodium</i> <i>succ</i> | 135, 136 | <i>morphine concentrate</i> | 5 |
| MEKTOVI..... | 31 | <i>metipranolol</i> | 158 | MOVANTIK..... | 129 |
| <i>meloxicam</i> | 9 | <i>metoclopramide hcl</i> | 129 | <i>moxifloxacin</i> | 21, 123 |
| <i>melphalan hcl</i> | 31 | <i>metolazone</i> | 95 | MOZOBIL..... | 80 |
| <i>memantine</i> | 45 | <i>metoprolol succinate</i> | 91 | MULPLETA..... | 80 |
| MENACTRA (PF)..... | 150 | <i>metoprolol ta-hydrochlorothiaz</i> | 91 | MULTAQ..... | 89 |
| MENQUADFI (PF)..... | 150 | <i>metoprolol tartrate</i> | 91 | <i>mupirocin</i> | 114 |
| MENVEO A-C-Y-W-135- DIP (PF)..... | 150 | <i>metronidazole</i> | 15, 57, 114 | MVASI..... | 32 |
| MEPSEVII..... | 120 | <i>metronidazole in nacl (iso-os)</i> .. | 15 | MYCAPSSA..... | 137 |
| <i>mercaptopurine</i> | 31 | <i>metyrosine</i> | 93 | <i>mycophenolate mofetil</i> | 145 |
| <i>meropenem</i> | 18 | <i>mexiletine</i> | 89 | <i>mycophenolate mofetil (hcl)</i> .. | 145 |
| <i>mesalamine</i> | 153 | MIACALCIN..... | 154 | MYLOTARG..... | 32 |
| | | <i>miconazole-3</i> | 55 | MYRBETRIQ..... | 131 |
| | | <i>microgestin fe 1/20 (28)</i> | 109 | <i>nabumetone</i> | 9 |
| | | <i>midazolam</i> | 13 | <i>nadolol</i> | 91 |
| | | <i>midodrine</i> | 86 | <i>nafcillin</i> | 20 |
| | | <i>miglitol</i> | 50 | <i>nafcillin in dextrose iso-osm</i> | 20 |
| | | <i>miglustat</i> | 120 | NAGLAZYME..... | 120 |
| | | | | <i>naloxone</i> | 11 |
| | | | | <i>naltrexone</i> | 11 |

| | | | | | |
|--|-----|--|----------|-------------------------------------|--------|
| NAMZARIC..... | 45 | <i>nitisinone</i> | 120 | NOVOLOG FLEXPEN U- | |
| <i>naproxen</i> | 9 | <i>nitrofurantoin macrocrystal</i> | 15 | 100 INSULIN..... | 53 |
| <i>naproxen-esomeprazole</i> | 9 | <i>nitrofurantoin monohydlm-</i> | | NOVOLOG MIX 70-30 U- | |
| <i>naratriptan</i> | 58 | <i>cryst</i> | 15 | 100 INSULN..... | 53 |
| NARCAN..... | 11 | <i>nitroglycerin</i> | 99 | NOVOLOG MIX 70- | |
| NATACYN..... | 123 | NITYR..... | 120 | 30FLEXPEN U-100..... | 53 |
| <i>nateglinide</i> | 50 | NIVESTYM..... | 80 | NOVOLOG PENFILL U-100 | |
| NATPARA..... | 154 | <i>nizatidine</i> | 127 | INSULIN..... | 53 |
| NAYZILAM..... | 42 | NOCDURNA (MEN)..... | 138 | NOVOLOG U-100 INSULIN | |
| <i>necon 0.5/35 (28)</i> | 109 | NOCDURNA (WOMEN).... | 138 | ASPART..... | 53 |
| <i>nefazodone</i> | 48 | NORDITROPIN FLEXPRO | | NOXAFIL..... | 55 |
| <i>neomycin</i> | 14 | | 138 | NPLATE..... | 80 |
| <i>neomycin-bacitracin-poly-hc</i> ... | 123 | <i>norethindrone (contraceptive)</i> | 109 | NUBEQA..... | 32 |
| <i>neomycin-bacitracin-</i> | | <i>acetate</i> | 140 | NUCALA..... | 165 |
| <i>polymyxin</i> | 123 | <i>norethindrone ac-eth estradiol</i> | | NUEDEXTA..... | 103 |
| <i>neomycin-polymyxin b gu</i> | 114 | | 109, 134 | NULOJIX..... | 145 |
| <i>neomycin-polymyxin b-</i> | | <i>norethindrone-e.estradiol-iron</i> | 109 | NUPLAZID..... | 68 |
| <i>dexameth</i> | 123 | <i>norgestimate-ethinyl estradiol</i> | 110 | NUTRILIPID..... | 85 |
| <i>neomycin-polymyxin-</i> | | <i>norlyda</i> | 110 | NUTROPIN AQ NUSPIN... 138 | |
| <i>gramicidin</i> | 123 | NORMOSOL-M IN 5% | | <i>nyamyc</i> | 55 |
| <i>neomycin-polymyxin-hc</i> | 124 | DEXTROSE..... | 160 | <i>nystatin</i> | 55, 56 |
| <i>neo-polycin</i> | 124 | NORMOSOL-R PH 7.4..... | 160 | <i>nystatin-triamcinolone</i> | 56 |
| <i>neo-polycin hc</i> | 124 | NORTHERA..... | 86 | <i>nystop</i> | 56 |
| NEPHRAMINE 5.4 %..... | 85 | <i>nortrel 0.5/35 (28)</i> | 110 | OCALIVA..... | 129 |
| NERLYNX..... | 32 | <i>nortrel 1/35 (21)</i> | 110 | OCREVUS..... | 103 |
| NEULASTA..... | 80 | <i>nortrel 1/35 (28)</i> | 110 | OCTAGAM..... | 145 |
| NEUPOGEN..... | 80 | <i>nortrel 7/7/7 (28)</i> | 110 | <i>octreotide acetate</i> | 138 |
| NEUPRO..... | 64 | <i>nortriptyline</i> | 48 | ODEFSEY..... | 73 |
| <i>nevirapine</i> | 73 | NORVIR..... | 73 | ODOMZO..... | 32 |
| NEXAVAR..... | 32 | NOVOLIN 70/30 U-100 | | OFEV..... | 166 |
| NEXLETOL..... | 97 | INSULIN..... | 52 | <i>ofloxacin</i> | 124 |
| NEXLIZET..... | 97 | NOVOLIN 70-30 FLEXPEN | | <i>ogestrel (28)</i> | 110 |
| <i>niacin</i> | 97 | U-100..... | 52 | OGIVRI..... | 32 |
| <i>niacor</i> | 97 | NOVOLIN N FLEXPEN..... | 52 | <i>okebo</i> | 22 |
| <i>nicardipine</i> | 94 | NOVOLIN N NPH U-100 | | <i>olanzapine</i> | 68, 69 |
| NICOTROL..... | 11 | INSULIN..... | 52 | <i>olmesartan</i> | 87 |
| <i>nifedipine</i> | 94 | NOVOLIN R FLEXPEN..... | 52 | <i>olmesartan-amlodipin-</i> | |
| <i>nikki (28)</i> | 109 | NOVOLIN R REGULAR U- | | <i>hcthiazyd</i> | 87 |
| <i>nilutamide</i> | 32 | 100 INSULN..... | 52 | <i>olmesartan-</i> | |
| NINLARO..... | 32 | | | <i>hydrochlorothiazide</i> | 87 |

| | | | | | |
|--|----------|---|--------|--|----------|
| <i>olopatadine</i> | 122 | <i>oxycodone-aspirin</i> | 6 | <i>pfizerpen-g</i> | 20 |
| OLUMIANT..... | 145 | OXYCONTIN..... | 6 | <i>phenadoz</i> | 61 |
| <i>omega-3 acid ethyl esters</i> | 97 | <i>oxymorphone</i> | 6, 7 | <i>phenelzine</i> | 48 |
| <i>omeprazole</i> | 127 | OZEMPIC..... | 50 | <i>phenobarbital</i> | 42, 43 |
| <i>omeprazole-sodium</i> | | <i>pacerone</i> | 89 | <i>phenylephrine hcl</i> | 86 |
| <i>bicarbonate</i> | 127 | <i>paclitaxel</i> | 33 | <i>phenytoin</i> | 43 |
| OMNIPOD DASH 5 PACK | | PADCEV..... | 33 | <i>phenytoin sodium</i> | 43 |
| POD..... | 119 | <i>paliperidone</i> | 69 | <i>phenytoin sodium extended</i> | 43 |
| OMNITROPE..... | 138 | PALYNZIQ..... | 120 | <i>philith</i> | 110 |
| ONCASPAR..... | 32 | <i>pamidronate</i> | 154 | PHOSLYRA..... | 130 |
| <i>ondansetron</i> | 61 | PANRETIN..... | 113 | PICATO..... | 113 |
| <i>ondansetron hcl</i> | 61 | <i>pantoprazole</i> | 127 | PIFELTRO..... | 73 |
| <i>ondansetron hcl (pf)</i> | 61 | <i>paricalcitol</i> | 154 | <i>pilocarpine hcl</i> | 112, 159 |
| ONGENTYS..... | 64 | <i>paroex oral rinse</i> | 112 | <i>pimecrolimus</i> | 117 |
| ONIVYDE..... | 32 | <i>paromomycin</i> | 62 | <i>pimozide</i> | 69 |
| ONTRUZANT..... | 32 | <i>paroxetine hcl</i> | 48 | <i>pimtrea (28)</i> | 110 |
| ONUREG..... | 32 | PAXIL..... | 48 | <i>pindolol</i> | 91 |
| OPDIVO..... | 33 | PEDIARIX (PF)..... | 150 | <i>pioglitazone</i> | 50 |
| OPSUMIT..... | 167 | PEDVAX HIB (PF)..... | 150 | <i>piperacillin-tazobactam</i> | 20 |
| <i>oralone</i> | 112 | PEGANONE..... | 42 | PIQRAY..... | 33 |
| ORENCIA..... | 145 | PEGASYS..... | 77 | <i>pirmella</i> | 110 |
| ORENCIA (WITH | | PEGINTRON..... | 77 | <i>piroxicam</i> | 9 |
| MALTOSE)..... | 145 | PEMAZYRE..... | 33 | PLASMA-LYTE 148..... | 160 |
| ORENCIA CLICKJECT..... | 145 | PEN NEEDLE, DIABETIC..... | 119 | PLASMA-LYTE A..... | 160 |
| ORFADIN..... | 120 | <i>penicillamine</i> | 132 | PLEGRIDY..... | 103 |
| ORLISSA..... | 138, 139 | <i>penicillin g potassium</i> | 20 | <i>podofilox</i> | 113 |
| ORKAMBI..... | 166 | <i>penicillin g procaine</i> | 20 | POLIVY..... | 33 |
| <i>orsythia</i> | 110 | <i>penicillin v potassium</i> | 20 | <i>polycin</i> | 124 |
| <i>oseltamivir</i> | 75 | PENNSAID..... | 9 | <i>polymyxin b sulfate</i> | 15 |
| OSMOLEX ER..... | 64 | PENTACEL (PF)..... | 150 | <i>polymyxin b sulf-trimethoprim</i> | 124 |
| OTEZLA..... | 145 | <i>pentamidine</i> | 62, 63 | POMALYST..... | 33 |
| OTEZLA STARTER..... | 145 | <i>pentoxifylline</i> | 82 | <i>portia 28</i> | 110 |
| <i>oxaliplatin</i> | 33 | PERIKABIVEN..... | 85 | PORTRAZZA..... | 33 |
| <i>oxandrolone</i> | 132 | <i>perindopril erbumine</i> | 89 | <i>posaconazole</i> | 56 |
| <i>oxazepam</i> | 13 | <i>perio gard</i> | 112 | <i>potassium chloride</i> | 160, 161 |
| <i>oxcarbazepine</i> | 42 | PERJETA..... | 33 | <i>potassium chloride-0.45 % nacl</i> | |
| OXTELLAR XR..... | 42 | <i>permethrin</i> | 118 | | 161 |
| <i>oxybutynin chloride</i> | 131 | <i>perphenazine</i> | 69 | <i>potassium citrate</i> | 161 |
| <i>oxycodone</i> | 6 | <i>perphenazine-amitriptyline</i> | 48 | PRADAXA..... | 79 |
| <i>oxycodone-acetaminophen</i> | 6 | PERSERIS..... | 69 | PRALUENT PEN..... | 98 |

| | | | | | |
|---|----------|---|----------|------------------------------------|--------|
| <i>pramipexole</i> | 65 | PROLENSA..... | 126 | REBIF (WITH ALBUMIN)..... | 103 |
| <i>prasugrel</i> | 82 | PROLEUKIN..... | 33 | REBIF REBIDOSE..... | 103 |
| <i>pravastatin</i> | 98 | PROLIA..... | 154 | REBIF TITRATION PACK..... | 103 |
| <i>prazosin</i> | 86 | PROMACTA..... | 81 | <i>reclipsen (28)</i> | 110 |
| <i>prednicarbate</i> | 117 | <i>promethazine</i> | 57, 61 | RECOMBIVAX HB (PF)..... | 151 |
| <i>prednisolone</i> | 136 | <i>promethegan</i> | 62 | RECTIV..... | 157 |
| <i>prednisolone acetate</i> | 126 | <i>propafenone</i> | 90 | REGANEX..... | 113 |
| <i>prednisolone sodium phosphate</i> | 126, 136 | <i>propantheline</i> | 129 | RELENZA DISKHALER..... | 76 |
| <i>prednisone</i> | 136 | <i>proparacaine</i> | 122 | RELISTOR..... | 129 |
| <i>pregabalin</i> | 43 | <i>propranolol</i> | 91 | REMICADE..... | 146 |
| PREMARIN..... | 134 | <i>propranolol-hydrochlorothiazid</i> | 91 | RENFLEXIS..... | 146 |
| PREMPHASE..... | 134 | <i>propylthiouracil</i> | 141 | <i>repaglinide</i> | 50 |
| PREMPRO..... | 134 | PROQUAD (PF)..... | 150 | <i>repaglinide-metformin</i> | 50 |
| PRETOMANID..... | 59 | PROSOL 20 %..... | 85 | REPATHA PUSHTRONEX..... | 98 |
| <i>prevalite</i> | 98 | <i>protamine</i> | 81 | REPATHA SURECLICK..... | 98 |
| <i>previfem</i> | 110 | <i>protriptyline</i> | 48 | REPATHA SYRINGE..... | 98 |
| PREVYMIS..... | 75 | PULMOZYME..... | 120 | RESCRIPTOR..... | 74 |
| PREZCOBIX..... | 73 | PURIXAN..... | 33 | RESTASIS..... | 126 |
| PREZISTA..... | 73, 74 | <i>pyrazinamide</i> | 59 | RETACRIT..... | 81 |
| PRIFTIN..... | 59 | <i>pyridostigmine bromide</i> | 157 | RETEVMO..... | 33, 34 |
| PRIMAQUINE..... | 63 | <i>pyrimethamine</i> | 63 | RETROVIR..... | 74 |
| <i>primidone</i> | 43 | QBRELIS..... | 89 | REVCovi..... | 120 |
| PRIVIGEN..... | 146 | QINLOCK..... | 33 | REVLIMID..... | 34 |
| PROAIR RESPICLICK..... | 164 | QUADRACEL (PF)..... | 150 | <i>revonto</i> | 166 |
| <i>probenecid</i> | 56 | <i>quetiapine</i> | 69 | REXULTI..... | 69 |
| <i>probenecid-colchicine</i> | 56 | <i>quinapril</i> | 89 | REYATAZ..... | 74 |
| <i>procainamide</i> | 90 | <i>quinapril-hydrochlorothiazide</i> | 89 | RHOPRESSA..... | 159 |
| PROCALAMINE 3%..... | 85 | <i>quinidine gluconate</i> | 90 | <i>ribasphere</i> | 77 |
| <i>prochlorperazine</i> | 61 | <i>quinidine sulfate</i> | 90 | <i>ribasphere ribapak</i> | 78 |
| <i>prochlorperazine edisylate</i> | 61 | <i>quinine sulfate</i> | 63 | <i>ribavirin</i> | 78 |
| <i>prochlorperazine maleate</i> | 61 | RABAVERT (PF)..... | 150 | RIDAURA..... | 146 |
| <i>procto-med hc</i> | 117 | <i>rabeprazole</i> | 127 | <i>rifabutin</i> | 59 |
| <i>procto-pak</i> | 117 | RADICAVA..... | 103 | <i>rifampin</i> | 59, 60 |
| <i>proctosol hc</i> | 117 | <i>raloxifene</i> | 134 | <i>riluzole</i> | 103 |
| <i>proctozone-hc</i> | 117 | <i>ramipril</i> | 89 | <i>rimantadine</i> | 76 |
| <i>progesterone</i> | 140 | <i>ranitidine hcl</i> | 127, 128 | RINVOQ..... | 146 |
| <i>progesterone micronized</i> | 140 | <i>ranolazine</i> | 93 | <i>risedronate</i> | 155 |
| PROGRAF..... | 146 | <i>rasagiline</i> | 65 | RISPERDAL CONSTA..... | 69 |
| PROLASTIN-C..... | 166 | RASUVO (PF)..... | 146 | <i>risperidone</i> | 69, 70 |
| | | RAVICTI..... | 129 | <i>ritonavir</i> | 74 |

| | | | | | |
|------------------------------------|-----|--|----------|---|-----|
| RITUXAN..... | 34 | SIGNIFOR..... | 139 | SPRYCEL..... | 34 |
| RITUXAN HYCELA..... | 34 | SIKLOS..... | 81 | <i>sps (with sorbitol)</i> | 129 |
| <i>rivastigmine</i> | 45 | <i>sildenafil (pulm.hypertension)</i> | | <i>sronyx</i> | 111 |
| <i>rivastigmine tartrate</i> | 45 | | 167, 168 | <i>ssd</i> | 114 |
| <i>rizatriptan</i> | 58 | SILIQ..... | 146 | <i>stavudine</i> | 74 |
| ROCKLATAN..... | 159 | <i>silver sulfadiazine</i> | 114 | STELARA..... | 147 |
| <i>ropinirole</i> | 65 | SIMBRINZA..... | 159 | STERILE PADS..... | 119 |
| <i>rosadan</i> | 114 | <i>simliya (28)</i> | 110 | STIMATE..... | 139 |
| <i>rosuvastatin</i> | 98 | <i>simpesse</i> | 110 | STIOLTO RESPIMAT..... | 164 |
| ROTARIX..... | 151 | SIMPONI..... | 146 | STIVARGA..... | 34 |
| ROTATEQ VACCINE..... | 151 | SIMPONI ARIA..... | 146 | STRENSIQ..... | 121 |
| ROZLYTREK..... | 34 | <i>simvastatin</i> | 98 | <i>streptomycin</i> | 14 |
| RUBRACA..... | 34 | <i>sirolimus</i> | 146 | STRIBILD..... | 74 |
| RUKOBIA..... | 74 | SIRTURO..... | 60 | STRIVERDI RESPIMAT.... | 164 |
| RUXIENCE..... | 34 | SKYRIZI..... | 147 | SUBLOCADE..... | 11 |
| RYBELSUS..... | 50 | SLYND..... | 110 | <i>subvenite</i> | 43 |
| RYDAPT..... | 34 | <i>sodium chloride 0.9%</i> | 161 | <i>sucralfate</i> | 128 |
| SAIZEN..... | 139 | <i>sodium phenylbutyrate</i> | 129 | <i>sulfacetamide sodium</i> | 124 |
| SAIZEN SAIZENPREP..... | 139 | <i>sodium polystyrene (sorb free)</i> | | <i>sulfacetamide sodium (acne)</i> .. | 114 |
| SANDOSTATIN LAR | | | 129 | <i>sulfacetamide-prednisolone</i> | 124 |
| DEPOT..... | 139 | <i>sodium polystyrene sulfonate</i> .. | 129 | <i>sulfadiazine</i> | 21 |
| SANTYL..... | 113 | <i>sofosbuvir-velpatasvir</i> | 76 | <i>sulfamethoxazole-</i> | |
| SAPHRIS..... | 70 | SOLQUA 100/33..... | 53 | <i>trimethoprim</i> | 21 |
| <i>sapropterin</i> | 120 | SOLTAMOX..... | 34 | <i>sulfasalazine</i> | 153 |
| SARCLISA..... | 34 | SOLU-CORTEF ACT-O- | | <i>sulindac</i> | 9 |
| SAVELLA..... | 104 | VIAL (PF)..... | 136 | <i>sumatriptan</i> | 58 |
| <i>scopolamine base</i> | 62 | SOMATULINE DEPOT..... | 139 | <i>sumatriptan succinate</i> | 59 |
| SECUADO..... | 70 | SOMAVERT..... | 139 | SUNOSI..... | 167 |
| <i>selegiline hcl</i> | 65 | <i>sorine</i> | 91 | SUPPRELIN LA..... | 139 |
| <i>selenium sulfide</i> | 114 | <i>sotalol</i> | 91 | SUPREP BOWEL PREP | |
| SELZENTRY..... | 74 | <i>sotalol af</i> | 91 | KIT..... | 130 |
| SE-NATAL-19..... | 168 | SOVALDI..... | 76 | SUTENT..... | 34 |
| SEREVENT DISKUS..... | 164 | SPIRIVA RESPIMAT..... | 164 | <i>syeda</i> | 111 |
| SEROSTIM..... | 139 | SPIRIVA WITH | | SYLATRON..... | 34 |
| <i>sertraline</i> | 48 | HANDIHALER..... | 164 | SYLVANT..... | 34 |
| <i>setlakin</i> | 110 | <i>spironolactone</i> | 95 | SYMDEKO..... | 166 |
| <i>sevelamer carbonate</i> | 130 | <i>spironolacton-hydrochlorothiaz</i> | 96 | SYMFI..... | 74 |
| <i>sevelamer hcl</i> | 130 | SPRAVATO..... | 48 | SYMFI LO..... | 74 |
| <i>sharobel</i> | 110 | <i>sprintec (28)</i> | 111 | SYMJEPI..... | 93 |
| SHINGRIX (PF)..... | 151 | SPRITAM..... | 43 | SYMLINPEN 120..... | 50 |

| | | | | | |
|---------------------------------------|----------|--|----------|---|--------------------|
| SYMLINPEN 60..... | 51 | TEMIXYS..... | 74 | TOLAK..... | 113 |
| SYMPAZAN..... | 43 | TEMODAR..... | 35 | <i>tolmetin</i> | 9, 10 |
| SYMTUZA..... | 74 | <i>temsirolimus</i> | 35 | <i>tolterodine</i> | 131 |
| SYNAGIS..... | 76 | <i>tencon</i> | 7 | <i>topiramate</i> | 43 |
| SYNAREL..... | 139 | TENIVAC (PF)..... | 151 | <i>toposar</i> | 36 |
| SYNDROS..... | 62 | <i>tenofovir disoproxil fumarate</i> ... | 74 | <i>topotecan</i> | 36 |
| SYNERCID..... | 15 | TEPEZZA..... | 122 | <i>toremifene</i> | 36 |
| SYNJARDY..... | 51 | <i>terazosin</i> | 131 | <i>torse mide</i> | 96 |
| SYNJARDY XR..... | 51 | <i>terbinafine hcl</i> | 56 | TOTECT..... | 157 |
| SYNRIBO..... | 35 | <i>terbutaline</i> | 164 | TOUJEO MAX U-300 | |
| TABLOID..... | 35 | <i>terconazole</i> | 57 | SOLOSTAR..... | 53 |
| TABRECTA..... | 35 | <i>testosterone</i> | 133 | TOUJEO SOLOSTAR U-300 | |
| <i>tacrolimus</i> | 117, 147 | <i>testosterone cypionate</i> | 132, 133 | INSULIN..... | 53 |
| <i>tadalafil</i> | 168 | <i>testosterone enanthate</i> | 133 | TOVIAZ..... | 131 |
| <i>tadalafil (pulm. hypertension)</i> | 168 | TETANUS,DIPHThERIA | | TRACLEER..... | 168 |
| TAFINLAR..... | 35 | TOX PED(PF)..... | 151 | TRADJENTA..... | 51 |
| TAGRISSO..... | 35 | <i>tetrabenazine</i> | 104 | <i>tramadol</i> | 7 |
| TAKHZYRO..... | 157 | <i>tetracycline</i> | 22 | <i>tramadol-acetaminophen</i> | 7 |
| TALTZ AUTOINJECTOR.. | 147 | THALOMID..... | 157 | <i>trandolapril</i> | 89 |
| TALTZ SYRINGE..... | 147 | <i>theophylline</i> | 164 | <i>tranexamic acid</i> | 81, 82 |
| TALZENNA..... | 35 | THIOLA..... | 132 | <i>tranylcypromine</i> | 48 |
| <i>tamoxifen</i> | 35 | THIOLA EC..... | 131 | TRAVASOL 10 %..... | 86 |
| <i>tamsulosin</i> | 131 | <i>thioridazine</i> | 70 | <i>travoprost</i> | 159 |
| TARGRETIN..... | 35 | <i>thiotepa</i> | 35 | TRAZIMERA..... | 36 |
| <i>tarina 24 fe</i> | 111 | <i>thiothixene</i> | 70 | <i>trazodone</i> | 48 |
| <i>tarina fe 1-20 eq (28)</i> | 111 | <i>tiadylt er</i> | 92 | TREANDA..... | 36 |
| TASIGNA..... | 35 | <i>tiagabine</i> | 43 | TRECTOR..... | 60 |
| TAVALISSE..... | 81 | TIBSOVO..... | 35 | TRELEGY ELLIPTA..... | 165 |
| <i>tazarotene</i> | 118 | TICE BCG..... | 36 | TRELSTAR..... | 36 |
| TAZORAC..... | 118 | <i>tigecycline</i> | 22 | TREMFYA..... | 147 |
| <i>taztia xt</i> | 92 | <i>timolol maleate</i> | 91, 159 | <i>treprostinil sodium</i> | 168 |
| TAZVERIK..... | 35 | <i>tinidazole</i> | 63 | <i>tretinoin</i> | 118 |
| TDVAX..... | 151 | TIVICAY..... | 74 | <i>tretinoin (antineoplastic)</i> | 36 |
| TECENTRIQ..... | 35 | TIVICAY PD..... | 75 | <i>tri femynor</i> | 111 |
| TECFIDERA..... | 104 | <i>tizanidine</i> | 167 | <i>triamcinolone acetoneide</i> | |
| TEFLARO..... | 17 | TOBI PODHALER..... | 14 | | 112, 117, 118, 136 |
| <i>telmisartan</i> | 87 | <i>tobramycin</i> | 124 | <i>triamterene-hydrochlorothiazid</i> | 96 |
| <i>telmisartan-amlodipine</i> | 87 | <i>tobramycin in 0.225 % nacl</i> | 14 | <i>triazolam</i> | 13 |
| <i>telmisartan-hydrochlorothiazid</i> | 88 | <i>tobramycin sulfate</i> | 14 | <i>trientine</i> | 132 |
| <i>temazepam</i> | 13 | <i>tobramycin-dexamethasone</i> | 124 | <i>tri-estarylla</i> | 111 |

| | | | | | |
|--|-----|--|--------|---------------------------|-----|
| <i>trifluoperazine</i> | 70 | TYSABRI..... | 147 | <i>vienna</i> | 112 |
| <i>trifluridine</i> | 124 | TYVASO..... | 168 | <i>vigabatrin</i> | 44 |
| <i>trihexyphenidyl</i> | 65 | UCERIS..... | 153 | <i>vigadrone</i> | 44 |
| TRIKAFTA..... | 166 | UDENYCA..... | 81 | VIIBRYD..... | 49 |
| <i>tri-legest fe</i> | 111 | UNITUXIN..... | 37 | VIMIZIM..... | 121 |
| <i>tri-lynyah</i> | 111 | UPTRAVI..... | 168 | VIMPAT..... | 44 |
| <i>tri-lo-estarylla</i> | 111 | <i>ursodiol</i> | 129 | <i>vinblastine</i> | 37 |
| <i>tri-lo-marzia</i> | 111 | <i>valacyclovir</i> | 78 | <i>vincasar pfs</i> | 37 |
| <i>tri-lo-mili</i> | 111 | VALCHLOR..... | 113 | <i>vincristine</i> | 37 |
| <i>tri-lo-sprintec</i> | 111 | <i>valganciclovir</i> | 78 | <i>vinorelbine</i> | 37 |
| <i>trilyte with flavor packets</i> | 130 | <i>valproate sodium</i> | 44 | <i>viorele (28)</i> | 112 |
| <i>trimethoprim</i> | 15 | <i>valproic acid</i> | 44 | VIRACEPT..... | 75 |
| <i>tri-mili</i> | 111 | <i>valproic acid (as sodium salt)</i> .. | 44 | VIREAD..... | 75 |
| <i>trimipramine</i> | 48 | <i>valrubicin</i> | 37 | VISTOGARD..... | 157 |
| TRINTELLIX..... | 48 | <i>valsartan</i> | 88 | VITRAKVI..... | 37 |
| <i>tri-previfem (28)</i> | 111 | <i>valsartan-hydrochlorothiazide</i> .. | 88 | VIZIMPRO..... | 38 |
| TRIPTODUR..... | 140 | VALTOCO..... | 44 | <i>volnea (28)</i> | 112 |
| <i>tri-sprintec (28)</i> | 111 | <i>vancomycin</i> | 16 | <i>voriconazole</i> | 56 |
| TRIUMEQ..... | 75 | VAQTA (PF)..... | 152 | VOSEVI..... | 76 |
| <i>trivora (28)</i> | 111 | VARIVAX (PF)..... | 152 | VOTRIENT..... | 38 |
| <i>tri-vylibra</i> | 111 | VASCEPA..... | 98 | VPRIV..... | 121 |
| <i>tri-vylibra lo</i> | 111 | VECTIBIX..... | 37 | VRAYLAR..... | 70 |
| TRODELVY..... | 36 | VELCADE..... | 37 | VUMERITY..... | 104 |
| TROGARZO..... | 75 | <i>velivet triphasic regimen (28)</i> .. | 112 | VYEPTI..... | 59 |
| TROPHAMINE 10 %..... | 86 | VELPHORO..... | 130 | <i>vyfemla (28)</i> | 112 |
| TROPHAMINE 6%..... | 86 | VEMLIDY..... | 75 | <i>vylibra</i> | 112 |
| <i>trospium</i> | 131 | VENCLEXTA..... | 37 | VYNDAMAX..... | 94 |
| TRULANCE..... | 129 | VENCLEXTA STARTING | | VYNDAQEL..... | 94 |
| TRULICITY..... | 51 | PACK..... | 37 | VYXEOS..... | 38 |
| TRUMENBA..... | 151 | <i>venlafaxine</i> | 48, 49 | VYZULTA..... | 159 |
| TRUVADA..... | 75 | <i>verapamil</i> | 92, 93 | <i>warfarin</i> | 79 |
| TRUXIMA..... | 36 | VEREGEN..... | 113 | WELCHOL..... | 98 |
| TUKYSA..... | 36 | VERSACLOZ..... | 70 | <i>wera (28)</i> | 112 |
| <i>tulana</i> | 111 | VERZENIO..... | 37 | XADAGO..... | 65 |
| TURALIO..... | 36 | VIBERZI..... | 130 | XALKORI..... | 38 |
| TWINRIX (PF)..... | 151 | <i>vicodin hp</i> | 7 | XARELTO..... | 79 |
| TYBOST..... | 157 | VICTOZA..... | 51 | XARELTO DVT-PE TREAT | |
| TYKERB..... | 37 | VIDEX 2 GRAM | | 30D START..... | 79 |
| TYMLOS..... | 155 | PEDIATRIC..... | 75 | XATMEP..... | 38 |
| TYPHIM VI..... | 152 | VIEKIRA PAK..... | 76 | XCOPRI..... | 44 |

| | | | |
|---------------------------------|-----|--|--------|
| XCOPRI MAINTENANCE PACK..... | 44 | ZEPOSIA..... | 104 |
| XCOPRI TITRATION PACK..... | 44 | ZEPOSIA STARTER KIT .. | 104 |
| XELJANZ..... | 147 | ZEPOSIA STARTER PACK | 104 |
| XELJANZ XR..... | 147 | ZEPZELCA..... | 39 |
| XELPROS..... | 159 | <i>zidovudine</i> | 75 |
| XERMELO..... | 130 | ZIEXTENZO..... | 81 |
| XGEVA..... | 155 | ZIOPTAN (PF)..... | 159 |
| XHANCE..... | 126 | <i>ziprasidone hcl</i> | 70 |
| XIFAXAN..... | 16 | <i>ziprasidone mesylate</i> | 70 |
| XIGDUO XR..... | 51 | ZIRABEV..... | 39 |
| XIIDRA..... | 126 | ZIRGAN..... | 125 |
| XOFLUZA..... | 76 | ZOLADEx..... | 39 |
| XOLAIR..... | 166 | <i>zoledronic acid</i> | 155 |
| XOSPATA..... | 38 | <i>zoledronic acid-mannitol-water</i> | 155 |
| XPOVIO..... | 38 | ZOLINZA..... | 39 |
| XTAMPZA ER..... | 7 | <i>zolmitriptan</i> | 59 |
| XTANDI..... | 38 | <i>zolpidem</i> | 167 |
| <i>xulane</i> | 112 | ZOMACTON..... | 140 |
| XULTOPHY 100/3.6..... | 53 | <i>zonisamide</i> | 45 |
| XURIDEN..... | 157 | ZORBTIVE..... | 140 |
| XYOSTED..... | 133 | ZORTRESS..... | 147 |
| XYREM..... | 167 | ZOSTAVAX (PF)..... | 152 |
| YERVOY..... | 38 | <i>zovia 1/35e (28)</i> | 112 |
| YF-VAX (PF)..... | 152 | ZTLIDO..... | 10 |
| YONDELIS..... | 38 | ZULRESSO..... | 49 |
| YONSA..... | 38 | <i>zumandimine (28)</i> | 112 |
| <i>yuvafem</i> | 134 | ZYDELIG..... | 39 |
| <i>zafirlukast</i> | 163 | ZYKADIA..... | 39 |
| <i>zaleplon</i> | 167 | ZYLET..... | 125 |
| ZALTRAP..... | 39 | ZYPREXA RELPREVV .. | 70, 71 |
| <i>zarah</i> | 112 | ZYTIGA..... | 39 |
| ZARXIO..... | 81 | | |
| <i>zebutal</i> | 7 | | |
| ZEJULA..... | 39 | | |
| ZELBORAF..... | 39 | | |
| <i>zenatane</i> | 114 | | |
| ZENPEP..... | 121 | | |
| ZEPATIER..... | 76 | | |

This formulary was updated on 10/05/2020. For more recent information or other questions, please contact ATRIO Health Plans at 1-877-672-8620 or, for TTY users, 1-800-735-2900, 8 a.m. to 8 p.m., daily, or visit www.atriohp.com.